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Summary  
Malaria case management using malaria rapid diagnosis tests (mRDTs) and artemisinin-based 
combinations therapies (ACTs), the only effective and widely used antimalrial treatment, is a 
key intervention to control malaria. In Tanzania, case management policies require 
parasitological confirmation of malaria prior to treatment for patients of all ages. To that aim, 
considerable efforts have been made to improve diagnosis availability and compliance to 
diagnosis results and to expand access to effective antimalarials in the public and private 
sector. Despite that, there are concerns that many patients with malaria do not receive ACTs 
while others suffering from non-malaria fever do. This indicates that treatments are not always 
targeted to those in need.  
Previous assessments of the impact of new diagnosis or treatment strategies on anti-malarial 
drug use relied either on longitudinal recording of drug stocks, prescription rates in health 
facilities, or on histories of drug intake recorded by community interviews. These measures 
are potentially biased and do not provide accurate estimates of overall levels of circulating 
drug, probably the most important driver for the development of drug resistance in 
pathogens.  
To address this issue of public health relevance, we used a community-based approach to test 
the usefulness of measuring concentrations of antimalarial drugs in the blood. This tool was 
used to monitor population drug use and study the relationships between factors such as 
malaria prevalence, diagnosis and treatment practices, drug pressure and drug resistance.  
In this sense, it was important to measure antimalarials using a sensitive analytical 
methodology adapted to field conditions. We have thus developed a liquid chromatography-
tandem mass spectrometry method (LC-MS/MS) for the simultaneous quantification of 7 
frequently used antimalarials and 2 active metabolites in 10-µl dried blood spots. Thanks to 
the good performances achieved in terms of trueness (-12.1 to +11.1%), precision (1.4 to 
15.0%) and sensitivity (lower limits of quantification comprised between 2 and 20 ng/ml) with 
a convenient extraction procedure, the proposed assay was found to be suitable for the 
analysis of residual antimalarials in dried blood spots (DBS) samples collected at large scale.  
The developed assay was applied within the frame of a pharmacokinetics study including 16 
healthy volunteers who received a single adult dose of artemether-lumefantrine. Lumefantrine 
(LF) concentrations in plasma and in DBS were highly correlated at all time points (R=0.97) 
and LF half-life calculated from plasma and DBS measurements was similar (101.9 hours in 
plasma versus 103.6 hours in DBS). This work allowed to validate the use of DBS to measure 
LF concentrations in field trials conditions.  
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The analytical method was then used for measuring residual antimalarial drugs concentrations 
in 6485 DBS samples collected in a community-based cross-sectional survey rolled-out in 
three regions of Tanzania (Mbeya, Mtwara and Mwanza) with different levels of malaria 
endemicity. This study showed that amongst 6391 participants included in the antimalarial 
analysis, close to one fifth [20.8% (1330/6391)] had antimalarials detected in their blood and 
only 28.0% (372/1330) of them reported the use of antimalarials within the previous month. 
Furthermore, participants who did not report any fever in the previous two weeks accounted 
for the majority of the individuals who had residual antimalarial levels detected in their blood 
[71.2% (947/1330)].   
There was also room for improvement with regard to diagnosis and treatment practices in 
case of febrile episode. Indeed, 31% of the individuals with fevers seeking care were 
appropriately tested (according to patient history) and 50% appropriately treated for malaria 
(according to the presence or absence of residual antimalarials measured in the blood).  
We then used a multivariate analysis to identify factors associated with the presence of 
lumefantrine and/or desbutyl-lumefantrine (LF/DLF) or sulfadoxine-pyrimethamine (SP) in the 
blood, the antimalarials most frequently identified in the surveyed population. The most 
significant predictors identified were expected. Fever in the previous two weeks, young age, 
higher district malaria prevalence and living in a ward in which all visited drug stores had ACTs 
in stocks were associated with higher odds of having LF/DLF in the blood. Pregnancy, living in 
Mwanza region, fever in the previous two weeks and older age were associated with higher 
odds of having SP in the blood.  
Subsequently, we investigated whether the presence of residual concentrations of LF or SP in 
the blood of individuals sampled in the community predicted the presence of Plasmodium 
falciparum harboring molecular markers of resistance. Indeed, the main consequence of drug 
pressure is the emergence of parasites resistance, which in turn threatens the sustainability of 
gains in malaria control. We found that having LF or SP in the blood was not associated with 
higher odds of carrying a parasite harboring mutations known to reduce parasites 
susceptibility. However, by multivariate analysis, having LF or SP in the blood at low 
concentrations was significantly associated with higher probability of carrying a mutant 
parasite.  
In conclusion, our methodology of antimalarial measurement in the blood represents a reliable 
tool to evaluate at community level the overall impact of case management strategies on 
population drug pressure. This thesis provides a deep insight on the relationship between 
parasite prevalence and resistance, individual factors such as age and health seeking behavior, 
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as well as diagnosis and treatment practices. Despite efforts made to improve access to 
diagnostic tools, there is still a high drug pressure in the population. These results suggest 
that there is a need to support the use of mRDTs with proper training in the public and private 
sector for a better targeted use of antimalarials in favor of parasitologically confirmed malaria 
cases. These findings should be integrated to more advanced statistical tools to understand 
the effect of drug pressure on parasite resistance at population level. This could help 
developing urgently needed targeted strategies to stop the spread of resistance to 
artemisinins and partner drugs.  
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1.1.  Malaria epidemiology and control in Tanzania 
Malaria is a major public health problem in Mainland Tanzania. The entire population is at risk 
due to the climatic conditions that remain favorable for transmission throughout almost the 
entire country, which makes Tanzania the 11th largest population at risk of stable malaria in 
Africa [1] and the fourth dominating country in the global burden of mortality after Nigeria, 
the Democratic Republic of Congo and Burkina Faso [2]. It is estimated that more than 26% of 
all outpatient attendances are attributable to malaria, resulting in approximately 6 million 
confirmed and clinical malaria cases and 22’000 deaths reported in 2017 [2]. There is a large 
disparity in malaria prevalence among children under age five across regions, from as high as 
41% in the North-Western Zone and 19% in the Lake Zone, to 1% in Northern and South-
Western Highlands Zones, and more than four times higher in rural areas than in urban areas 
[3]. Plasmodium falciparum accounts for 96% of malaria infections in this country and is 
principally transmitted by Anopheles gambiae [4]. Seasonal malaria peaks occur at the end of 
the rainy seasons, with short rains taking place from November to January and long rains from 
March to May.  
Tanzania enjoys one of the best annual economic growth rates in sub-Saharan Africa [5] and 
between 2003 and 2015, increased contributions have been used to deliver preventive and 
curative services. The successful implementation of insecticide-treated nets (ITNs), long lasting 
insecticidal nets (LLINs) and Intermittent Preventive Treatment of malaria in pregnancy (IPTp) 
together with consistent increase in consumption of artemisinin-based combination therapies 
(ACTs) [1] led to a dramatic decrease in case incidence of more than 75% between 2000 and 
2015 [6]. The latest reports showed that malaria prevalence among children under age five 
decreased from  14.0% in 2015-2016 to 7.5% in 2017 [3].  
1.2. Malaria diagnosis  
Malaria is suspected clinically on the basis of fever but no signs or symptoms reliably 
distinguish malaria from other causes of fever [7]. This lack of specificity makes clinical 
diagnosis unacceptable [8]. Correct diagnosis is particularly important to reduce overuse of 
antimalarial medicines and to improve the diagnosis of other febrile illnesses. Therefore, since 
2010, the World Health Organization (WHO) recommendations include the need to confirm a 
malaria infection by either microscopy or rapid diagnostic tests (mRDTs) in all settings before 
dispensing any antimalarial treatment [7]. When parasitological diagnosis is not possible only, 
a decision to provide an antimalarial should be based on the probability that the illness is 
malaria. mRDTs are considered to be the best option for an accurate and easy to perform 
diagnosis of malaria in routine practice [8].  They are rapid (can be performed in about 15 
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minutes), highly sensitive and specific with a high diagnostic reliability [1] and can be done by 
minimally trained personnel. These rapid tests are qualitative techniques based on the 
detection of malaria parasite antigens, relying on antibodies - antigens reactions. Due to the 
persistence of antigens in the blood stream after parasite clearance, the tests may remain 
positive for up to one month after treatment even though the patient has been cured [1]. In 
2015, mRDTs accounted for 74% of all malaria testing [9]. 
1.3. Malaria treatments 
1.3.1. Artemisinin-based combination therapies  
ACTs are the only effective and widely used antimalarial treatments at the moment and their 
introduction was the intervention that had the second highest effect on malaria control 
between 2000 and 2015 worldwide [10]. In response to development of drug resistance to 
conventional antimalarial drugs, the WHO has been recommending ACTs as first-line therapy 
[7]. All countries in sub-Saharan Africa have then adopted an ACT (either artemisinin-
amodiaquine, dihydroartemisinin-piperaquine or artemether-lumefantrine) as first-line drug 
for treatment of uncomplicated malaria [6] and thanks to the support of large initiatives and 
funding agencies, including The Global Fund for AIDS Malaria and Tuberculosis and the World 
Bank, ACTs are now being deployed intensively [11]. The therapeutic efficacy of ACTs is high in 
sub-Saharan Africa, with a median treatment failure rate of less than 10% [6] but resistance has 
been detected in South East Asia and is expected to occur in Africa in the longer term [12]. The 
first known case of artemisinin resistance has been identified recently in Equatorial Guinea [13]. 
Currently, less than 30 antimalarials are under clinical development and only a limited number 
of them are potential alternatives to artemisinin-based therapies. Furthermore, six candidates 
are endoperoxides or synthetic artemisinins, which could be subjected to cross-resistances with 
artemisinin-resistant parasites [12].   
Artemether-lumefantrine (ALu), the currently recommended ACT in Tanzania, combines the 
short-acting artemisinin derivative artemether (AM) with the long-acting lumefantrine (LF). AM 
has a rapid onset of action resulting in prompt parasite clearance, and their short elimination 
half-life (2 hours) reduces the probability of development of resistance. Most of the parasites 
are killed during the course of the 3-days therapy (108 reductions in parasite biomass), most 
likely due to the effect of AM and its metabolite dihydroartemisinin. By contrast, LF has a slower 
onset of action but longer elimination half-life of 2-3 days allowing the drug to accumulate 
after the course of the treatment which enables the killing of the few remaining parasites (10-
104) [14] and decreasing the relapse rate [15][14]. Both drugs protect each other from the 
emergence of resistance [16].  
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1.3.2. Malaria treatments in Tanzania  
In Tanzania, delayed parasitological clearance and resistance following standard treatment 
courses of chloroquine (CQ) began to emerge rapidly and by 1999, many sites had documented 
CQ clinical failure rates in excess of 40% [1]. This advocated for a change from CQ to 
sulfadoxine-pyrimethamine (SP) in 2001, but in a period of five years, parasite resistance to SP 
had gone up to 25% on average. From 2006 to 2007, a decision for another change in favor of 
ALu was therefore unavoidable, thereby providing access to more effective antimalarials [17]. 
Moreover, sale of oral artemisinin-based monotherapies has been banned in 2006 [17]. In 
Tanzania, ALu’s efficacy was shown to be still very high in 2011-2012 [1]. Besides ALu, 
artesunate plus amodiaquine (AQ) or mefloquine (MF) is also considered as an option for 
treatment of uncomplicated malaria in Tanzania. Quinine (Q) is the second line drug in case of 
treatment failure and, as well as injectable artesunate, a drug of choice for treatment of severe 
malaria [6]. Although SP had been abandoned as first line treatment, it was retained at lower 
dose for prevention purposes as the drug of choice for IPTp, because no suitable alternative to 
SP was available and its lower efficacy is acceptable to prevent worst effects of malaria infection 
during pregnancy [17].  
1.4. Access to diagnosis and treatments in Tanzania 
Mainland Tanzania is divided into regions and district councils, which are further divided into 
divisions and wards (formed by five to seven villages) [18]. The health care services are provided 
through a hierarchical system which includes dispensaries (primary health care), health centers 
(secondary health care), regional and district hospitals (tertiary health care). A dispensary serves 
a population of 6,000 to 10,000 people; a health centre serves 50,000–80,000; and a district 
hospital serves more than 250,000 people [1]. Faith-based organizations and for-profit private 
sector are also parts of the health system [18]. The private retail sector includes both 
unregistered outlets and registered Accredited Drug Dispensing Outlets (ADDOs) and 
Pharmacies. Registered outlets only are permitted to stock and sell ACTs [19] although a few 
unregistered drug stores also do [20]. ALu is free of charge in the public health facilities (HFs) 
and faith based organizations for children under the age of five, pregnant women, elderly and 
at a minimal cost for adults [21]. In 2014, Tanzania reported sufficient ACTs distributed to treat 
all malaria patients attending public HFs [6]. Since 2009, following WHO recommendations [7], 
the Tanzania National Malaria Control Programme (NMCP) case management policies require 
that patients of all ages should receive a diagnostic test prior to treatment [6,17], which is free 
of charge in the public sector [6]. Malaria mRDTs have therefore been deployed in the public 
sector between 2010 and 2012 and health workers have been trained in using them [6]. 
According to demographic health surveys (DHS) [3], more than 70% of suspected cases were 
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tested in 2014 in the public sector. In practice however, more than half of those seeking 
treatment for suspected malaria first visit the private sector (including both registered and 
unregistered outlets), especially in rural areas [19]. Since the Ministry of Health recognized the 
importance of engaging the private sector in the malaria case management [22], efforts have 
also been made to strengthening the delivery of medicines through retail outlets (Figure 1.1) 
[19].    
 
 
Figure 1-1: Percentage of public and private outlets with A) mRDTs and B) ACTs in stock on the day of 
the survey. Outlets were considered to have stocks if at least one mRDT or ACT was observed. DLDB = Duka 
La Dawa Baridi, unregistered dispensing outlet. Source: ACT Watch [23] 
 
A. 
B. 
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1.5. New diagnosis and treatment strategies  
1.5.1. The aim of new diagnosis and treatment strategies  
The implementation of ACTs and mRDTs has been a cornerstone in the management of fever 
cases. New diagnosis strategies are aimed at improving health outcome by helping in 
ascertaining disease etiology and better evaluating the level of severity. As ACTs are frequently 
used to treat causes of fever other than malaria [24,25], treatments can also be better targeted 
to those in need with the help of mRDTs, leading to more rational use of drugs. Such a 
beneficial effect has been clearly demonstrated in Dar es Salaam in 2007, where the 
introduction of mRDTs led to 77% reduction of antimalarial consumption [26] and 43% 
reduction in Senegal after  deployment of mRDTs at large scale between 2007 and 2009 [27]. 
Such a decrease should have important implications in terms of drug pressure and occurrence 
of Plasmodium resistance [28]. Unfortunately, these new drugs policies have difficulties to be 
implemented sustainably. In spite of considerable efforts to increase access to essential 
medicines, uptake of first-line antimalarials and antibiotics is still low and/or erratic in most 
developing countries. Availability of diagnostic tests for malaria (microscopy, mRDTs) is 
improving but remains well under the estimated global need, especially in remote settings [29]. 
There is a mixture of underuse and overuse of antimalarials [30,31]. Underuse can be due to 
access problems, non-compliance of the HF to treatment guidelines, non-adherence of the 
patient or stock-outs. Overuse can be due to non-availability of malaria tests, variability in the 
quality and performance of mRDTs [25] or lack of expertise of clinicians in the management of 
non-malaria fevers, which has become a concern increasingly important, especially with global 
decrease in proportion of febrile illnesses due to malaria [24,32]. Incorrect malaria prescriptions 
result in wastage of medication, delays in obtaining effective treatment for the true cause of 
illness and important drug pressure in the population [19].   
While a relatively large number of different drugs are now available against malaria, the 
parasites have progressively developed resistance against many of existing molecules. This is 
mainly due to inadequate uncontrolled use of drugs taken as monotherapy, but also because 
patients might poorly adhere to treatment and finally because of the worldwide distribution of 
counterfeit drugs containing insufficient drug dosage [33]. More generally, antiparasite 
resistance is highly dependent on the overall drug pressure, namely the quantity of circulating 
drugs in the general population [34].  
The use of antimalarials as combination therapy is mandatory and clearly beneficial [35], but 
artemisinin is rapidly eliminated and the “partner drugs” persist in the bloodstream as 
monotherapy for weeks due to their long half-lives, particularly at subtherapeutic 
concentrations, selecting for newly acquired resistant parasites [10,36,37]. For example, a 
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recently published meta-analysis [38] showed that the principal determinant of treatment 
outcome with ALu is the plasma concentration of LF at day 7, with values >200 ng/mL being 
associated with >98% cure rates in most uncomplicated malaria patients. Lower concentrations 
are predictive of treatment failures and at such sub-therapeutic levels, the parasite’s 
susceptibility to LF decreases and it is therefore a favorable environment for the development 
of resistance. Sulfadoxine (SD) and pyrimethamine (PM) also have long half-lives. The extensive 
(often inadequate [39]) use of these long-acting compounds is a critical factor contributing to 
drug pressure, which in turn is a potent force selecting resistant parasites [34,40]. Thus, correct 
use of antimalarials is now one of the five goals and recommendations of WHO Global plan for 
artemisinin resistance containment [12]. Renewed efforts must therefore be made overall to 
optimise drug use and exposure for ensuring an optimal treatment while limiting the 
opportunities for emergence of drug resistance [39]. Monitoring the impact of new treatment 
strategies in terms of use and adherence to mRDTs, use of medicines as well as dynamic of 
resistance are of paramount importance to evaluate the public health benefit they confer.   
1.5.2. Methodologies to evaluate new diagnosis and treatment strategies and their 
impact on drug pressure  
There are as yet no standardized methodologies for investigating access to curative health care. 
Most studies have used cross-sectional surveys in communities, in HFs or in the retail sector to 
estimate whether or not good quality drugs have been accessed. Interviews have targeted 
caretakers of small children and focused on health seeking and management for children who 
suffered from fever in the previous two weeks [41–43]. In the last decade, a great deal of 
research has been done on access to antimalarial medicines in relation to the changes of first-
line treatment policies, mainly from CQ to SP, and then from SP to ACTs. Besides access to 
drugs, there is a need to evaluate new diagnosis or treatment strategies. Often, consultation 
processes (completeness of medical history and clinical examination, accuracy of diagnosis, 
appropriateness of treatment proposed etc.) are compared in intervention and control HFs, or 
before-and after intervention [44–46]. Exit interviews of patients are also used to check on 
diagnostic procedures applied and treatment prescribed. If these studies are relatively 
appropriate to measure effectiveness in small-scale studies, they are certainly suboptimal to 
assess public health impact of diagnosis or treatment strategies. Indeed, they are more likely 
to detect a positive effect since they are usually conducted in places where intense training and 
supervision have been undertaken or they are biased from the Hawthorne effect (people 
change their behaviour due to the fact they are observed) [47]. Also, even if a treatment has 
been prescribed, there is no indication on whether the prescribed treatment has been bought 
and ingested. Moreover, the likelihood of detecting a difference between intervention and 
control areas in community surveys is much lower than in studies conducted in HFs because of 
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the rather low prevalence rate of persons being sick and seeking treatment. The net result 
obtained from community surveys is however much more meaningful for health authorities 
who need to know the real public health benefit of specific case management strategies, and 
hence to decide on the relevance of their wide implementation. Cross-sectional surveys in the 
community have the advantage to provide data on the overall health services recourse and 
drug use after introduction of a new intervention. These studies are certainly informative but 
suffer from potential biases [48]. Recall bias is one of those, but many other factors such as fear 
to be judged or fear of not being appropriately cared for can give an inaccurate picture of what 
is really done in terms of diagnosis or treatment in the field. For all these reasons, the overall 
impact of the implementation of mRDTs and ACTs is difficult to assess precisely.  
Two recent studies, one in Tanzania [49] and one in Cambodia [50] have shown that self-
reported history is not reliable in terms of actual drug use. Indeed, 75% of patients presenting 
in a HF in Tanzania, and 50% in Cambodia had a detectable concentrations of antimalarial(s) in 
the blood, although all stated that they did not take any drug in the previous month. These 
studies show that population drug use can only be captured through community surveys using 
methodologies that rely on more objective and standardized endpoints. 
Changes in diagnosis or first-line treatment strategies and/or policies should be reflected in 
the prevalence of individuals harboring particular drug(s) in their blood. Measuring of 
antimalarials concentrations in the blood of the general population is certainly the most 
accurate method to estimate overall drug pressure, as a result of diagnosis and treatment 
environment. Drug pressure can then be related to molecular markers of resistance since 
specific Plasmodium polymorphisms have been associated with reduced susceptibility to CQ, 
AQ,  Q, SD, PM, MF, LF [51], and even more recently to artemisinin [52].  
Studies investigating antimalarial consumption in community surveys using drug 
concentrations in bio-fluids have been searched through a literature review. Amongst the 37 
studies first selected, 28 were excluded because they used drug concentrations to assess 
treatment adherence or because they included patients with suspected malaria presenting at a 
health centre or included in a clinical trial [49-50,53–78]. The 9 studies remaining are presented 
in Table 1.1. Most of them have been published more than a decade ago, during the CQ or SP 
eras and none studied ACTs consumption. The reported prevalence rates of individuals with 
detectable drug in urine or blood range from 0 to 91%. The most extensive study was 
performed in 2008 and included 3052 participants [34] and showed that between 9-91% of 
individual had detectable CQ levels and 0-21% PM, with a high variation between sites. Three 
studies showed that the presence of residual levels of CQ or PM in participants were associated 
with an increased proportion of mutant parasite isolates [79,80] and one showed that mutant 
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parasite isolates were only observed at high concentrations of CQ [81]. Only one mutation was 
less frequent in children with CQ than in children without CQ detected [80]. Among other 
studies including malaria patients (not presented in the table), Talisuna et al. showed that drug 
use was inversely related to parasite prevalence, and that, in areas of low transmission, drug 
pressure was the critical factor for parasite resistance, which was not the case in high 
transmission places [69].  
  
Table 1-1: Studies investigating antimalarial consumption in community surveys using drug concentrations in bio-fluids 
Number and 
reference 
Publication 
Year 
Antimalarial Country 
Survey type and 
population 
Number of 
participants 
Analytical 
method  
Proportion of 
antimalarials 
detected 
Relationship with parasite resistance 
1. [80] 2012 CQ and PM* Rwanda 
Household survey, 
children < 5 
749 
ELISA** in 
plasma 
CQ in 17.6% of 
participants, PM in 
0%. 
Pfmdr1 Y86 mutation less frequent in isolates of 
children with CQ levels than of children without CQ 
levels (16.7 vs 44.0%). Pfcrt T76  more frequent in 
isolates of children with CQ levels than of children 
without CQ levels (83.3% vs. 73.8%, p = 0.39). 
2. [34] 2008 CQ 
Senegal, 
Burkina Faso, 
Cameroon 
Household survey, 
all ages 
3052 
ELISA and 
HPLC-UV*** in 
urine 
CQ and PM ranged 
from 9% to 91% 
and from 0% to 
21%, respectively. 
NA 
3. [81] 2003 CQ Nigeria 
Schools and health 
posts, children 
228  
HPLC-UV in 
blood 
CQ in 31% of 
participants.  
Prevalence of the Pfcrt T76 increased with blood levels 
of CQ (P < 0.0001). K76 allele more frequent in 
individuals without detectable CQ levels. Pfcrt T76 only 
observed in children with CQ levels > 150 nmol/L. 
4. [82] 2001 CQ Nigeria 
Schools and health 
posts, children 
405  
HPLC-UV in 
blood 
CQ in 52% of 
participants. 
NA 
5. [79] 2001 CQ and PM Ghana 
Pregnant women 
presenting for 
antenatal care in a 
hospital 
172  
ELISA in urine 
and serum 
CQ and PM in 45% 
and 12% of the 
participants, 
respectively. 
Resistance markers to CQ more prevalent in samples 
with residual CQ. 
6. [83] 2000 CQ and PM Ghana 
Pregnant women 
presenting for 
antenatal care in a 
hospital 
530  ELISA in urine 
CQ or PM in 65% 
of the participants. 
Residual levels of CQ or PM associated with a reduced 
prevalence of P. falciparum infections and raised 
proportion of submicroscopic parasitaemia. 
7. [84] 1999 PM Nigeria 
Schools and 
vaccination 
programs, children 
146  ELISA in blood 
PM in 4% of the 
participants. 
NA 
8. [40] 1999 CQ and SD* Kenya 
Household survey, 
children  
318  ELISA in blood 
CQ and SD in 37% 
and 4% of the 
participants, 
respectively. 
NA 
9. [85] 1994 CQ Tanzania Schools, children 163  
HPLC-UV in 
blood 
CQ in 78% of the 
participants 
Drug levels were not sufficient to affect parasites.  
*CQ = chloroquine, PM = pyrimethamine, SD = sulfadoxine 
**ELISA = enzyme-linked immunosorbent assay  
***HPLC-UV = liquid chromatography coupled to UV detection  
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These varying results illustrate the complex interplay between health system, drug pressure, 
immunity and individual behaviour (Figure 1.2). They call for more research in the field, using 
sensitive and reliable methods for drug concentration assessment, and careful analysis 
integrating all possible determinants.  
 
Figure 1-2: Relationship between malaria prevalence, diagnosis and treatment strategies, drug use and 
drug resistance.    
1.6. Analysis of antimalarials in dried blood spots  
The main constraints in research field trials at the population level in low-income areas are the 
issues of difficult sample handling, limited storage and transportation facilities. The dried 
blood spot (DBS) sampling technique can overcome part of these problems and samples solid 
state may improve stability of the drugs. This technique is also less invasive because it allows 
avoiding venipuncture by sampling capillary blood using a simple fingerpick [86]. Some 
analytical advantages are also to take into consideration: the current sampling standard for 
drugs quantification allows the measurement of the drugs levels in plasma, whereas the site 
of action of antimalarials is mostly within erythrocytes [87,88]. For that reason, the DBS 
technique provides the advantage of measuring total levels in whole blood (i.e. comprising 
erythrocytes) [89]. The concentration of antimalarial drug measured in whole blood may thus 
better reflect the exposure at the site of antiparasitic activity.  
However, the many logistical and practical advantages of DBS over conventional venous 
sampling are potentially offset by errors related to volume of blood applied onto the filter 
paper card, haematocrit (especially with patient infected by malaria wherein protozoan 
multiplication induce significant red blood cells lysis) [86,90], sample collection (e.g expression 
of interstitial tissue fluid [91]) and drug distribution (some drugs have complex venous-
capillary and blood-plasma concentration relations). Due to the limited volume of blood on 
the filter paper cards (typically less than 30μl), extreme analytical sensitivity is required for 
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accurate and precise drug levels measurements. This can be provided by the liquid 
chromatography coupled to tandem mass-spectrometry (LC-MS/MS) technique, the gold 
standard for the quantification of drugs in bio-fluids. Furthermore, for the analysis of a large 
sample size, as encountered in cross-sectional surveys, the LC-MS/MS is a method of choice 
due to the minimal sample preparation required. In our study, the already existing LC-MS/MS 
method for the quantification of 14 antimalarials in plasma [89] needed to be adapted and 
fully validated according to requirements inherent to the DBS sampling technology [92,93].   
Artemisinin derivatives have not been analysed in this project because of their very short half-
life, typically 2 hours. Also, when using the DBS sampling method, they are rapidly degraded 
in the presence of ferrous iron (Fe2+) which is released during red blood cells haemolysis. 
Their known high reactivity with ferrous ion is necessary for their antimalarial activity but 
creates serious problems for measurement in biological samples [94].  
1.7. Main molecular markers of resistance to antimalarials   
Decreased susceptibility to CQ and AQ has been associated with the presence of the pfcrt 76T 
and pfmdr1 86Y mutations [51]. Inversely, decreased susceptibility to LF has been associated 
with the wild pfcrt K76 allele [95,96] and on the pfmdr1 gene, gradually acquired tolerance to 
LF has been suggested, starting with the wild N86 allele, followed by the combination of the 
N86 and D1246 wild types and finally the triple combination of the N86, the 184F mutation 
and the D1246 [97]. Increased pfmdr1 copy number has been correlated with treatment failure 
following MF and LF [51,98]. Increased treatment failure to SP has been associated to the 
pfdhfr single 108N and triple 51I, 59R and 108N mutations [95]. The pfdhfr-pfdhps quintuple 
mutant (the combination of the pfdhfr 51I, 59R and 108N triple mutations with the pfdhps 
540E, 581G double mutations) correlated with high level resistance to SP and occurs after the 
pfdhfr triple mutations. More recently, a mutation on the propeller region of the Kelch gene 
(known as K13 marker) has been identified as causing resistance to artemisinin [52].   
1.8. Rationale for this study 
The impact of new diagnosis or treatment strategies on drug use has previously been 
evaluated by longitudinal recording of HF drugs stocks and/or their prescription rates in 
intervention and control areas, or before and after an intervention implementation. 
Alternatively, information on recent history of fever, diagnosis and drug intake was gathered 
through community surveys. But the biases potentially affecting these measured are 
numerous and these study might therefore not reflect accurately the amount of drugs 
circulating among the population. This latter variable is probably the most important 
determinant to the development of pathogen resistance to drugs.  
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We therefore propose to evaluate such a community-based approach to test the usefulness 
of measuring concentrations of antimalarial drugs in the blood to monitor population drug 
use and study the relationships between factors such as malaria prevalence,  diagnosis and 
treatment conditions and practices, drug pressure and drug resistance (see Figure 1.2).  
The present work complements the efforts made in previous projects that assessed 
management of childhood illnesses, quality of care, access and rational use of drugs in 
Tanzania [8,25,26,99,100] and explores new perspectives never used to assess drug pressure 
at large scale. The performances of the LC-MS/MS and the molecular diagnosis platforms have 
already been shown in previous studies [49,50,89,101,102] led by our research group at the 
Swiss Tropical and Public Health Institute (Swiss TPH). A strong collaboration with the Ifakara 
Health Institute (IHI) had already been set up on the above issues. Furthermore, a project 
aimed at exploring the impact of introducing mRDTs and a highly subsidized ACT in the private 
retail sector in Tanzania (IMPACT2) conducted jointly by the IHI, the Center for Disease Control 
and the London School of Hygiene and Tropical Medicine [20,103] served as a basis for the 
design of our study and facilitated the implementation of our project.
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2.1. General goal  
To use the measurement of antimalarials blood concentrations as an objective and reliable 
tool to assess drug pressure in the general population and to understand how levels of 
residual antimalarial drugs in community surveys interrelate with malaria prevalence, access 
to care, diagnosis and treatment practices as well as drug resistance.    
 
2.2. Specific objectives  
A) To develop and validate a LC-MS/MS assay for the simultaneous analysis in dried blood 
spots (DBS) of the main antimalarial drugs used in combination with artemisinin 
derivatives in Tanzania. (CHAPTERS IV) 
 
B) To measure blood concentrations of residual antimalarial drugs [primarily lumefantrine 
(LF) and sulfadoxine-pyrimethamine (SP)] in representative samples of people in 
malaria endemic areas and to compare these results with self-reported history of drug 
use. (CHAPTER V) 
 
C) To use antimalarials blood measurements in community surveys to assess diagnosis 
and treatment appropriateness in case of fever episode at population level. (CHAPTER 
V)  
 
D) To use antimalarials blood measurements in community surveys to evaluate the actual 
state of population drug pressure and to identify the factors associated with the 
presence of LF or SP in the blood. (CHAPTER VI) 
 
E) To investigate whether the presence of residual LF or SP in the blood of individuals 
sampled in the community predicts the presence of Plasmodium falciparum 
harbouring molecular markers of resistance. (CHAPTER VII) 
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Preliminary comment 
To answer objective A, the DBS-ALU project has been carried out in Switzerland. To answer 
objectives B-E, the AMACO project has been conducted in Tanzania.  
3.1. Objective A   
3.1.1. Collaboration  
The LC–MS/MS assay development and the DBS sample analysis were carried out in the 
Laboratory of Clinical Pharmacology of the University Hospital of Lausanne (CHUV), 
Switzerland. The pharmacokinetic (PK) study was carried out in the service of Clinical 
Pharmacology of the CHUV.  
3.1.2. Study design and population  
To assess the relationship between LF concentrations measured in plasma and in DBS samples, 
a PK study was conducted in Switzerland in June 2016. This study was a prospective open-
label one-group interventional trial. Sixteen healthy male and female subjects aged between 
18 and 45 years with a body mass index (BMI) between 18 and 29 kg/m2 were included. The 
specific eligibility criteria are presented in Appendix 1.   
All the participants received a single adult dose of Riamet® (artemether-lumefantrine, 
Novartis), followed by 6 to 10 capillary and venous blood sampling, from hour 0 to hour 336 
after drug intake. All visits were ambulatory.  
3.1.3. Laboratory analysis  
An LC-MS/MS assay for the multiplex analysis of 7 antimalarials and 2 active metabolites in 
DBS was developed. This essay was used to measure antimalarial concentrations in DBS 
samples collected during the PK study in Switzerland. This methodology was adapted to 
measure LF concentrations in erythrocytes and whole venous blood and a previously 
developed method [89] was used to measure LF concentrations in plasma.     
3.1.4. Ethics  
This PK study was approved by the “Commission cantonale d’éthique de la recherche sur l’être 
humain” of Canton de Vaud (CER-VD), Switzerland. Written informed consents were obtained 
from all participants.  
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3.2. Objectives B-E   
3.2.1. Collaboration  
One cross-sectional survey was carried out in Tanzania in collaboration with the IHI of Dar es 
Salaam, Tanzania. The assessment of Single Nucleotide Polymorphisms (SNPs) related to 
parasite resistance to drugs was done in the Laboratory of Molecular Parasitology and 
Epidemiology of the Swiss TPH, Basel, Switzerland.   
3.2.2. Study area, design and population  
The survey took place from May to August 2015, after the rainy season in  three regions of 
Tanzania: Mtwara, Mwanza and Mbeya with populations of 1’270’854, 2’772’509 and 2’707’410 
respectively [104]. The regions are located in South-Eastern, North-Western and South-
Western zones of mainland Tanzania, respectively (Figure 3.1) and cover a range of malaria 
endemicity, different geographic and ecological zones, different settings (rural, urban) as well 
as different levels of access to diagnosis and treatment facilities. The choice of the regions in 
this study was based on the IMPACT2 project [20], which reported that the level of malaria 
prevalence amongst all age groups in 2012 was moderately high for Mtwara and Mwanza 
(17.4% and 16.1% respectively), and low for Mbeya (2.3%). According to the latest DHS survey 
[3], malaria prevalence among children under age five in 2015 was 20% in Mtwara, 15% in 
Mwanza and 1% in Mbeya (Figure 3.1).  
The cross-sectional survey included three types of surveys conducted concurrently in 
randomly selected wards:   
1) HH-based surveys: up to six members were randomly selected amongst all consenting 
individuals of the HH. The exclusion criteria were individuals under three months of age 
and those with a severe illness requiring immediate referral. Interviews were conducted 
with a questionnaire in Swahili including demographic characteristics, information on time 
to the closest HF and closest pharmacy or drug retailer, history of fever in the previous 
two weeks as well as history of antimalarial use in the previous months. In addition, 
capillary blood spots were collected from finger prick to assess the presence of malaria 
antigens by mRDT and applied onto filter paper for further drug concentrations 
measurements by LC-MS/MS.  
2) drug outlet-based surveys: all private and public drug dispensing outlets surrounding 
and serving the selected villages were visited. Details about antimalarials stocks and 
diagnostic tools (mRDTs and microscope) available at the time of the visit were recorded. 
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3) exit interviews in HF-based surveys: in each ward, the main HFs serving the surveyed 
villages were selected. After completion of their consultation with HF staff and after 
visiting the HF pharmacy for possible treatment procurement, patients who consulted for 
fever were interviewed to collect information on demographics, malaria diagnostic test 
performed, test result and drug obtained.  
 
Figure 3-1: Malaria prevalence in Tanzania in children under age five, by region (assessed by mRDTs) in 
2015 Source: DHS surveys [3]  
3.2.3. Laboratory analysis  
The LC-MS/MS assay has been used for the multiplex analysis 7 antimalarials and 2 active 
metabolites in DBS samples collected during the cross-sectional survey in Tanzania. SNPs 
related to parasite resistance to drugs were analysed by polymerase chain reaction (PCR) 
followed by sequencing in DBS samples of individuals tested positive for malaria during the 
cross-sectional survey in Tanzania (Objective E). To assess resistance to LF, the pfmdr1 
mutations N86Y, Y184F, the pfcrt mutations C72S, M74I, N75E, K76T/I/N as well as the number 
of copy of the pfmdr1 gene were analysed. To assess resistance to SP, the pfdhfr mutations 
A16V/S, N51I, C59R, S108N/T, I164L and pfdhps mutations S436A/F, A437G, K540E, A581G, 
A613T/S were analysed. 
3.2.4. Ethics  
This cross-sectional study was approved by three different Ethics Committees (Swiss Ethics 
Committees on research involving humans, Institutional Review Board of the Ifakara Health 
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Institute and National Institute for Medical Research in Tanzania). Written informed consents 
were obtained from all participants or their responsible caretaker. 
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4.1. A) Abstract  
In epidemiological studies, antimalarials measurements in blood represent the best available 
marker of drugs exposure at population level, an important driver for the emergence of drug 
resistance. We have developed a liquid chromatography-tandem mass spectrometry method 
(LC-MS/MS) for the simultaneous quantification of 7 frequently used antimalarials 
(amodiaquine, chloroquine, quinine, sulfadoxine, pyrimethamine, mefloquine, lumefantrine) 
and 2 active metabolites (N-desethyl-amodiaquine, desbutyl-lumefantrine) in 10-µl dried 
blood spots (DBS). This sampling approach is suitable for field studies wherein blood samples 
processing, transportation and storage are problematic. Sample preparation included 
extraction from a 3 mm-disk punched out of the DBS with 100-μl of methanol + 1% formic 
acid containing deuterated internal standards for all drugs. Good performances were achieved 
in terms of trueness (-12.1 to +11.1%), precision (1.4 to 15.0%) and sensitivity, with lower limits 
of quantification comprised between 2 ng/ml (sulfadoxine) and 20 ng/ml (chloroquine, 
quinine, pyrimethamine, mefloquine, lumefantrine and desbutyl-lumefantrine). All analytes 
were stable in DBS kept for 24h at room temperature and at 37°C. The developed assay was 
applied within the frame of a pharmacokinetics study including 16 healthy volunteers who 
received a single dose of artemether-lumefantrine. Lumefantrine concentrations in plasma 
and in DBS were highly correlated (R=0.97) at all time points, confirming the assumption that 
lumefantrine concentrations determined in DBS confidently reflect blood concentrations. The 
blood/plasma ratio of 0.56 obtained using the Bland-Altman approach (and corresponding to 
the slope of the linear regression) is in line with negligible penetration of lumefantrine into 
blood cells. This sensitive multiplex LC-MS/MS assay enabling the simultaneous analysis of 
antimalarials in DBS is suitable for epidemiological studies in field conditions. 
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4.2. A) Introduction 
While a relatively large number of different drugs are now available against malaria, the 
emergence of parasites resistant against current, frequently used antimalarial agents appears 
inexorable [105]. One of the leading causes of drug resistance to antimalarials is the frequently 
unrecognized intake of doses without prescription, often in insufficient amounts or over 
insufficient durations. Such poorly structured use of treatments produce residual drug levels 
in blood that remain below target minimal inhibitory concentrations for prolonged periods of 
time, thus exerting a strong selective pressure on parasites. Renewed efforts must therefore 
be encouraged to optimise drug use and exposure while decreasing the risk of drug resistance 
development [39].  
To determine overall drug exposure and resulting selection pressure in a population, 
interviewing individual patient is possibly the most straightforward approach. However it only 
represents an indirect surrogate, likely to be flawed by numerous confounding factors. Indeed, 
interviewees reports have been previously shown not to give a comprehensive and accurate 
picture of drug use in a population [49,50,106]. Direct measurement of antimalarials 
concentrations in blood samples might represent a more accurate method to estimate overall 
drug pressure in the general population.  
In that perspective, blood samples collection onto filter paper cards using the dried blood 
spot (DBS) approach has attracted much interest. It actually appears to be the most convenient 
approach for collecting blood specimens in field conditions, wherein samples handling, 
transportation and available storage facilities are well recognized issues. However, this 
approach raises a number of bioanalytical challenges [107] and because of the limited whole 
blood volume applied onto the paper cards (i.e. less than 30 µl), extreme analytical sensitivity 
is required for accurate and precise drug levels measurements.  
Liquid chromatography coupled to mass spectrometry (LC-MS) has progressively become the 
reference bioanalytical method because of its unsurpassed sensitivity, selectivity and the 
extremely low limits of quantification this technique can provide.  While a number of analytical 
methods have been developed for measuring antimalarials in DBS [108–127] only three, to the 
best of our knowledge, have used mass spectrometry combined with liquid chromatography 
(LC-MS) [113,128,129]. In fact,  the LC-MS technique has so far been applied for quantifying 
antimalarials mostly in plasma or in whole blood samples [130–134,134–146]. Moreover, 
amongst all published methods that use liquid chromatography (LC), very few allow the 
analysis of multiple antimalarials simultaneously: sulfadoxine, pyrimethamine, chloroquine, 
amodiaquine and N-desethyl-amodiaquine in whole blood by HPLC and UV detection [147]; 
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as  much as 14 antimalarials and their metabolites in plasma using triple stage quadrupole 
tandem mass spectrometry (LC-MS/MS) [131];  and quinine, mefloquine, sulfadoxine, 
pyrimethamine, lumefantrine and chloroquine in DBS by LC-MS with ion trap detection [113]. 
The latter, despite using mass spectrometry, did not allow reaching very low limits of 
quantification, which would preclude its general application for screening samples for the 
presence of low residual levels.  
The aim of the present work was to develop and validate a LC-MS/MS method for the 
simultaneous sensitive analysis in DBS of the major antimalarial agents quinine (Q), 
chloroquine (CQ), amodiaquine (AQ), sulfadoxine (SD), pyrimethamine (PM), mefloquine (MF) 
and lumefantrine (LF) [and their active metabolite desbutyl-lumefantrine (DLF), N-desethyl-
amodiaquine(DAQ)], most of them used at present in combination with artemisinin 
derivatives. Those latter however undergo complex chemical reactions in the presence of 
ferrous iron (Fe2+) [94], thus precluding their direct analysis in the lysed whole blood matrix of 
DBS paper cards. The proposed method is a powerful tool for determining antimalarials levels 
in individuals from a large population. Since all pharmacokinetic/pharmacodynamic (PK/PD) 
studies for lumefantrine [38] have been as yet based on plasma concentrations, a required 
validation step necessitated to study the strength of the correlation between lumefantrine (the 
most widely used antimalarial in combination with artemisinin derivates at present) measured 
in DBS and in plasma. A clinical validation to translate DBS measurements into plasma 
concentrations should always be performed when developing any DBS sampling [92]. In 
addition, we have examined the concentrations of lumefantrine found in vivo in red blood 
cells, the site of erythrocytic stages of Plasmodium falciparum.  
 
4.3. A) Materials and methods 
4.3.1. A) Chemicals and reagents  
CQ diphosphate and Q hydrochlorine were purchased from Sigma-Aldrich (Buchs, 
Switzerland) and Novartis Pharma AG (Basel, Switzerland), respectively. AQ, DAQ, SD, PM, MF, 
LF and DLF were obtained from Toronto Research Chemicals (TRC, Ontario, Canada). The 
internal standards (I.S.) CQ-D4 diphosphate, Q-D3, AQ-D10, DAQ-D5, PM-D3, SD-D3, MF-D9 
hydrochloride, LF-D9 and DLF-D9 were purchased at TRC (Ontario, Canada). Ultrapure water 
was prepared using a Milli-Q® Advantage A10 apparatus (Millipore Corp., Burlington, MA, 
USA). Chromatography was performed using HPLC-grade acetonitrile (ACN), methanol 
(MeOH), isopropanol and formic acid 98% (FA) and ammonium acetate, all purchased from 
Merck (Darmstadt, Germany).  Whole blood used for the preparation of calibration and control 
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samples as well as for the determination of matrix effect was obtained from blood withdrawn 
from patients with Vaquez Disease at the occasion of their regular phlebotomy at the CHUV 
(Lausanne, Switzerland). This blood was immediately stored at -20°C and consequently 
haemolysed. 
4.3.2. A) LC-MS equipment 
The liquid chromatography system used consisted of Rheos 2200 quaternary pumps and a 
HTS PAL autosampler used for sample injection (CTC Analytics AG, Zwingen, Switzerland) 
controlled by the Janeiro-CNS software (Flux Instruments, AG, Thermofischer Scientific Inc., 
Waltham, MA).  The LC-MS/MS system comprised an XSelect® UPLC HSS T3 2.5 µm; 75 x 2.1 
mm analytical column (Waters, Milford, MA, USA) used for the chromatographic separation 
coupled to a triple stage quadrupole (TSQ) Quantum Ion mass spectrometer (MS) from 
Thermofischer Scientific, equipped with an electrospray ionization (ESI) interface operated in 
the positive mode.  
4.3.3. A) Internal standards, calibration standards and quality controls (QCs) preparation 
Primary stock solutions of 1 mg/ml (except 2.5 mg/ml for sulfadoxine-D3) prepared using each 
pure internal standards compound dissolved in MeOH were further diluted with MeOH to 
obtain 1µg/ml stock solutions (free form). A single sample extraction solution was 
subsequently prepared with MeOH containing 1% formic acid and all I.S. at 5 ng/ml (AQ-D10 
and DAQ-D5) and 50 ng/ml (CQ-D4, DLF-D9, SD-D3, PM-D3, Q-D3, LF-D9 and MF-D9). All 
solutions were stored at -20°C. 
Standard stock solutions of antimalarial drugs and metabolites (chemical structures depicted 
in Figure 4.1a) were prepared in suitable solvents reported in Table 4.1.a and stored in 
polypropylene tubes at -20°C. Serial dilutions of stock solutions with MeOH/H2O (1:1, v/v) 
were performed to obtain working solutions at concentrations suitable for the subsequent 
preparation of calibration and quality control samples.  
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Figure 4-1.a: Chemical structures of antimalarials/metabolites. (1: N-desethyl-amodiaquine (DAQ) 2: 
chloroquine (CQ), 3: amodiaquine (AQ), 4: quinine (Q), 5: pyrimethamine (PM), 6: sulfadoxine (SD), 7: 
mefloquine (MF), 8: desbutyl-lumefantrine (DLF), 9: lumefantrine (LF)). Drawn with ChemDraw software 
(version Prime 16.0).  
Each working solution was diluted in blank haemolysed whole human blood to obtain 
calibration samples and the corresponding 3 quality control samples at low (L), medium (M) 
and high (H) levels (Table 4.1.a) and kept at -20°C prior to analysis. Blood haemolysis had been 
carried out by freezing human whole blood at -20°C followed by a thawing cycle. DBS 
calibration and QC samples were prepared on the day of analysis by spotting 10-µl aliquots 
of each thawed calibration and quality control samples onto FTA DMPK-B cards (Whatman®, 
Maidstone, UK). The blood spots were then allowed to dry for at least 2 hours at room 
temperature prior to DBS processing.  
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Table 4-1.a: Preparation of calibration standards and quality control samples. 
Compound Concentration (ng/ml) and 
solvent of stock solutions  
Calibration range in 
haemolyzed whole blood 
(ng/ml) 
QCs controls (ng/ml) 
N-desethyl-
amodiaquine 
1 (in MeOH) 6-1500 18, 120, 1200 
Chloroquine 10 (in H2O) 20-5000 60, 400, 4000 
Amodiaquine 5 (in MeOH) 15-3750 45, 300, 3000 
Quinine  10 (in H2O) 20-5000 60, 400, 4000 
Sulfadoxine 1 (in MeOH) 20-5000 60, 400, 4000 
Pyrimethamine 1 (in MeOH) 2-500 6, 40, 400 
Mefloquine  4 (in MeOH) 20-5000 60, 400, 4000 
Desbutyl-
lumefantrine 
1 (in MeOH/DMSO 4 :1 
+1%FA) 
20-5000 60, 400, 4000 
Lumefantrine 1 (in MeOH/DMSO 4 :1 
+1%FA) 
20-5000 60, 400, 4000 
 
4.3.4. A) LC-MS/MS analysis conditions  
The mobile phases used for the chromatography consisted of 2 mM ammonium acetate + 
0.1% FA in ultra-pure water (mobile phase A) and acetonitrile + 0.1% FA (mobile phase B).  The 
mobile phase A was also used for the dilution of organic DBS extracts prior to their HPLC 
injection (see below).  
The chromatographic program comprised 3 steps, namely a 11-min separative step followed 
by a 4-min washing with mobile phase B and isopropanol (mobile phase C) and a 4-min 
column re-equilibration step. The mobile phase was delivered using a stepwise gradient 
elution according to the sequence reported in Table 4.2.a. The injection volume was 20 µl and 
the autosampler injection syringe and injection valve were rinsed 5 times automatically after 
each sample injection using 2 solutions, i.e. MeOH/H2O (1:1, v/v, weak wash) +1% FA and ACN 
+ 1% FA (strong wash) to reduce sample carry-over (see below).  
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Table 4-2.a: LC-gradient elution program.  
Time (min) Mobile 
phase A* 
(%) 
Mobile 
phase B* 
(%) 
Mobile 
phase C* 
(%) 
Flow rate 
(µl/min) 
0.0 98 2 0 300 
10.5 10 90 0 300 
11.0 2 98 0 600 
11.5 2 98 0 600 
12.0 0 0 100 500 
13.5 0 0 100 500 
14.0 2 98 0 600 
14.5 2 98 0 600 
15.0 98 2 0 300 
19.0 (total 
analysis time) 
98 2 0 300 
*Mobile phase A: 2mM ammonium acetate + 0.1% FA in MeOH 
  Mobile phase B: acetonitrile + 0.1% FA  
  Mobile phase C : isopropanol 100% 
 
Mass spectrometry acquisition has been set using the Selected Reaction Monitoring mode 
using 3 consecutive time segments with ESI in the positive mode. The selection of MS/MS 
transitions for antimalarials and their corresponding I.S. have been performed by continuous 
infusion of a solution of each pure standard at 1 µg/ml in MeOH directly into the mass 
spectrometer. The selected MS/MS transitions, the tube lens and collision energy for each 
analyte and I.S. are reported in Table 4.3.a. The Xcalibur software package (version 2.0) 
(ThermoQuest, Thermofischer Scientific Inc., Waltham, MA) was used to control the 
instruments and chromatographic data acquisition, peak integration and quantification.  
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Table 4-3.a: MS/MS conditions and retention times for antimalarial drugs, metabolites and internal 
standards.  
Compound Precurs
or ion 
(m/z) 
Product 
ion (m/z) 
CE* 
(eV) 
Tube 
Lens 
(V) 
Segment 
n° 
Retention 
time (min) 
N-desethyl-amodiaquine 328.3 283.0 26 60 1 3.58 
N-desethyl-amodiaquine-d5  333.0 282.9 27 60 1 3.58 
Chloroquine 322.2 142.2 27 74 1 3.65 
Chloroquine-d4 326.1 146.2 24 72 1 3.64 
Amodiaquine 357.3 284.1 16    73 1 3.75 
Amodiaquine-d10  366.1 282.9 26 72 1 3.75 
Quinine  325.1 307.1 24 89 2,3 4.16 
Quinine-d3 328.1 310.1 26 60 2,3 4.15 
Sulfadoxine 311.0 155.9 28 68 3 5.28 
Sulfadoxine-d3 314.5 156.0 25 63 3 5.24 
Pyrimethamine 249.1 233.0 38 87 3 5.28 
Pyrimethamine-d3 253.1 234.0 38 87 3 5.28 
Mefloquine  380.0 361.0 26 94 4 6.91 
Mefloquine-d9 389.0 371.0 26 94 4 6.90 
Desbutyl-lumefantrine 472.1 454.0 22 82 5 9.50 
Desbutyl-lumefantrine-d9 481.3 463.1 22 82 5 9.49 
Lumefantrine 531.1 512.1 29 95 5 10.49 
Lumefantrine-d9 539.0 521.1 34 95 5 10.46 
*CE=collision energy 
 
4.3.5. A) Blood sample collection for antimalarials measurements 
Comparative PK study of DBS versus plasma, in healthy subjects 
A PK study with 16 healthy volunteers monitored over 14 days after a single adult dose of 
artemether-lumefantrine was conducted at the University Hospital of Lausanne (Switzerland) 
for a formal head-to-head comparison of concentrations of LF measured in DBS and 
simultaneously in plasma and red blood cells. It also helped to determine the time during 
which LF could still be detected in DBS after a single antimalarial drug dose. Venous and 
capillary blood samples were obtained at 11 time points in 16 volunteers after administration 
of a single adult dose of artemether-lumefantrine (Riamet®, Novartis, Basel, Switzerland), 
consisting of 4 tablets containing each 20 mg artemether and 80 mg LF, together with light 
standardized food (one glass of milk and a croissant). Venous blood samples (10 ml, as two 
4.9-ml aliquots) were collected on EDTA anticoagulant, just before treatment initiation and at 
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various time points on Day 0, Day 1, Day 2, Day 6 and Day 13. Venous blood tubes were then 
centrifuged at 2000 g for 10 min at 4°C and the collected plasma stored at -80°C prior to 
analysis. After discarding the residual plasma and buffy coat at the upper layer interface of red 
blood cells pellets, the packed erythrocytes from the first tube were directly placed at -80°C. 
The erythrocytes from the second tube were subjected to a quick single washing step with 5 
ml NaCl 0.9% and this suspension was centrifuged again. After removing the supernatant 
rinsing solution, the erythrocytes were stored at -80°C. 
At each time point, capillary blood was also obtained in parallel by skin puncture at a fingertip 
with a lancet, and collected in a graduated heparin-coated capillary tube. Three separate 10-
µl drops of capillary blood were applied with the capillary tube onto DBS cards. The cards were 
allowed to dry for at least 2 hours at room temperature before being sealed in a zip-lock bag 
with desiccant and stored at -80°C for long term storage (up to 2 months) until analysis. On 
the first blood sampling time and on the last visit, one drop of blood was used to measure the 
volunteer’s haematocrit using a micro-haematrocrit centrifuge (HAEMATOKRIT 200®, Hettich 
Zentrifugen, Lauenau, Germany). 
DBS samples collection in field conditions 
Within the frame of a cross-sectional survey initiated by the Swiss Tropical Institute (Basel, 
Switzerland) in collaboration with the Ifakara Health Institute (Tanzania), a total of 6485 DBS 
samples were collected in Tanzania in 2015 for the detection of the 9 antimalarials/metabolites 
using the present analytical method. During the survey, 4 drops of capillary blood were 
collected from every consenting individual, aged 3 months to 100 years and sampled as DBS.  
4.3.6. A) Sample processing  
DBS extraction procedure 
Several extraction solutions were tested: MeOH, ACN and MeOH/H2O mixtures. The influence 
of pH on extraction yield has also been examined by adding 1% FA or 1% ammonia into the 
extracting solvent. The extraction solution that provided the best recovery rates and suitable 
calibration curves for the considered drugs overall was found to be a solution of MeOH with 
1% FA. 
A 3-mm diameter disk was punched out from the centre of the DBS and transferred into a 1-
ml polypropylene tube. A 100-μl aliquot of extraction solution (MeOH + 1% FA) containing 
the 9 labelled I.S. and the sample was vortex-mixed for 10 seconds prior to incubation into an 
ultrasonic bath  for 10 min without heating (Fischerbrand®, Thermofischer Scientific, United 
Kingdom). The suspension was centrifuged for 10 min at 14’000 rpm (19’000 g) with a 
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benchtop centrifuge (Mikro 200R, Hettich Zentrifugen, Lauenau, Germany) in order to remove 
filter paper fibres and other remnant solid materials. A 70-μl aliquot of the supernatant was 
finally reconstituted in 70 μl of 2 mM ammonium acetate + 0.1% FA buffer into a glass HPLC 
vial prior the injection of a 20-μl sample into the LC-MS/MS system for the analysis. Vials were 
maintained at +10°C in the thermostated autosampler rack during the entire analysis.   
Lumefantrine measurements in plasma, DBS and erythrocytes  
For the comparative study with healthy subjects, concentrations of LF were measured in 
plasma, erythrocytes and capillary blood spotted onto DBS cards. Capillary blood DBS samples 
were analysed with the above-method. Plasma samples were analysed using an optimized 
method previously developed in our lab for the simultaneous determination of 14 antimalarial 
drugs and their metabolites in human plasma [131], which has been further improved with the 
use of stable isotopically labelled  I.S. The LF concentrations were measured in erythrocytes 
using an adaptation of the methodology applied to DBS samples analysis. Briefly, after 
complete thawing, 100 μl of haemolyzed erythrocyte suspension was mixed with 900 μl of 
phosphate buffered saline solution (pH 7.4) and ground using a Precellys®24 bead mill 
homogenizer. A 100-μl aliquot of this suspension was extracted with 400 μl of MeOH + 1% FA 
containing the I.S. The same procedure used for DBS extraction was applied thereafter (i.e. 10 
min incubation in an ultrasonic bath, centrifugation, reconstitution (1:1, v/v) of the supernatant 
with 2 mM ammonium acetate + 0.1% FA before injection of 20-μl into the LC-MS/MS).   
4.3.7. A) Analytical method validation  
The LC-MS/MS method validation was based on the FDA guidelines [148] as well as on the 
approach of Matuszewski et al.  [149] and on the recommendations of Li et al. for quantitative 
analysis of small molecules in DBS [93]. Comprehensive characterization of the analytical 
method includes selectivity, matrix effect, extraction recovery, process efficiency, calibration 
curve, trueness and precision, sensitivity and carry-over as well as drugs stability in the 
considered biological matrix in various conditions. The influence of punching position, blood 
spot volume and haematocrit on DBS sampling was also assessed. 
Selectivity  
To ensure method selectivity, DBS extracts from 6 different blank blood sources were analysed 
with and without I.S. and screened for potential interfering endogenous matrix components 
and cross-talk interferences.  
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Matrix effect, extraction recovery and process efficiency 
The matrix effect (ME) was first evaluated qualitatively by a post-column infusion of a neat 
clear solution containing 1 µg/ml of all the 9 antimalarial drugs and all I.S. in MeOH into the 
MS/MS detector during the chromatographic analysis of blank DBS extracts from 6 different 
blood sources. The LC-MS signal of each drug was visually examined in order to identify any 
perturbation (drift or shift) at the analyte’s retention time. Additionally, ME was evaluated 
quantitatively (as well as its variability) according to Matuszeswky methodology [149]. 3 series 
of QC samples at L, M and H concentrations were prepared as following: 
A) Matrix-free solution of analytes and I.S. in MeOH + 1%FA;  
B) Blank DBS extracts samples spiked with antimalarials/metabolites and I.S. after 
extraction; 
C) Complete procedure, i.e. antimalarials spiked in whole blood samples that are spotted 
onto filter paper, dried for 2 hours and subjected to the previously described extraction 
procedure. 
For the series B and C, each of the 3 concentrations were measured in DBS from whole blood 
from 6 different sources and serie A was measured in triplicate. The 3 series of samples were 
diluted 1:1 (v/v) in 2 mM ammonium acetate buffer + 0.1% FA prior to their injection onto the 
column. For the series A and B, the amount of analytes and I.S. spiked in the MeOH + 1% FA 
solution and in the blank extracts were calculated in order to obtain the total amount (100%) 
of drugs  theoretically recovered after extraction in series C. The volume of whole blood 
contained a in 3-mm filter paper punched disk was obtained by the rules of three, as the ratio 
of the mean spot area of a series of 10 µl whole blood applications, versus the calculated (π·r2) 
area of the 3-mm punched disk. The resultant volume was then 2.1 µl, which was similar to 
the one previously reported in the literature [150].  
The MEs were expressed as the ratio of the mean peak areas of analytes added into blank 
whole blood extracts spiked after extraction (B) to the mean peak areas of pure analytes 
solubilised in MeOH + 1%FA (A) (B/A ratio in %). The extraction recovery (ER) of each 
antimalarial drug/metabolite and I.S. were measured as the ratio of the mean peak areas of 
analytes in processed DBS samples (i.e spiked before extraction) (C) to the mean peak areas 
of analytes added into blank whole blood extracts spiked after extraction (B) (C/B ratio in %). 
The process efficiency (PE) of antimalarial drugs/metabolites and I.S. were calculated as the 
ratio of the mean peak areas of analytes in processed DBS samples (i.e spiked before 
extraction) (C) to the mean peak areas of pure analytes solubilised in MeOH + 1%FA (A) (C/A 
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ratio in %). Internal standard-normalization of the parameters was assessed by using ratios of 
analyte peak areas to the corresponding I.S. peak area (i.e. A2, B2 and C2 ratios).  
Calibration curve 
According to the FDA [148], a minimum of 75% of the matrix-based standard calibration 
samples have to fall within ±15% (LLOQ: ±20%) of the nominal value when back-calculated. 
In addition, the regression coefficient (R2) should be at least ≥0.99. An eight levels calibration 
curve was calculated by quadratic log-log regression of the peak area ratio of the drug to 
corresponding I.S. versus the concentration of the drug. Different regression models were 
tested and the quadratic log-log regression was the one with lowest total bias across the 
whole calibration range, due to the large range of concentrations measured and the large 
range of areas resulting. The log-log approach has been extensively studied on the 
antimalarial piperaquine, as reported by Singtoroj, et al. [151]. The calibration range was 
selected to cover concentrations previously reported in pharmacokinetic studies (see Table 
4.1.a). Each level of calibration was measured twice, i.e. at the beginning and at the end of the 
analytical run, with satisfactory concentrations/responses relationships (R2>0.99).   
Trueness and precision 
The 3 concentrations of the low (L), medium (M) and high (H) quality control samples were 
chosen to encompass the calibration ranges and the low (L) QC sample corresponded to 3 
times the respective lower limit of quantification (i.e. lower calibration level), according to FDA 
[148]. Trueness and precision were determined by the analysis of 5 different QCs replicates 
(n=5) during a single run for the intra-assay, and by triplicate analysis of the 3 different QCs 
replicates repeated on 3 different days (n=9) for the inter-assay. All samples (calibration 
standards and QCs) were spotted on the filter paper cards on the same day. The intra- and 
inter-days precision correspond to the coefficient of variation (CV%) within a single run and 
between different days, respectively and should be ≤ 15%. The trueness was expressed as the 
bias or percentage of deviation between nominal and back-calculated concentrations. The 
analytical runs were considered valid if mean bias for QCs were within ±15%.   
Sensitivity and carry-over 
The lowest levels of the calibration curves (i.e. also the lower limits of quantification) were 
selected initially to reflect the residual concentrations, based on previously published 
pharmacokinetics studies measuring plasma exposure. However, the low volume of blood 
spotted onto the paper card (10 µl) hampers to achieve concentrations as low as those 
reported for plasma analysis for all compounds. The concentration of the lowest calibration 
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standard had thus to be increased for achieving a bias that would be comprised within ±20%, 
in accordance to the FDA recommendations [148]. The limit of detection (LOD) was calculated 
using the instrument detection limit (IDL), which is the minimum amount of analyte required 
producing a LC-MS signal that is statistically distinguishable from the background noise level 
within a specified confidence level (99%). This approach is based the following well-
established statistical formula: IDL = t × (RSD/100 %) × amount measured, where the 
confidence factor t is determined using Student t-distribution with a 99 % confidence level 
and the RSD (relative standard deviation) = standard deviation/mean value. This formula  gives 
more reliable LOD values as it takes into account the signal intensity and its consistency [152]. 
Carry-over effect was assessed by injecting series of blank DBS extracts just after the highest 
calibration standard and determining the peak area of each analyte at their respective 
expected retention time. The residual peak area was expressed as percentage of the absolute 
peak area of the highest calibration standard. 
Stability of antimalarials and their metabolites 
The stability experiments included freeze-thaw cycles, bench- and long- term stabilities. To 
investigate the freeze-thaw cycles stability, whole fresh blood was spiked at L, M and H QCs 
levels and separated into 3 aliquots. One set of whole blood aliquots was directly employed 
as DBS, extracted and analysed in triplicate while the 2 others were stored at -80°C and 
subjected to 1 or 2 freezing-thawing cycles (i.e. kept at -80°C for 2 hours followed by thawing 
at room temperature for 30 min) before being spotted onto DBS cards. Analytes were 
considered to be stable when mean measured values did not deviate by more than 15% from 
the nominal values, with a CV ≤15%. For the bench stability experiments, L, M and H QCs were 
spotted in triplicate onto the DBS cards. After drying, the DBS cards were placed in a plastic 
bag with desiccant and either kept at laboratory temperature (24-25°C) or in an incubator at 
37°C with 80% humidity for 24 hours, before being processed and analysed using freshly 
spotted DBS calibrators. Information on medium to long-term stability of DBS samples were 
obtained by storing series of DBS cards at -20°C and -80°C for 1 month. Concentrations 
variations were expressed as percentage of the concentration measured at T=0. 
Influence of punching position, blood spot volume and haematocrit on DBS sampling  
The influence of the actual position of the punched paper disk within the blood spot was 
examined, as blood cells together with soluble analytes are likely to interact differently with 
the solid cellulose support of DBS card, leading to chromatography-wise repartition during 
spot deposit and heterogeneous levels from central to peripheral areas within the same spot 
(also called “chromatographic” effect) [93]. The importance of such potential intra-spot 
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heterogeneity was ascertained by the quantitative analysis of three 3-mm diameter disks 
punched one at the centre, intermediate and outer zone of blood spot of DBS samples 
containing L, M and H QC concentrations from 6 different sources of blood. These samples 
were analysed with a standard set of calibration samples rigorously punched at the centre. 
The chromatographic effect was considered negligible if the intra-spot trueness at L, M and H 
QC concentration levels lie within the acceptable (≤15%) limits.   
We also examined the effect of blood volume variability applied on filter paper on analytical 
performance: 5-, 10- and 15-µl aliquots of whole blood at L, M and H QC concentrations 
(spiked in 6 different sources of blood) were spotted onto the filter paper and a standard 3-
mm disk was punched out from the centre of all DBS. Results were expressed as the relative 
difference between concentrations measured with the 10-µl aliquot (used for calibration and 
considered as the reference volume) and the 5- and 15- µl aliquot volumes.  
Haematocrit is known to affect blood rheological properties (i.e. viscosity) [93] and therefore 
affects blood distribution on the card during application, leading to erratic volume of blood 
per punch and hence drug concentrations. The effect of the haematocrit on analytical 
performance was investigated by measuring L, M and H QCs spiked in 6 different sources of 
blood adjusted with plasma to obtain values at 25, 30, 35, 40, 45 and 50% haematocrit that 
were analysed with calibrators prepared in blood at standard fixed 40% haematocrit.  
4.3.8. A) Statistical analysis 
An ordinary linear regression was performed to test for the significance of the haematocrit 
effect on the concentrations of antimalarials measured, using p-values with significance 
defined as p <0.05. The correlation between LF levels measured in parallel in DBS and venous 
plasma was calculated by linear regression using the approach proposed by Bland-Altman 
[153]. Calculations were done with Microsoft Office Excel (version 2010) and RStudio (version 
3.4.0).  
4.3.9. A) Ethical approval  
The epidemiological study in Tanzania has been approved by three different Ethics 
Committees (Swiss Ethics Committees on research involving humans, Institutional Review 
Board of the Ifakara Research Institute and National Institute for Medical Research in 
Tanzania). The clinical study was approved by the “Commission cantonale d’éthique de la 
recherche sur l’être humain” of Canton de Vaud (CER-VD), Switzerland. Written informed 
consents were obtained from all volunteers.   
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4.4. A) Results 
4.4.1. A) Selectivity  
The chromatographic profiles of the 9 antimalarial drugs extracted from a DBS sample and 
their corresponding deuterated analogues simultaneously analysed by LC-MS/MS are shown 
in Figure 4.2.a, whereas analytes retention times and selected MS/MS transitions are reported 
in Table 4.3.a. No cross-talk interferences were observed, notably between AQ and its 
metabolite DAQ and their respective I.S., despite the same product ions used.  Of note, a minor 
interfering peak was observed on the LC-MS/MS trace for DAQ at a retention time 
corresponding to that of Q and Q-D3 (Figure 4.2.a). Its peak area was constant in all calibration 
levels, suggesting cross talk interference between DAQ and Q-D3, due to the identical m/z 
value of their respective precursor ions (328.3 for DAQ and 328.1 for Q-D3). Yet, thanks to the 
efficient chromatographic separation, the accurate quantification of DAQ and Q would not be 
compromised. 
No co-eluting peaks could be detected at the corresponding retention time of 
antimalarials/metabolites, when blank DBS are processed either with or without I.S. In good 
agreement with FDA guidelines, the signal-to-noise ratio at LLOQ was at least 5:1 and 20:1 of 
the mean response of the I.S. for all analytes at their respective retention times. A 
chromatogram of a DBS extract containing all analytes at LLOQ superimposed on a blank DBS 
extract are presented in Figure 4.3.a. The method is therefore sufficiently selective at the 
selected m/z transitions without significant contribution and signal cross-talks due to isotopic 
composition from I.S. to its respective analyte.   
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Figure 4-2.a: Example of a LC-MS/MS chromatogram of an extracted DBS calibration standard (one 
quarter of the highest QC, see Table 4.1.a) containing each antimalarial drug and their respective 
internal standards at the chosen concentrations (see section 4.3.3.A). Details of the LC gradient program 
and MS/MS detection are reported in Table 4.2.a and 4.3.a, respectively. 
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Figure 4-3.a: LC-MS/MS chromatogram of a DBS extract containing all analytes at LLOQ superimposed 
on a blank DBS extract. The concentrations of each analytes at LLOQ are the following: DAQ=6ng/ml; 
CQ=20 ng/ml; AQ=15 ng/ml; Q=20 ng/ml; SD=20 ng/ml; PM=2 ng/ml; MF=20 ng/ml; DLF=20 ng/ml; LF=20 
ng/ml.    
4.4.2. A) Matrix effect, extraction recovery and process efficiency  
Due to the complex nature of whole blood matrix and the generic sample preparation 
employed, most attention focused to characterize and control the matrix effects (MEs). Indeed, 
a number of endogenous components from whole blood (e.g. proteins, phospholipids, 
glucides or salts) potentially co-eluting with target analytes are likely to influence the 
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ionization efficiency of the compounds and consequently their signal intensities. The MEs were 
first examined qualitatively (Figure 4.4.a). No significant matrix effects (drift or shift of the 
signals) were noticeable for all antimalarials, with limited variabilities, as all traces at the 
retention time of analytes were superimposable. Exception were observed for Q and CQ, and 
to a lesser extent LF and DLF, whereby the signal intensity of one out of the 6 different blank 
extracts differ, underscoring the uselfulness of isotopically labelled I.S. The good 
chromatographic retention developed for antimalarial drugs was necessary to avoid massive 
signal suppression coming from early polar components contained in whole blood matrix. 
Conversely, lipophilic endogenous compounds – most probably phospholipids – that were 
eluted between 8 and 9 min appeared to perturb DLF and LF signals. An enhancement of the 
signal was also observed just after the retention times of these two compounds but due to 
the reproducibility of this effect over the 6 DBS extracts batches, no impact on quantitative 
measurements should be expected. Indeed, associated co-eluting I.S. will be affected in the 
same way and peak area ratios of the analytes to I.S. will correct for the matrix effect. 
The quantitative ME, extraction recovery (ER) and process efficiency (PE) are reported in Table 
4.4.a. Regarding ME, values above or below 100% indicate an ionization enhancement or 
suppression, respectively, due to the co-eluting matrix components. An important positive 
matrix effect for CQ and AQ was observed, whereas a negative matrix effect for Q, SD, MF, DLF 
and LF was assessed, especially at lower concentrations. Most importantly however, the I.S.-
normalization for all compounds (B2/A2 ratio in %) was comprised between 94.3% and 118.1% 
indicating a successful correction of DBS-related matrix effect.  
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Figure 4-4.a: Qualitative evaluation of the matrix effect. LC-MS/MS chromatograms of 6 blanks 
extracts obtained during post-column infusion of a matrix-free (MeOH) solution containing 7 
antimalarial drugs and 2 metabolites (each at 1µg/ml) and their respective I.S.
  
 
Table 4-4.a: Matrix effect (ME), extraction recovery (ER) and process efficiency (PE) assessment for antimalarials and metabolites. 
Compound CNominal (ng/ml) Mean peak area Mean peak-area ratio 
ME 
(%) CV (%) 
ME 
(%) 
Extraction 
ER % CV (%) 
Analysis 
ER (%) CV (%) PE % CV (%) 
  A* (n=6) B (n=6) C (n=6) A2* B2 C2 B/A  B2/A2 C/B  C2/B2  C/A  
DAQ 18 82’625 90’505 28’978 0.062 0.068 0.025 109.5 5.9 110.0 32.0 13.4 37.3 12.8 35.1 13.8 
 120 542’363 532’958 206’896 0.384 0.412 0.163 98.3 3.7 107.3 38.8 6.2 39.6 10.7 38.1 7.5 
 1200 7378’557 6’613’487 3’214’987 3.604 4.128 1.922 89.6 7.7 114.5 48.6 12.7 46.6 4.1 43.6 10.0 
CQ 60 5’432 12’463 14’362 0.068 0.080 0.087 229.4 6.6 118.1 115.2 18.8 108.7 12.9 264.4 15.6 
 400 39’161 89’572 109’004 0.481 0.495 0.564 228.7 5.5 102.9 121.7 4.9 114.0 14.0 278.3 5.9 
 4000 534’410 1’097’129 1’318’823 4.538 5.067 5.614 205.3 6.7 111.6 120.2 10.3 110.8 14.4 246.8 5.9 
AQ 45 120’824 154’284 61’106 0.027 0.028 0.012 127.7 6.4 104.4 39.6 10.8 43.1 7.7 50.6 8.9 
 300 733’633 1’033’774 458’737 0.151 0.176 0.079 140.9 4.6 116.8 44.4 8.9 44.9 10.7 62.5 11.3 
 3000 9’392’344 11’013’241 5’819’910 1.516 1.749 0.874 117.3 6.6 115.4 52.8 11.3 49.9 5.0 62.0 8.0 
Q 60 69’428 33’572 29’192 0.032 0.030 0.031 48.4 11.3 94.5 87.0 22.4 104.4 13.5 42.0 14.2 
 400 450’461 213’563 230’789 0.185 0.192 0.207 47.4 7.7 103.6 108.1 11.1 107.9 9.5 51.2 8.3 
 4000 5’866’036 2’634’814 3’030’599 1.661 1.870 2.016 44.9 6.5 112.6 115.0 14.6 107.8 9.5 51.7 10.0 
PM 60 90’255 81’396 82’330 0.017 0.016 0.017 90.2 9.5 97.0 101.1 11.3 107.2 8.4 91.2 6.0 
 400 407’602 392’467 435’589 0.093 0.103 0.111 96.3 10.4 110.1 111.0 12.0 108.1 10.7 106.9 10.7 
 4000 4’416’292 3’999’055 4’616’256 0.869 1.002 1.089 90.6 6.0 115.3 115.4 14.4 108.7 8.6 104.5 9.1 
SD 6 50’925 26’791 18’069 0.033 0.033 0.030 52.6 12.0 99.5 67.4 14.0 89.9 16.7 35.5 7.6 
 40 334’718 140’774 136’743 0.190 0.203 0.200 42.1 10.2 107.3 97.1 7.7 98.4 14.6 40.9 6.6 
 400 3’426’490 1’342’894 1’354’144 1.751 2.013 1.916 39.2 4.2 115.0 100.8 8.2 95.2 15.2 39.5 4.7 
MF 60 13’023 8’574 7’953 0.007 0.007 0.008 65.8 13.4 96.9 92.8 14.8 117.4 13.6 61.1 11.4 
 400 94’897 55’572 65’364 0.044 0.046 0.053 58.6 9.1 104.7 117.6 15.6 115.1 15.7 68.9 14.6 
 4000 829’761 451’452 592’871 0.422 0.456 0.523 54.4 4.4 108.0 131.3 13.9 114.6 13.4 71.5 15.3 
DLF 60 173’997 104’097 60’693 0.072 0.068 0.053 59.8 14.0 94.3 58.3 7.7 77.6 10.7 34.9 7.7 
 400 1’115’653 475’867 490’227 0.412 0.409 0.363 42.7 12.6 99.4 103.0 16.3 88.7 7.5 43.9 7.7 
 4000 14’962’544 6’069’955 7’562’842 3.929 4.172 4.053 40.6 10.8 106.2 124.6 12.4 97.2 7.2 50.5 5.7 
LF 60 599’395 471’095 298’327 0.061 0.057 0.040 78.6 11.6 94.3 63.3 11.0 69.6 11.4 49.8 6.7 
 400 4’685’718 3’042’437 2’759’016 0.357 0.364 0.269 64.9 8.4 101.8 90.7 8.9 73.8 19.4 58.9 4.1 
 4000 33’605’099 18’124’918 22’392’317 3.651 3.671 3.404 53.9 12.1 100.6 123.5 12.8 92.7 10.5 66.6 11.9 
*A = Matrix-free solution of analytes and I.S. in MeOH + 1%FA. A2 = internal standard-normalization using ratios of analyte peak areas to the corresponding I.S. peak area B = Blank DBS extracts 
samples spiked with antimalarials/metabolites and I.S. after extraction. B2 = internal standard-normalization using ratios of analyte peak areas to the corresponding I.S. peak area C = Complete 
procedure. C2 = internal standard-normalization using ratios of analyte peak areas to the corresponding I.S. peak area  
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The ER (C/B ratio) was comprised between 32.0% and 131.3% and was always decreased for 
low QC samples.  
The PE (C/A ratio) takes into account the extraction recovery and the matrix effect. The PE was 
especially high for CQ mostly due to the contribution of high matrix effect.  
More generally, this is not the matrix effect per se that constitutes an analytical issue, but 
rather its variability. Overall, the observed variability (CV%) for the ME, ER and PE were rather 
limited with only few values above the recommended ±15%. Thus, both the use of isotopically-
labelled I.S. and whole blood matrix-matched calibration samples were found to correct for 
most of these matrix effects, which overall would only limitedly affect calibration, trueness and 
precision.  
4.4.3. A) Calibration curve, trueness and precision 
Over the chosen ranges of concentrations (reported in supplementary Table 4.1.a), an excellent 
relationship with measured analyte/I.S. peak area ratios was observed by applying quadratic 
log-log regression.  With this model, a regression coefficient (R2) greater than 0.99 was always 
obtained and the back-calculated concentration of calibration samples were within the ±15% 
(±20% at LLOQ) margins.   
As shown in Table 4.5.a, the intra-assay precision for all antimalarial drugs and metabolites for 
all QC levels was within ±14.3% and inter-assay dispersion was ≤15.0% overall. Globally, the 
intra-assay trueness ranged from -12.1 to +11.1%, whereas from -5.2 to 9.9% for inter-assay 
measurements.  
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Table 4-5.a: Intra- and inter-assay trueness (bias%) and precision (CV%) for the analysis of 9 
antimalarials and 2 metabolites in DBS calculated for QC samples at low (L), medium (M) and high (H) 
concentrations.  
Compound  QCNominal 
(ng/ml) 
Intra-assay (n=5) Inter-assay (n=9) 
 L 
M 
H 
CMeasured (ng/ml) Trueness bias (%) (CV 
(%)) 
CMeasured (ng/ml) Trueness bias (%)   
(CV (%)) 
N-desethyl-amodiaquine 18 18.0 0.1 (10.4) 18.1 0.5 (10.6) 
 120 118.5 -1.2 ±(5.2) 124.6 3.9 (11.3) 
 1200 1326.4 10.5 ( 3.6) 1229.2 2.4 (10.2) 
Chloroquine 60 58.8 -2.0 (10.6) 57.3 -4.6 (11.3) 
 400 389.7 -2.6 (5.8) 416.8 4.2 (11.7) 
 4000 4227.4 5.7 (2.3)  4200.6 5.0 (5.4) 
Amodiaquine 45 43.4 -3.8 (12.6) 49.0 8.9 (14.4) 
 300 304.4 1.5 (8.7) 311.9 4.0 (9.4)  
 3000 3334.1 11.1 (3.2)  3117.4 3.9 (10.8) 
Quinine  60 59.7 -0.5 (4.7)  62.7 4.5 (9.11) 
 400 396.2 -0.9 (2.6) 414.4 3.6 (8.0) 
 4000 4103.0 2.6 (2.4) 4056.6 1.4 (5.9) 
Sulfadoxine 60 61.2 1.9 (6.7) 63.6 6.1 (15.0) 
 400 390.0 -2.5 (5.3) 432.7 8.2 (13.0) 
 4000 4122.3 3.1 (2.0) 4097.5 2.4 (6.3) 
Pyrimethamine 6 5.5 -9.6 (7.7) 5.7 -5.2 (13.6) 
 40 38.6 -3.5 (5.5) 41.8 4.5 (13.4) 
 400 400.9 0.2 (1.4) 401.0 0.3 (4.2) 
Mefloquine  60 61.6 2.6 (14.3) 65.9 9.9 (14.9) 
 400 419.4 4.8 (8.2) 428.8 7.2 (10.5) 
 4000 4023.6 0.6 (5.5) 4012.8 0.3 (8.0) 
Desbutyl-lumefantrine 60 57.5 -4.3 (3.3) 61.4 2.3 (6.0) 
 400 407.7 1.9 (4.9) 413.9 3.5 (5.9) 
 4000 4140.7 3.5 (2.9) 4058.2 1.5 (5.0) 
Lumefantrine 60 53.5 -12.1 (6.1) 58.3 -2.9 (9.2) 
 400 389.7 -2.6 (5.2) 392.7 -1.8 (5.1) 
 4000 3878.4 -3.0 (2.1) 3869.9 -3.2 (3.2) 
 
4.4.4. A) Sensitivity and carry-over 
The LLOQs correspond to the concentrations of the lower calibration standard, given in Table 
4.1.a. The LLOQ of PM, DAQ and AQ were 2, 6 and 15 ng/ml, respectively, and 20 ng/ml for all 
other antimalarials. The LOD (calculated according to the IDL and the injection volume) were 
the lowest for DAQ and PM at 1 ng/ml, followed by AQ, Q and CQ at 2, 5 and 7 ng/mL 
respectively. The LOD was 8 ng/ml for LF, DLF and SD, and 12 ng/ml for MQ. The carry-over 
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produced by the highest calibration sample on the following injected blank DBS extract was 
found non negligible for DLF and LF, even with a prolonged rinsing step, with residual signals 
corresponding to a carry-over of 0.64% and 0.35% of the highest calibration level, respectively. 
This 0.64% carry-over for DLF corresponds to a signal higher than the LLOQ signals peak areas. 
In the subsequent injection of blank extracts, residual DLF and LF signals decreased down to 
0.15% and 0.11%, respectively, of the peak areas of highest calibration level. For this reason, 
at least two blank samples should be programmed after the highest calibration sample prior 
to the subjects’ samples analysis series.  
4.4.5. A) Stability of antimalarials/metabolites in whole blood and in DBS 
The stability of the antimalarials/metabolites in whole blood subjected to freeze-thaw cycles 
was found to be satisfactory in whole blood calibration samples. After 2 freezing-thawing 
cycles, the mean concentrations did not deviate by more than ±15% from the nominal values 
for the L, M and H QCs, indicating that when repetitive analyses of samples are considered, 
the spiked haemolysed whole blood can be frozen and thawed at least twice (data not shown).   
Results of the short-term stability experiments for antimalarials in DBS samples (assessed to 
reflect field trial conditions whereby DBS frequently cannot be stored at negative 
temperatures) are given in Table 4.6.a. For the L, M and H QC levels, the stability was 
satisfactory with variations up to 24h not exceeding ±15.0% of the initial concentrations, 
except for SD (-17.6% at L QC). These results indicate that, taking into account the analytical 
variability, analytes can be considered sufficiently stable for at least 24h at room temperature. 
A slight decrease in concentrations was nevertheless noticed overall and for this reason, DBS 
samples should not allowed be left at ambient temperature for more than 24h. Variations of 
antimalarials concentrations in DBS stored at -20°C and -80°C (Table 4.6.a) were mostly 
comprised within the acceptable limits (±15.0%) and compounds stabilities could be hence 
considered satisfactory after 1 month, except for AQ , its metabolite DAQ and SD. Of interest, 
storage of DBS cards at -80°C instead of -20° appeared to limit the sample degradation.   
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Table 4-6.a: Stability of antimalarials and metabolites in DBS stored for 24h at room temperature (RT) 
and 37°C and for 1 month at -20°C and -80°C. Variations of QC concentrations (at L, M and H levels) are 
expressed as percentage of the concentration measured at T=0.  
 24 hours 
 RT  37°C 
  QC    QC  
 L M H  L M H 
 Variation (%) from T=0  Variation (%) from T=0 
N-desethyl-amodiaquine -1.5 -10.2 9.0  -6.6 8.2 5.5 
Chloroquine 10.9 4.6 12.2  -3.6 7.6 1.5 
Amodiaquine -8.6 0.1 11.4  -15.4 5.6 0.1 
Quinine  7.6 3.1 13.1  -16.3 10.0 4.7 
Sulfadoxine 17.6 1.5 10.1  14.8 11.6 9.5 
Pyrimethamine 12.0 0.3 10.7  3.7 6.8 5.7 
Mefloquine  4.6 2.8 16.7  -7.3 13.7 7.7 
Desbutyl-lumefantrine 0.0 -5.4 12.8  11.3 10.9 12.1 
Lumefantrine 4.7 -0.9 5.6  6.7 8.6 3.9 
 1 month 
 -20°C  -80°C 
  QC    QC  
 L M H  L M H 
 Variation (%) from T=0  Variation (%) from T=0 
N-desethyl-amodiaquine -27.5 -5.0 -18.7  -27.8 -13.5 -13.7 
Chloroquine 10.0 9.0 12.0  9.8 5.5 -0.5 
Amodiaquine -24.4 -12.4 -10.6  -3.6 -4.7 -6.0 
Quinine  15.2 -12.1 8.9  7.4 9.8 12.8 
Sulfadoxine -21.7 -19.6 -18.8  -9.6 -19.4 -8.8 
Pyrimethamine 2.7 -3.7 -8.4  3.8 0.7 -1.4 
Mefloquine  8.5 -7.4 4.9  1.2 8.9 16.5 
Desbutyl-lumefantrine 14.8 6.3 -9.1  -0.6 -5.9 3.2 
Lumefantrine -13.7 6.4 7.7  -6.4 5.8 13.8 
 
4.4.6. A) Influence of punching location, blood spot volume and haematocrit on DBS 
analysis  
Overall, the bias between concentrations (mean of 6 values) measured in the paper disk 
punched out from the centre, intermediate, and outer zone of DBS did not exceed ±15.0 % 
with the exceptions of DAQ (-17.9%), AQ (-17.6%) and MF (17.5%) at low QC level  and LF (-
21.4%) at high QC level, when measured in the border of blood spot. Hence, for minimizing 
analytical variability, it is recommended to rigorously punch out the paper disk in the centre 
of DBS. 
52      CHAPTER IV: ANTIMALARIAL DOSAGE IN DRIED BLOOD SPOTS 
 
The volume of blood spotted onto the DBS cards impacted the measured concentrations. For 
each analyte, the concentrations measured with 5 µl were systematically lower, with a bias 
ranging from -3.6% (low QC for CQ) to -24.6% (medium QC for LF). Conversely, the 15-µl 
blood spots resulted in higher concentrations with a bias ranging from +0.5% (high QC for Q) 
to +35.7% (low QC for CQ).  
As reported in Table 4.7.a, the measured concentrations of all analytes increased significantly 
with increasing haematocrit (p<0.05 for all QCs, except for H QC of DAQ, M QC of AQ and  MF 
and L QC of DLF). The concentrations of all antimalarials/metabolites deviated by more than 
±15% across the entire considered haematocrit range, using 40% as reference haematocrit.   
 
Table 4-7.a: Influence of haematocrit values on the measured DBS concentrations. Differences are 
expressed as the bias (%) between the DBS concentrations measured with each haematocrit value and those 
measured with a 40% haematocrit, used as reference. P-values were measured by linear regression.  
Compound QC level 
Haematocrit value  
p-
value* 
40% 
(reference) 
25% 30% 35% 45% 50% 
CMeasured 
(ng/ml) 
CMeasured 
(ng/ml) 
Bias 
(%) 
CMeasured 
(ng/ml) 
Bias 
(%) 
CMeasured 
(ng/ml) 
Bias 
(%) 
CMeasured 
(ng/ml) 
Bias 
(%) 
CMeasured 
(ng/ml) 
Bias 
(%) 
DAQ L 29.7 21.3 -28.3 23.6 -20.6 25.7 -13.3 32.7 10.3 33.4 12.6 <0.001 
 M 193.7 132.4 -31.7 149.2 -23.0 198.7 2.6 188.7 -2.6 195.7 1.1 0.049 
 H 1576.0 1127.6 -28.4 1425.2 -9.6 1258.1 -20.2 1511.9 -4.1 1558.0 -1.1 0.052 
CQ L 73.8 57.8 -21.7 54.5 -26.1 59.5 -19.4 74.3 0.8 81.5 10.5 0.007 
 M 407.6 357.8 -12.2 308.5 -24.3 344.8 -15.4 412.1 1.1 458.1 12.4 0.027 
 H 7276.6 6315.6 -13.2 6219.1 -14.5 7484.5 2.9 7777.7 6.9 8297.2 14.0 0.006 
AQ L 47.5 41.8 -12.0 35.5 -25.3 35.8 -24.7 50.3 5.8 54.1 13.7 0.049 
 M 293.3 271.2 -7.5 236.8 -19.3 223.0 -24.0 310.1 5.7 342.4 16.8 0.076 
 H 5304.0 4630.4 -12.7 4455.6 -16.0 5059.1 -4.6 5569.7 5.0 5710.4 7.7 0.003 
Q L 66.0 53.1 -19.6 51.9 -21.4 56.1 -15.1 69.9 5.9 75.2 13.9 0.002 
 M 420.8 362.5 -13.8 308.2 -26.8 357.7 -15.0 436.0 3.6 480.8 14.3 0.019 
 H 7345.4 6209.7 -15.5 6104.4 -16.9 7306.5 -0.5 7664.4 4.3 8242.4 12.2 0.004 
PM L 6.6 5.9 -11.1 5.6 -14.8 6.7 1.5 7.1 7.6 7.9 19.2 0.006 
 M 42.1 32.4 -23.0 35.0 -16.9 41.1 -2.2 43.7 3.8 43.7 3.9 0.007 
 H 414.5 321.4 -22.5 365.7 -11.8 351.5 -15.2 434.9 4.9 439.1 6.0 0.004 
SD L 66.0 56.8 -13.9 54.9 -16.8 59.9 -9.3 68.6 4.0 80.5 22.0 0.006 
 M 434.2 387.9 -10.7 322.2 -25.8 363.3 -16.3 440.3 1.4 471.1 8.5 0.050 
 H 7348.7 6225.6 -15.3 6281.2 -14.5 7097.1 -3.4 7540.4 2.6 8056.9 9.6 <0.001 
MF L 68.9 59.7 -13.4 55.7 -19.1 66.5 -3.5 71.7 4.0 74.1 7.4 0.009 
 M 428.6 387.3 -9.6 321.3 -25.0 357.7 -16.5 419.6 -2.1 465.4 8.6 0.069 
 H 7425.4 6587.3 -11.3 6520.0 -12.2 7375.8 -0.7 7449.7 0.3 8027.5 8.1 0.007 
DLF L 77.2 71.4 -7.5 69.9 -9.5 77.3 0.1 91.3 18.3 78.5 1.6 0.120 
 M 532.3 454.0 -14.7 481.0 -9.6 541.1 1.7 578.0 8.6 543.0 2.0 0.030 
 H 4692.2 3840.5 -18.2 4230.2 -9.8 4214.9 -10.2 4909.1 4.6 4782.1 1.9 0.006 
LF L 94.4 86.1 -8.8 85.8 -9.2 91.2 -3.4 105.9 12.1 97.5 3.2 0.034 
 M 551.6 462.1 -16.2 494.3 -10.4 553.2 0.3 582.3 5.6 547.7 -0.7 0.042 
 H 5117.8 3942.7 -23.0 4401.0 -14.0 4505.8 -12.0 5229.5 2.2 5221.0 2.0 0.003 
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4.4.7. A) Lumefantrine measurements in plasma, DBS and erythrocytes in healthy 
volunteers   
The relationship between concentrations of LF measured in DBS and in plasma was examined 
at different time-points after the administration of a single oral adult dose of artemether-
lumefantrine. As shown in Figure 4.5.a, LF concentrations measured in plasma and in DBS over 
all time points were highly correlated (R=0.97). This excellent correlation was especially found 
for concentrations below 600 ng/ml (close-up insert in Figure 4.5.a), which were measured in 
the latest samples (i.e. taken up to 72 to 336 hours after single drug dose intake). In the Bland-
Altman analysis plot (Figure 4.6.a), the geometric mean ratios of LF concentration in DBS 
versus plasma was 0.57 (95% Confidence Interval: 0.55-0.59), which was also supported by the 
linear regression slope (Figure 4.5.a). The percentage ratios were generally consistent across 
concentrations and had an acceptable variation.  
 
 
Figure 4-5.a: Relationship between total plasma and DBS concentrations of LF simultaneously 
measured in healthy volunteers over 14 days after drug intake. A zoom on the lower concentration range 
(0-600 ng/ml in plasma) is reported. 
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Figure 4-6.a: Bland-Altman plot for total plasma and DBS concentrations of LF on a logarithmic scale, 
simultaneously measured in healthy volunteers over 14 days after drug intake. The solid line represents 
the mean ratio, while the dotted lines the 95% CI of agreement (mean ratio ± 1.96 x SD).  
The concentrations of LF measured in erythrocytes were less well correlated either with DBS 
(R=0.88) and with plasma (R=0.87) (data not shown). We found that the washing procedure 
significantly impacted LF concentrations results in red blood cells, which corresponded to 3.6% 
and 9.0% of plasma levels, respectively, when erythrocytes were subjected or not to the NaCl 
0.9% washing step. Figure 4.7.a shows the chromatographic profiles of LF and DLF determined 
in DBS and plasma samples collected from one healthy volunteer who participated in the 
clinical pharmacokinetic study in Switzerland 24 hours after receiving a single adult dose of 
artemether-lumefantrine (Riamet®). Measured concentrations in DBS were 1161 ng/ml and 
50 ng/ml, for LF and DLF, respectively (Figure 4.7.a, left), and 2059 ng/ml and 10 ng/ml for LF 
and DLF, respectively, in plasma (Figure 4.7.a, right).  Of note, because only LF and DLF were 
measured in this pharmacokinetic study, the chromatographic program has been adapted to 
speed-up the chromatographic separation step (7 min instead of 12). 
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Figure 4-7.a: LC-MS/MS chromatogram of a DBS sample (left) and the corresponding –associated - 
plasma sample (right) from a volunteer receiving artemether and lumefantrine (as Riamet®; details 
in the manuscript). 
4.4.8. A) Epidemiological applications 
This analytical method was applied in a cross-sectional survey for measuring residual 
antimalarial drugs concentrations in 6485 DBS samples collected in a field trial in Tanzania. 
Only concentrations higher than LLOQ were considered positive for the epidemiological 
analysis. Figure 4.8.a shows representative examples of chromatograms from positive DBS 
samples extracts collected during the field study (through household surveys) in which PM, 
SD, DLF, LF and DAQ, CQ, AQ, Q, PM, SD, MF were detected. The full results and data analysis 
of the epidemiological study will be reported elsewhere (CHAPTER V, VI).  
 
 
 
DLF DLF 
DLF-d9 DLF-d9 
LF LF 
LF-d9 LF-d9 
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Figure 4-8.a: LC-MS/MS chromatogram of a processed DBS sample collected during a field trial in 
Tanzania containing A) SD (3812 ng/ml), PM (22 ng/ml), DLF (23 ng/ml) and LF (1560 ng/ml) (left) 
and their corresponding internal standards (right) and B) DAQ (7 ng/ml), CQ (32 ng/ml), AQ (18 
ng/ml), Q (40 ng/ml), SD (43 ng/ml), PM (4 ng/ml) and MF (35 ng/ml) (left) and their corresponding 
internal standards (right).  
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4.5. A) Discussion & conclusion  
We developed a sensitive LC-MS/MS assay for the simultaneous analysis of 7 antimalarials 
and 2 active metabolites in DBS. Thanks to the excellent chromatographic separation, to the 
high selectivity of tandem mass spectrometry detection and to the availability of stable 
isotopically-labelled I.S., this analytical method offered the convenience of a single extraction 
procedure from a 3-mm diameter disk paper card with MeOH + 1% FA. To our knowledge, 
this is the first method that considers the multiplex analysis of 9 antimalarials/metabolites 
simultaneously in DBS with the required selectivity, trueness and precision.  
Overall, both precision and trueness of the lowest calibration standard (corresponding to the 
LLOQ) were within the ±20% limit recommended by the FDA for all antimalarials. These LLOQ 
values were generally higher than those reached in plasma [131], but still remained lower than 
those from the single previously published  LC-MS/MS method employing ion-trap MS 
detection for multiple antimalarials in DBS [113]. The proposed assay was found suitable for 
the analysis of residual antimalarials in DBS samples collected in a large-scale cross-sectional 
survey in Tanzania. The high sensitivity of the method was a key element for the assessment 
of residual antimalarial drug exposure at a population level in the context of epidemiological 
studies. Indeed, very low residual concentrations are encountered in a large number of 
samples, which could be analysed without the need of tedious sample preparation.  
The good stability of antimalarials in whole blood after 2 freeze-thaw cycles indicates that 
haemolysed whole blood is suitable for preparation and storage of calibration curves, even 
though some authors have recommended to use fresh whole blood for the preparation of 
matrix-matched calibration samples, not always available on demand [93,127,154]. Short and 
long term stability assays indicated that DBS samples can be kept at room temperature for up 
to 24h and should be transferred without delay at -80°C, where they can be stored for a 
prolonged time prior to analysis.    
In contrast with previous examples reported in the literature [155], the matrix effect in our 
hands appeared to depend on the matrix-to-analyte concentration ratio, explaining why the 
signal enhancement found for CQ and AQ was especially important at low concentrations. The 
recovery appeared to be lower than previously reported for plasma [131] with a similar 
extraction method. Irreversible adsorption of analytes onto the solid filter paper support might 
be possibly incriminated [156], as the recovery assessment in method validation implied the 
addition of antimalarials into liquid blank DBS extracts (i.e. spiked after DBS extraction). Yet, 
the present recovery rates were satisfactory given the large number of drugs extracted 
simultaneously and the convenience of the process. Adsorption phenomenon onto the filter 
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paper appears to be a saturable process as it especially affects low QC levels while having less 
impact on high concentration QCs.  The repeatability of extraction recoveries between all QC 
levels was improved after I.S.-normalization. Of note, extraction recoveries for CQ, Q, PM, MF, 
DLF and LF were found in some instances to exceed 100%. A potential explanation could derive 
from calculations of nominal drugs concentrations in solutions B, which were based on the 
extrapolated volume of whole blood contained in the 3-mm filter paper punched disk, 
assuming that blood and analytes were evenly distributed within the 10-µl DBS. However, as 
shown in section 3.7, there was a heterogeneous drug distribution within the blood spot, and 
the concentrations spiked after extraction might therefore have been underestimated. It must 
be acknowledged that since the I.S. were not spotted onto the DBS card with the blood sample 
but were only contained in the extracting organic solvent, they did not confidently reflect 
every step of DBS solid state extraction of target analytes from paper cards. Yet, their use 
remains key element to normalize matrix effect variability that potentially detrimentally affects 
performance analysis of particularly complex biological extracts.  
The DBS sampling technique offers many advantages including facilitated logistics especially 
suitable for field trials. However, its advantages must be weighed against the degree of 
potential uncertainty associated with DBS sampling methods [157]. In our assay, the 
concentrations in DBS were shown to be influenced by the volume of blood spotted onto DBS 
cards and the so-called “chromatographic” effect occurring after blood spot deposition. In 
fact, the studied compounds appeared to interact with the solid DBS card material during the 
transfer of the drop of whole blood. These results underscore the need of precise sample 
pipetting when collecting blood as DBS for accurate measurements. For the sake of 
standardisation, it is therefore recommended to punch paper disk rigorously at the same 
location within DBS (ideally, the centre). While those parameters can be controlled during 
blood collection and analysis, the impact of haematocrit on drug concentrations, although 
apparently more trivial, is not a factor that can be easily normalized during field trials. 
Haematocrit normally ranges from 41-51% for men and 37-47% for women [158]. Yet 
particular attention should be paid to individuals suffering from malaria, as they are likely to 
have lower haematocrit values, due to significant red blood cells lysis after protozoan 
multiplication. For example, an emblematic symptoms of malaria is anaemia with haematocrit 
<30% [159]. Consequently, blood viscosity and hence the rate and extent of diffusion of blood 
onto the filter paper after blood drop deposition can be affected. This in turn would mean 
that smaller amounts of blood per punched disk will be available for analysis, leading to 
spuriously low measured drug concentrations. Ideally, haematocrit value should be measured 
and recorded for each enrolled subject.  For more accurate measurements, the haematocrit 
value of DBS calibration samples should be standardized according to study population. 
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Moreover, the haematocrit effect could be circumvented by analysing the entire DBS, as long 
as a defined and reproducible volume of blood is spotted on the filter paper card [92].   
A critical part of the method optimisation was the reduction of carry-over, a current issue when 
analysing basic lipophilic compounds such as DLF and LF because of their tendency to get 
strongly adsorbed onto various components of the LC system (i.e. injection valve and syringe) 
as well as onto the reverse-phase chromatography packing of the column. The efficiency of 
the washing program of the injection syringe was hence finally improved by adding 1% of FA 
into the two different washing solutions (MeOH/H2O 1:1 + 1% FA and ACN + 1% FA). The 
carry-over was mainly reduced by programming a prolonged rinsing step of the LC-MS system 
with 1 min of ACN (1000 µl/min) followed by 2 min of isopropanol (500 µl/min) and again 1 
min of ACN (1000 µl/min) at the end of each analysis. However, the level of carry-over currently 
remains an important limitation and it implies that future samples following highly 
concentrated samples should be systematically re-analysed if concentration of DLF show 
higher than the LLOQ in blank analysis. Alternatively, when the analysis of DBS samples 
collected over an entire dosing interval (i.e. for PK studies) will be considered, it will be advised 
to program the analytical sequence in reverse chronological order (i.e. by injecting the late -
low levels- samples first) for overcoming carry-over issue. The long analytical time – at the 
current UHPLC (ultra-high performance liquid chromatography) era – due to the prolonged 
but necessary rinsing step represents another limitation of the present method.   
A comparison between simultaneous plasma and DBS concentrations is recommended as part 
of the assay method validation, and a good correlation between both measurements is 
required before giving  trust to the quantitative analysis [93]. An excellent correlation was 
actually found between LF concentrations measured in DBS and those determined in parallel 
in plasma samples. However, the concentrations measured in both matrices were not identical 
(i.e the slope was not equal to 1.0). Our observations indicate that LF is predominantly 
distributed in the plasma, as LF concentrations measured in separated red blood cells pellets 
were remarkably low, while differing significantly (i.e. 3.6% vs 9.0% of plasma levels) depending 
on whether erythrocytes were subjected or not to a washing procedure with NaCl 0.9% (to 
remove interstitial remnant plasma). These results were in line with a prior in vitro study using 
radio-labelled tracers, in which the fraction of LF in erythrocytes was around 10% of plasma 
using the erythrocyte partitioning method (no wash of erythrocytes) [160,161]. We found 
previously that the volume of residual plasma trapped between red blood cells after a single 
centrifugation corresponds to 11.2 ± 2.7% of the total volume of the erythrocytes [162]. Thus, 
the concentration of LF measured in erythrocytes collected without washing in our healthy 
subjects was elevated essentially due to LF emanating from residual plasma present in the 
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erythrocytes layer. In our study, the mean haematocrit value for healthy volunteers was 41% 
(i.e. a 10-µl whole blood spotted onto DBS card would correspond to 4.1 µl of erythrocytes 
and 5.9 µl of plasma), while LF levels in DBS were about 0.6 times lower than those measured 
in plasma, confirming that plasma contributes for essentially all the LF measured in DBS. Our 
results are thus in good accordance with the formula suggested by Eyles et al.  for correlating 
analytes concentrations between plasma and DBS [163]. This suggests that the fraction of LF 
that reaches its site of action – expected to occur mostly inside cells wherein the drug inhibits 
the intraerythrocytic development of the Plasmodium [87,88] – is remarkably low but yet 
sufficient to inhibit parasites growth. Of note, LF circulates in two forms in plasma: a fraction 
bound (99.7%) to plasma proteins and the remainder unbound (free). Total plasma LF levels 
have been determined in our study, while only the unbound LF fraction is likely to diffuse into 
tissues equilibrate with cells to exert its pharmacological activity. Our in vivo study focused on 
LF because it is the most widely antimalarial used in combination with artemisinin derivates in 
Tanzania. A literature review presented all analytical strategies to determine antimalarials in 
bio fluids [164] but none of the studies included in this article compared plasma and DBS 
concentrations. One [127] showed a good correlation between Q concentrations measured in 
DBS and in whole venous blood and one [116] showed a good correlation between AQ and 
DAQ concentrations measured in whole venous blood and whole venous blood spotted onto 
filter paper cards. Another older study showed that MF concentrations in serum where 
significantly higher than in whole blood with a mean ratio of 1.28 and a good correlation 
between both type of measurements [165].   
This sensitive LC-MS/MS method, enabling the simultaneous analysis of 7 antimalarial drugs 
and 2 active metabolites in DBS is suitable for measuring drug exposure in a population. 
Furthermore, to the best of our knowledge, no PK/PD studies have yet been realized using LF 
concentrations measured in DBS. The present study provides therefore useful information to 
perform an indirect extrapolation based on DBS/venous LF levels comparison. A recently 
published meta-analysis from Study Group of the WorldWide Antimalarial Resistance Network 
(WWARN) showed that the principal determinant of treatment outcome is the plasma 
concentration of LF at day 7, with plasma values >200 ng/ml being associated with >98% cure 
rates in most uncomplicated malaria patients [38]. Lower concentrations are predictive of 
treatment failure. Moreover, at such sub-therapeutic levels, the parasite’s susceptibility to LF 
decreases, therefore offering favourable conditions for the development of resistance. When 
tested in vitro, 99% of P. falciparum isolates from Tanzania were inhibited at 60 ng/ml and 
100% at 159 ng/ml [166]. This additional level of complexity brought by protein binding has 
also to be addressed when considering general comparisons between in vivo PK and in vitro 
sensitivity tests results.  
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In conclusion, knowledge of the excellent correlation and of the ratio between plasma and 
DBS levels of LF is of importance for field trials aiming at assessing actual circulating 
concentrations of this antimalarial at a population-wide scale, and their potential relationship 
with the emergence of parasite resistance.  
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4.1. B) Introduction 
The current sampling standard for drug measurement is blood withdrawn by venous puncture, 
that needs to be centrifuged prior to plasma collection and storage generally in the frozen 
state. In comparison, the use of the dried blood spots (DBS) sampling strategy can make some 
aspects of field trials conditions more convenient, for example easier sampling technique, 
lighter transportation, and cheaper storage of samples. A recently published meta-analysis 
including 21 studies on the pharmacokinetics (PK) and pharmacodynamic relationships of 
artemether-lumefantrine, showed that the principal determinant of treatment outcome is the 
plasma concentration of lumefantrine (LF) at day 7, where values >200 ng/ml have been 
associated with >98% cure rates in most uncomplicated malaria patients [167]. Conversely, 
lower concentrations are predictive of treatment failures and through the exposition to such 
sub-therapeutic concentrations for a prolonged period, parasite’s susceptibility to LF 
decreases opening the way to resistance development. In CHAPTER IVa, a good correlation, 
albeit not identity, was observed between LF concentrations measured in plasma and in DBS. 
These results called for more detailed characterization of the PK profile of LF in DBS in order 
to explore the impact of DBS sampling on LF PK parameters. This will help assessing to what 
extent this sampling method could be used as a good surrogate to plasma measurements in 
efficacy studies or in the frame of population PK of antimalarials in field studies.   
4.2. B) Materials and methods 
The present investigation was a prospective open-label one-group interventional study. The 
clinical study was approved by the “Commission cantonale d’éthique de la recherche sur l’être 
humain” of Canton de Vaud (CER-VD), Switzerland. A total of 16 healthy male and female 
subjects aged 18-45 years and with a body mass index (BMI) within 18-29 kg/m2 range were 
included in the study. Detailed inclusion and exclusion criteria are detailed in Appendix 1. 
Written informed consent was obtained from all subjects before enrolment in the study. All 
the participants received a single adult dose of artemether-lumefantrine [Riamet® (Novartis 
Pharma Schweiz AG)], corresponding to 4 tablets of 20 mg artemether and 120 mg LF. 
Capillary and venous blood sampling was made in parallel at 11 time points including the 
blood collection at time 0 and up to hour 336 (14 days) after drug intake. Venous blood was 
collected by venous puncture in 4.9 ml tubes containing citrate as anticoagulant. The tube was 
centrifuged at 2000g for 10 min at 4°C and the collected plasma kept at -80°C. Capillary blood 
was obtained by fingerprick and collected into a graduated heparin-coated capillary tube. 
Three 15 µl drops of capillary blood were applied next to each other onto a DBS card which 
were allowed to dry at least 2 hours at room temperature before being stored at -80°C. LF 
concentrations in plasma and in DBS were measured within the next month using a liquid 
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chromatography coupled to tandem mass spectrometry (LC-MS/MS) assay described in 
CHAPTER IVa.   
The PK analysis of LF in plasma and DBS was performed separately using a nonlinear mixed-
effects modelling approach (NONMEM®, version 7.4.1). This approach allows to estimate 
population means and variances of the PK parameters and to identify factors influencing them 
[168]. Neither of the previously published models was found to be suitable to depict our data 
as they either used a one-compartment model, included children or pregnant women with 
malaria, or were not sufficiently described [168–174]. One- and two-compartment PK 
structural models were tested. The half-life and AUC of LF were calculated using the final 
model parameters estimates. We then simulated 1) predicted LF concentrations in DBS and in 
plasma over 336 hours for 1000 individuals after a single dose intake and 2) predicted LF 
concentrations in DBS over 1080 hours (45 days)  for 1000 individuals after a full artemether-
lumefantrine course (6 doses at hours 0, 8, 24, 36, 48 and 60). RStudio (version 3.4.0) was used 
to output descriptive PK analysis and plots. Covariate analysis, including testing body weight, 
hematocrit and plasma protein binding, will be performed at a later stage.  
4.3. B) Results and discussion 
In total, 8 males and 8 females aged from 24 to 36 years were included in our study. The two-
compartment model was chosen as it described most adequately the data [170,171]. The final 
parameters estimated by the model were systemic apparent clearance (CL/F), inter-
compartmental apparent clearance (Q/F), apparent central volume of distribution (Vc/F), 
apparent peripheral volume of distribution (Vp/F) and apparent absorption rate constant (ka). 
One volunteer out of the 16 was excluded from the present analysis due to outlying apparent 
central volume of distribution (Vc/F). At this step of the analysis, we decided to construct the 
model without this individual as the difference in central volume of distribution could be 
explained by the influence of a covariate which hindered the fit of our structural model. As 
shown in Figure 4.1.b, DBS and plasma half-life of LF at individual level (for each of the 15 
healthy volunteers) showed a strong correlation (R=0.97) and a good agreement between LF 
half-life in plasma and in DBS (slope of the regression=0.98).  
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Figure 4-1.b: Relationship between LF half-life in DBS and in plasma calculated at individual level (in 
16 heathy volunteers) using parameters estimated with NONMEM®.  
 
The average Cmax (maximum concentration), AUC (area under the curve) and half-life for LF 
in DBS and in plasma as well as a simulated PK profile after a single adult dose intake are 
presented in Table 4.1.b and Figure 4.2.b, respectively. Cmax measured in plasma (4111.2 
ng/mL, 95% CI: 3858.8 - 4310.9) was higher than that measured in DBS (2416.0 ng/mL, 95% 
CI: 2230.6 - 2556.1) but half-life was equivalent [101.9 hours (97.1-106.7) when measured in 
plasma versus 103.6 hours (96.7-110.4) in DBS]. These values are similar to those obtained 
from plasma in the literature [171,172,174], although this study was conducted with healthy 
volunteers. As a result, because the difference between DBS and plasma PK profiles is due to 
higher apparent concentrations in plasma but are eliminated at the same rate, AUC obtained 
from plasma measurement was higher. The DBS/plasma AUC ratio of 0.57 was very close to 
the blood/plasma ratio of 0.56 obtained using linear regression and Bland-Altman approach 
(CHAPTER IVa), indicating that our model fitted well our data. This ratio is expected since the 
apparent difference in PK parameters between DBS and plasma measurements is due to the 
predominant distribution of LF in the plasma. Erythrocytes occupy 41% (mean haematocrit 
value for healthy volunteers) of the volume in the blood compartment explaining why LF 
concentrations in DBS were about 0.6 times lower than those measured in plasma. This also 
implies that LF elimination rate is not affected by this phenomenon.   
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Table 4-1.b: Summary of LF pharmacokinetic parameters measured in DBS and in plasma 
Dose 
Measured in DBS Measured in Plasma AUC 
DBS:Plasma 
ratio 
Cmax 
 (ng/mL) 
Half-life 
(hours) 
AUC 
(mg*h/L) 
Cmax 
 (ng/mL) 
Half-life 
(hours) 
AUC 
(mg*h/L) 
Single 
dose of 
LF 480 
mg 
2416.0 
(2230.6 - 
2556.1) 
103.6 
(96.7-110.4) 
65.6 
(55.6 -
75.7) 
4111.2 
(3858.8 - 
4310.9) 
101.9 
(97.1-
106.7) 
114.5 
(99.5-
129.4) 
0.57 
(0.55-0.59) 
 
Figure 4.2.b illustrates well these parameters, with a higher Cmax for LF measured in plasma 
and parallel terminal concentrations on a log-scale, indicating the similar half-life of LF 
obtained using the two sampling methods. This figure also demonstrates the long terminal 
half-life of LF due to the elimination of the drug from the peripheral compartment. Due to the 
highest sensitivity of the measurements in plasma (resulting in a lower limit of detection), the 
concentrations of LF will be detectable for a longer period in plasma than in DBS.     
 
Figure 4-2.b: Estimated pharmacokinetic profiles of LF in DBS and in plasma after administration of a 
single adult dose of artemether-lumefantrine (480 mg of LF). The solid lines represent the median 
population prediction and the transparent margin represent the 95% prediction interval. The insert represent 
the same profiles on a log-scale.  
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In order to assess the day on which LF levels in DBS would become undetectable after a full 
artemether-lumefantrine course, predicted LF concentrations were simulated for 1000 
individuals using the parameters obtained with the two-compartment model over 1080 hours 
(45 days). The median time point on which LF became undetectable for the 1000 individuals 
was 624 hours (26 days) and ranged from 360 hours (15 days) to 1056 hours (44 days). These 
estimations show the important inter-individual variability in LF concentrations [168] and that 
residual levels of LF can persist in the blood for a considerable amount of days therefore 
offering favorable conditions for the development of parasite resistance. At 720 hours (30 
days), 23% of the individuals had concentrations above the analytical method’s limit of 
quantification (LOQ) of 20 ng/mL (CHAPTER IVa). This is a valuable information as it indicates 
that a one-month record is a valid estimate to compare history of drug intake and drug 
measurements in epidemiological studies (although usually a two-weeks recall period is used 
for history of fever).   
4.4. B) Conclusion  
The current work validates the use of DBS to measure LF concentrations in field trials 
conditions. This study shows the feasibility of PK models and therapeutic drug monitoring 
using DBS. This is of importance given the fact that these fields have a wide potential to be 
explored, especially for infectious and parasitic diseases in developing countries.  A refined PK 
analysis will be performed at a later stage to describe LF distribution in blood compartments 
using plasma proteins binding, hematocrit, erythrocyte and whole blood concentrations, 
aimed at improving our understanding of LF distribution in the blood compartments.  
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5.1. Abstract  
Background 
Monitoring the impact of case management strategies at large scale is essential to evaluate 
the public health benefit they confer. The use of methodologies relying on objective and 
standardized endpoints such as drug levels in the blood should be encouraged. We evaluated 
population drug use, diagnosis and treatment appropriateness in case of fever according to 
patient history and antimalarials blood concentration.  
Methods 
A cross-sectional survey took place between May and August 2015 in three regions of 
Tanzania with different levels of malaria endemicity. Interviews were conducted and blood 
samples were collected by dried blood spots through household surveys for further 
antimalarial measurements. Appropriate testing when individuals attended care was defined 
as a patient with history of fever being tested for malaria and appropriate treatment as i) 
having antimalarial in the blood if the test result was positive ii) having antimalarial in the 
blood if the person was not tested, and iii) no antimalarial in the blood when the test result 
was negative. 
Results 
Amongst 6391 participants included in the antimalarial analysis, 20.8% (1330/6391) had 
antimalarial drug detected in the blood. Only 28.0% (372/1330) of the individuals with 
antimalarials in their blood reported the use of antimalarials within the previous month. 
Amongst all participants, 16.0% (1021/6391) reported having had a fever in the previous two 
weeks and 37.5% of them (383/1021) had detectable levels of antimalarials in the blood. Of 
the individuals who sought care in health facilities, 69.4% (172/248) were tested and 52.0% 
(129/248) appropriately treated. When other providers were sought, 6% (23/382) of the 
persons were appropriately tested and 44.2% (169/382) appropriately treated. Overall, the 
proportion of individuals treated was larger than that being tested [47.3% (298/630) treated, 
31.0% (195/630) tested].  
Conclusion  
Our study showed high prevalence of circulating antimalarial drug in the sampled population. 
Efforts should be made to increase mRDT use at all levels of health care and improve 
compliance to test result in order to target febrile patients that are sick with malaria and 
reduce drug pressure. Objective measurements collected at community level represent a 
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reliable tool to evaluate overall impact of case management strategies on population drug 
pressure.   
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5.2. Introduction 
The implementation of artemisinin-based combination therapies (ACTs) and malaria rapid 
diagnostic tests (mRDTs) has been a cornerstone in the management of fever cases. These 
tools are essential components of the current global malaria control strategy [1,8,175].  In 
Tanzania, a good coverage of preventive and curative interventions, including the distribution 
of insecticide-treated nets and the adoption of ACTs as first-line therapy, has led to a decrease 
in the number of malaria cases of more than 75% between 2000 and 2015 [6]. Considerable 
efforts have been made to expand access to effective antimalarials in the public and private 
sector. In 2014, Tanzania has reported that sufficient ACTs had been distributed across the 
country to treat all patients attending public health facilities [20]. Malaria rapid diagnostic tests 
(mRDTs) have also been deployed to reach half of the population so far, and health workers 
have been trained in using them [6,103]. Recent surveys have reported that availability of 
malaria testing was 83% in the public sector where more than 70% of the suspected cases 
were tested [6,176]. This was not the case in the private sector where there was only 16% of 
testing available [176]. Diagnosis availability and compliance to diagnosis results are major 
factors to reach rational use of treatments. Although the Tanzania National Malaria Control 
Programme (NMCP) case management policies, recommended by the World Health 
Organization (WHO) requires parasitological confirmation of malaria prior to treatment for 
patients of all ages, there are concerns that many patients with malaria do not receive ACTs 
while others suffering from non-malaria fever do. This indicates that treatments are not always 
targeted to those in need [1,103,175]. While under-treatment needs to be addressed with 
improved access to drugs, over-treatment due to non-availability of malaria tests or lack of 
expertise of clinicians in the management of non-malaria fevers has becomes a concern 
increasingly important, especially with global decrease in proportion of febrile illnesses due 
to malaria [24,32]. Incorrect malaria prescriptions result in wastage of medication, delays in 
obtaining effective treatment for the true cause of illness, important drug pressure in the 
population [19] and hence emergence of parasite resistance to drugs [11].  
Monitoring case management strategies and evaluating their impact are important activities 
to ensure that they confer the foreseen individual and public health benefit they are supposed 
to. To that end, interviews targeting caretakers of small children in community based cross-
sectional surveys as well as data collection in health facilities or in the retail sector have been 
used to estimate levels of access to good quality drugs and the impact of mRDTs use on drug 
prescription  [20,41,42,103,177]. These studies inherently suffer from potential biases, such as 
recall bias and inaccurate reporting due to fear to be judged or fear of not being appropriately 
cared for [47].  They are also more likely to detect a positive effect since they are usually 
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conducted in places where intense training and supervision have been undertaken, or are 
biased due to the Hawthorne effect [48]. Two studies conducted in Tanzania and in Cambodia 
showed that self-reported history is not reliable in terms of actual drug use. Indeed, 75% of 
patients presenting in a health facility in Tanzania and 50% in Cambodia had detectable 
concentrations of antimalarials in the blood, although all stated that they did not take any 
drug in the previous month [49,50]. Besides recourse to public health facilities, febrile patients 
often seek care in the private sector, and especially so among drug retailers that are usually 
prohibited to sell and perform mRDT testing which is the case in Tanzania, except for 
registered accredited drug dispensing outlets (ADDOs) [19,20,32,178,179]. As a result, a 
considerable amount of patients are prescribed antimalarial treatments presumptively. For all 
these reasons, the overall impact of the implementation of mRDTs and ACTs is difficult to 
assess precisely. There is a need to apply more rigorous and reliable methodologies to 
evaluate the appropriateness of case management for fever episodes at large scale. The aim 
of this study was to use antimalarials blood levels as an objective and standardized endpoint 
to evaluate population drug use, to compare these results with self-reported history, and to 
assess diagnosis and treatment appropriateness in case of fever episode at population level.        
5.3. Materials and methods 
5.3.1. Study design  
This cross-sectional survey included three types of surveys conducted concurrently in 
randomly selected wards (which is the smallest administrative area and includes five to seven 
villages):  1) household-based surveys, 2) drug outlet-based surveys and 3) exit interviews in 
health facility-based surveys.   
5.3.2. Study areas and population 
The surveys took place in 2015, after the rainy season in  three regions of Tanzania: Mtwara, 
Mwanza and Mbeya with populations of 1 270 854, 2 772 509 and 2 707 410 respectively [104]. 
The IMPACT2 project [20], whose main objective was to assess the impact of the Affordable 
Medicines Facility-malaria (AMFm) initiative on the supply and demand of ACTs, served as a 
basis for the choice of the regions in this study. In this study performed in 2012, the level of 
malaria prevalence amongst all age groups was moderately high for Mtwara and Mwanza 
(17.4% and 16.1% respectively), and low for Mbeya (2.3%). Tanzania is an area of year-round 
malaria transmission, with a bimodal pattern, peaking after the rainy season. Each region 
includes urban and rural districts, although the populations are predominantly rural. Tanzania 
has four different administrative levels, the highest level being the region. Regions are divided 
into districts and these are sub-divided into divisions and further into wards. Fever case 
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management in the public sector is provided by a network of regional and district hospitals 
as well as health centres and dispensaries at lower administrative levels [18]. The private sector 
includes for profit and not-for-profit facilities (hospital and clinics) and a drug outlets network 
which is mainly constituted of regulated and non-regulated drug shops, while registered 
pharmacies are almost exclusively located in major urban areas [180,181].  
5.3.3. Study sampling  
One urban and two rural districts were selected in each study region. Three wards were 
randomly selected proportionally to their population size in each district. In each urban ward, 
four streets and in each rural ward, two villages as well as two sub villages in each village were 
randomly selected. After obtaining the list of the households within each village/street, 20 
households were randomly sampled for the household surveys. In each sampled household, 
up to six participants were randomly selected from the complete list of the household 
members until a total of 60 individuals per sub village/street was reached, resulting in 240 
individuals sampled per ward. All consenting individuals were eligible to participate. The 
exclusion criteria were individuals with a severe illness requiring immediate referral and those 
under three months of age. 
5.3.4. Data collection procedures  
Household surveys 
Interviews were conducted with a questionnaire in Swahili, first with the head of household. 
The questions also included information on time to the closest health facility and closest 
pharmacy or drug retailers. Randomly selected members were then asked about demographic 
information, history of fever in the previous two weeks as well as history of antimalarial use in 
the previous months. Members who reported fever in the previous two weeks were asked 
about treatment seeking behaviour including place where they sought care, information on 
malaria diagnosis testing and drugs received and ingested. Data was collected using electronic 
tablets with the help of the Open Data Kit collection tool (ODK). Each visited household was 
mapped using Global Positioning System. In addition, blood spots were collected from finger 
prick onto filter paper to assess the presence of malaria antigens and for further drug 
concentrations measurements. 
Outlet surveys  
Drug-outlet surveys were conducted in all private and public outlets surrounding and serving 
the selected villages. These included small district hospitals, public and private health centres, 
dispensaries, pharmacies, registered ADDOs and non-registered drug retailers, general stores 
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and kiosks. Following verbal consent of the most senior staff present at the moment of the 
survey, details about antimalarials stocks and diagnostic tools (mRDTs and microscope) 
available at the time of the visit were recorded.  
Exit interviews of patients in health facilities 
In each ward, the main health facilities (which included district hospitals, health centres and/or 
dispensaries) serving the surveyed villages were selected for the exit interviews. After 
completion of their consultation with health facility staff and after visiting the health facility 
pharmacy for possible treatment procurement, patients were interviewed and information 
were collected on demographics, administration of malaria diagnostic testing (microscopy or 
mRDTs), test result and drug obtention. In addition, mRDT was performed on site by our field 
investigators. 
5.3.5. Laboratory procedures 
Capillary blood samples were taken by fingerprick on all subjects interviewed during the 
household surveys. One drop of blood was immediately used for mRDTs analysis (ParaHIT-
f test, Span diagnostic Ltd, Surat, India, detecting HRP-2 antigens) and four drops were applied 
on filter paper cards (FTA DMPK-B cards, Whatman, GE Healthcare). These were able to dry at 
room temperature for at least two hours before being placed in a specific bag with desiccant 
and stored in a -10°C freezer at the end of the day and finally transferred to a -80°C freezer 
within one month. Concentrations of seven antimalarials and two metabolites, namely 
amodiaquine, N-desethyl-amodiaquine, lumefantrine, desbutyl-lumefantrine, mefloquine, 
chloroquine, quinine, sulfadoxine and pyrimethamine, were determined in the dried blood 
spots (DBS) samples by liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS) [27, CHAPTER IV]. The LC-MS/MS platform enables to detect residual blood levels if 
the drug was taken up to four weeks prior to the analysis (given the long half-lives of the 
measured antimalarials). Due the very short half-life of artemisinin compounds, and because 
they are rapidly degraded due to haemolysis with the current collection procedure, their 
analysis were not performed in these DBS samples.   
5.3.6. Definitions  
Fever was defined as any illness with fever reported in the two weeks prior to the survey. 
Malaria infection was defined as a positive mRDT result on the day of the survey. Antimalarials 
identified during the outlet surveys were classified according to their active ingredients and 
drug formulation. For data analysis, outlets were considered to have mRDTs and antimalarials 
in stock if the study team observed at least one non-expired test or at least one complete 
non-expired treatment of any antimalarial for any age/weight group. Individuals were 
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considered having antimalarials in the blood if at least one of the nine 
antimalarials/metabolites were measured in their corresponding DBS sample, at a 
concentration equal or higher than the lower limit of quantification. The latter is the minimal 
concentration that confidently provides a bias and coefficient of variation within ±20% [148]. 
For our analysis, dispensaries, public, private or mission health centres and small district 
hospitals were classified as “health facilities”. Pharmacies, registered (ADDOs) and non-
registered drug retailers, general stores and kiosks were grouped as “non-health facility 
antimalarial providers”. Traditional practitioner, neighbours, friends or even home (if 
medication available) were classified as “other places”. Appropriate diagnosis was defined as 
a patient with history of fever being tested for malaria (by mRDT or microscopy) and 
appropriate treatment as having antimalarial in the blood or in agreement with mRDT result. 
Treatment was also considered as being appropriate if a febrile individual was not tested and 
had antimalarials detected in the blood, as per WHO guidelines when diagnostic testing is not 
possible [175].   
5.3.7. Data management and statistical analysis 
Data was stored on the ODK Aggregate data repository at the end of each survey day. During 
each interview, key data such as demographic information and mRDT results were also 
collected on paper forms. These data were cross-checked twice with electronic data at the end 
of each day.  R (version 3.4.0) was used for data cleaning and management and to produce 
summary statistics as well as graphics using the ggplot2 package. P-values were calculated 
using Pearson Χ2 statistics with significance defined as p <0.05.  
5.4. Results 
The household survey included a total of 6485 participants. On average, 120 individuals were 
interviewed in each village. The outlet survey included 2 hospitals, 19 health centres, 39 
dispensaries, 78 ADDOs, 57 drug stores, 9 pharmacies and 4 general stores or kiosks.  
5.4.1. Population characteristics in the household surveys  
In the household survey, 4503/6485 (69.4%) participants were sampled in the two regions with 
moderately high malaria endemicity [2141/6485 (33.0%) in Mtwara and 2362/6485 (36.4%) in 
Mwanza] and 1982/6485 (30.6%) in the region with low endemicity (Mbeya) (Table 5.1). The 
majority of the participants lived in rural districts (4280/6485, 66.0%). The sample included 
3573 (56.0%) females with a median age of 20 years (age range from three months to 95 years) 
and 2802 (44.0%) males with a median age of 14 years (age range from three months to 100 
years). On the day of the survey, 1039/6485 (16.0%) participants reported a history of fever in 
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the last two weeks prior the survey and 1136/6485 (17.5%) were tested positive for malaria by 
mRDT.  
 
Table 5-1: Population characteristics of participants in household surveys and febrile outpatients 
exiting health facilities 
 
Participants in household surveys 
(N=6485) 
Febrile outpatients, 
health facility exit interviews  (N=226) 
 N % 95% CI N % 95% CI 
Total 6485 100.0 - 226 100.0 - 
Sex       
Male 2846 43.9 (42.9-45.0) 99 43.8 (38.4-49.2) 
Female 3623 55.9 (55.0-57.0) 127 56.2 (50.8-61.6) 
Missing 16 0.2 - 0 0.0 - 
Age       
0-4 years 1153 18.1 (17.3-18.9) 148 65.5 (60.3-70.7) 
5-9 years 1014 15.9 (15.1-16.6) 48 21.2 (16.8-25.7) 
10-14 years 775 12.1 (11.5-12.8) 9 4.0 (1.8-6.1) 
15-24 years 990 15.5 (14.8-16.3) 6 2.7 (0.9-4.4) 
25-44 years 1437 22.5 (21.7-23.4) 10 4.4 (2.2-6.7) 
45-59 years 559 8.8 (8.2-9.3) 3 1.3 (0.1-2.6) 
60-100 years 454 7.1 (6.6-7.6) 2 0.9 (-0.1-1.9) 
Missing 103 1.6 - 0 0.0 - 
Area   
Urban 2205 34.0 (33.0-35.0) 50 22.1 (17.6-26.7) 
Rural  4280 66.0 (65.0-67.0) 176 77.9 (73.3-82.4) 
Missing  0 0.0  0 0.0  
Region    
Mwanza 2362 36.4 (35.4-37.4) 45 19.9 (15.5-24.3) 
Mbeya 1982 30.6 (29.6-31.5) 37 16.4 (12.3-20.4) 
Mtwara 2141 33.0 (32.1-34.0) 144 63.7 (58.5-69.0) 
Missing  0 0.0 - 0 0.0 - 
Had a fever in the previous 
2 weeks* 
 
     
Yes  1039 16.0 (15.3-16.8) 100 - - 
No  5440 83.9 (83.1-84.6) 0 - - 
Don't know 6 0.1 - 0 - - 
RDT result   
Positive  1136 17.5 (16.7-18.3) 106 47.1 (41.6-52.6) 
Negative  5346 82.5 (81.7-83.3) 119 52.9 (47.4-58.4) 
Missing 3 0.0 - 1 0.4 - 
Took any antimalarial drugs 
in the previous 4 weeks* 
 
     
Yes 810 12.5 (11.8-13.2) NA**   
No 5664 87.3 (86.7-88.0) NA   
Don't know 11 0.2 - NA   
*based on self-report , ** Not applicable 
80      CHAPTER V: APPROPRIATENESS OF MALARIA DIAGNOSIS AND TREATMENT 
 
5.4.2. Prevalence of Plasmodium falciparum and antimalarials in the blood of the 
surveyed population 
Out of the 6485 participants, 94 were excluded from the antimalarial analysis because their 
blood samples were not found or were mislabelled. Thus, 6391 participants remained with a 
valid antimalarial measurement.   
Mtwara was the region with the highest malaria prevalence [25.9%, 95% Confidence interval 
(CI): 24.4-27.5], followed by Mwanza (21.1%, 95%CI: 19.7-22.5) and Mbeya (4.1%, 95%CI: 3.4-
4.9). The presence of antimalarials was detected in the blood of 20.8% (95%CI: 20.0-21.6, 
1330/6391) of individuals in total. The proportion of individuals with residual levels of 
antimalarials in the blood was 19.3% (95%CI: 17.9-20.7) in Mtwara, 28.0% (95%CI: 26.4-29.5) 
in Mwanza and 14.1% (95%CI: 12.8-15.3) in Mbeya (Figure 5.1).  
 
Figure 5-1: Proportions of individuals with residual antimalarials in their blood and individuals with 
Plasmodium falciparum. The presence of antimalarials in the blood was measured using dried blood spots 
samples and parasite prevalence using mRDT. These proportions were obtained from household surveys in 
three regions of Tanzania.  
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5.4.3. Reliability of medical history 
Out of the 1330 individuals with antimalarials in their blood, only 28.0% (372/1330) reported 
the use of antimalarials within the previous month, irrespective of fever status in the previous 
two weeks, as represented in Figure 5.2A. There was only a 21% (372/1768) overlap between 
the individuals reporting antimalarial use and those having detectable concentrations of 
antimalarials in their blood.    
Amongst the 6391 participants with a valid antimalarial measurement, 16.0% (1021/6391) 
reported having had a fever in the previous two weeks. About 37.5% (383/1021) of them had 
detectable levels of antiamalarials in the blood (Figure 5.2B). The overlap between the 
individuals reporting a fever and those having detectable concentrations of antimalarials in 
their blood was 20% (383/1968). Participants who did not report any fever in the previous two 
weeks accounted for the majority of the individuals who had residual antimalarial levels 
detected in their blood [71.2% (947/1330)]. 
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Figure 5-2: Overlap between self-reported history of antimalarial use (A) or fever (B) and antimalarials 
in the blood. Overlap between: (A) individuals reporting antimalarial use in the previous month or (B) 
individuals reporting fever in the previous two weeks, and individuals with detectable concentrations of 
antimalarial drugs in their blood (dried blood spots samples) in the household surveys. 
 
5.4.4. Seeking care behaviour in case of fever 
Figure 5.3 presents the proportion of febrile individuals who sought care and those amongst 
them who had antimalarials in their blood, according to the type of care providers they visited. 
Amongst the 37.5% (383/1021) of febrile individuals who had antimalarials in the blood, the 
proportion who sought care in health facilities was lower than in non-health facility 
antimalarial providers [11.3% (115/1021) vs 16.6% (170/1021)]. 8.3% (84/1021) said they did 
not seek care and 1.3% (13/1021) reported seeking care by a friend or by a traditional healer 
or took a drug from their home. 
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Figure 5-3: Prevalence of individuals with antimalarials in their blood according to health seeking 
behaviour. The top of the chart is based on the self-reported history of health-seeking behaviour of 
individuals who had a febrile episode in the previous two weeks. The bottom of the chart presents the 
corresponding prevalence of individuals with antimalarial drug in their blood.  
 
5.4.5. Appropriateness of malaria diagnosis (according to medical history) and 
treatment (based on antimalarials in the blood) in health facilities and non-health 
facility antimalarial providers   
As shown in Figure 5.4, proportion of participants with fever who reported they had been 
tested for malaria at the place they sought care was 31.0% (195/630), with a large statistically 
significant difference between health facilities and non-health facility antimalarial providers 
[69.4% (172/248) versus 6.0% (23/382) respectively; p<0.001)]. The overall proportion of 
people being appropriately treated was 47.3% (298/630). This proportion was 52.0% (129/248) 
in health facilities vs 44.2% (169/382) for non-health facility antimlarial providers (p=0.04).  
Only half of the individuals who were tested positive by mRDT in the health facilities had 
antimalarials detected in their blood [52.9% (74/140)]. This was close to those who were not 
tested [44% (33/73) in health facilities and 42.9% (154/359) in non-health facility antiamalarial 
providers]. One third of the individuals tested negative in the health facilities had detectable 
levels of antimalarials in their blood [36.4% (8/22)]. Overall, the proportion of individuals 
treated was larger than that being tested [45.2% (285/630) treated, 31.0% (195/630) tested].  
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Figure 5-4: Proportion of febrile individuals appropriately diagnosed and treated for malaria. 
Appropriate diagnosis was defined as a patient with history of fever being tested for malaria (by mRDT or 
microscopy) and appropriate treatment as having antimalarials in the blood if the mRDT result was positive 
or if the person had not been tested. The left side of the figure reports individuals who sought care in health 
facilities and the right side of the figure those who sought care in non-health facility antimalarial providers. 
The upper part of the organigram is built upon self-reported history and the bottom part on results of 
antimalarials measured in blood samples collected during the household survey, which constitute more 
objective information.    
5.4.6. Appropriateness of malaria treatments assessed by medical history and 
antimalarials in the blood in household surveys  
When assessed based on participant’s medical history recorded in household surveys, the 
proportion of individuals who mentioned being appropriately treated according to diagnostic 
test result or who stated being treated presumptively was significantly higher than when it 
was assessed on the basis of presence or absence of antimalarials in the blood, as shown in 
Figure 5.5 (65.3% versus 52.0%, p<0.01 in health facilities and 66.0% versus 44.3%, p<0.001 
for non-health facility antimalarial providers).  
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Figure 5-5: Comparison between appropriateness of treatment assessed according to self-reported 
medical history and antimalarials blood measurements. Proportions of febrile individuals interviewed in 
household surveys appropriately treated for malaria when they sought care in health facilities (left side of the 
figure) and non-health facility antimalarial providers (right side of the figure) assessed according to self-
reported medical history and antimalarials blood measurements. There is a significant difference (٭: p<0.01, 
**: p<0.001) between the proportion of febrile patients appropriately treated for malaria assessed according 
to self-reported medical history and antimalarials blood measurements.  
5.4.7. Availability of antimalarial treatments and mRDTs in each region 
Mbeya was the only region in which all health care providers (health facilities and non-
health facility antimalarial providers) had antimalarials in stock (Table 5.2). The availability of 
malaria blood testing (by mRDT or microscopy) was the highest in Mbeya in all types of care 
providers (88.9% in health facilities and 7.9% in non-health facility antimalarial providers). 
68.8% of the health facilities in Mtwara and 80.8% in Mwanza had malaria diagnosis tools 
available. Very few non-health facility antimalarial providers had mRDTs in stock in these 
two regions (0.0% in Mtwara and 1.1% in Mwanza). In both types of care providers and 
in each region, the commodities to treat were higher than the potential to test for malaria.   
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Table 5-2: Proportion of screened outlets with antimalarials and malaria diagnosis tools available in stock. 
This table reports stocks available on the day of the survey. Health facilities include hospitals, public and 
private health facilities and dispensaries. Non-health facility antimalarial providers include pharmacies, 
drug stores, ADDOs and general stores. Malaria diagnosis tools include mRDTs and microscopy. 
Mbeya Mtwara Mwanza 
Health facilities 
(N=18) 
Non-HF AM* 
providers 
(N=38) 
Health 
facilities 
(N=16) 
Non-HF AM 
providers 
(N=21) 
Health 
facilities 
(N=26) 
Non-HF AM 
providers 
(N=89) 
N % (95%CI) N 
% 
(95%CI) 
N % (95%CI) N % (95%CI) N % (95%CI) N % (95%CI) 
% of outlets 
with 
antimalarials in 
stock 
18 100.0 38 100.0 16 100.0 20 
95.2 
(87.6-
102.9) 
26 100.0 81 
91.0 
 (86.0-96.0) 
% of outlets 
with mRDTs in 
stock or 
microscopy 
16 
88.9 
(76.7-
101.1) 
3 
7.9 
 (0.7-15.1) 
11 
68.8 
(49.7-87.8) 
0 0.0 21 
80.8 
(68.1-935.) 
1 
1.1 
(-0.71-2.96) 
Non-HF AM* =non-health facility antimalarial. 
5.4.8. Exit interviews 
A total of 456 outpatients were interviewed in 37 nearby health facilities (3 hospitals, 17 health 
centres and 17 dispensaries) but for the present analysis, only the 226 febrile patients were 
considered (Table 5.1). The proportion of interviewees that reported they had been tested at 
the health facility was 65.9% (149/226), a proportion that is close to that obtained through 
household surveys [69.4% (172/248)]. 65.0% (147/226) had received appropriate treatment, a 
proportion that is higher than that in household surveys, although this difference was not 
statistically significant (p=0.16). During the interviews, 47.1% (106/226) febrile participants 
were tested positive by mRDT by our field investigators, a proportion which is lower than that 
reported through household surveys [81.4% (140/172), p<0.01].  
5.5. Discussion 
To our knowledge, this is the first study investigating the presence of antimalarials in the blood 
of the general population. The measurement of nine antimalarials provided a reliable endpoint 
and allowed a comprehensive assessment of drug use and current malaria case management 
landscape in the studied communities. 
This study showed that close to one fifth (20.8%) of individuals in the community had residual 
antimalarials in their blood, even in Mbeya, a region of low endemicity of malaria. The absence 
of relationship between the level of transmission and the drug-prescribing behaviour has also 
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been observed in another study in Tanzania [182]. The high prevalence of individuals with 
antimalarials in the blood in Mwanza and Mbeya in comparison to the prevalence of 
Plasmodium falciparum does not seem to be related to low testing available since these two 
regions had higher proportions of health care facilities with malaria diagnostic tools in stock. 
However, having diagnostic tools available does not guarantee their usage, or that clinicians 
are compliant to tests results. The testing habits might be lower in these two regions, and 
especially so in Mbeya where the probability of a fever being malaria is much lower than in 
Mwanza or Mtwara because of the higher altitude [18]. More access to drugs might be one 
explanation. Indeed our team was able to visit 115 nearby outlets in Mwanza, 56 in Mbeya but 
only 37 in Mtwara for roughly the same number of individuals in the vicinity. Mwanza was the 
region with the highest proportion of individuals with antimalarials in the blood, and also the 
highest prevalence of fever (34.0% in Mwanza vs 14.6% in Mtwara and 9.3% in Mbeya). More 
febrile episodes in Mwanza could be due to a higher prevalence of other causes of fever (e.g. 
arboviruses) which might be wrongly allocated to malaria [183]. Alternatively, the population 
of Mwanza might have a  lower level of malaria immunity than that of Mtwara, with a 
proportion of Plasmodium infections that progress to clinical manifestations being higher in 
this setting of lower endemicity, and hence higher prevalence of individuals treated with 
antimalarials [184]. Our results confirm this hypothesis with 35% of the individuals tested 
positive for malaria in Mwanza reporting having had a fever in the previous two weeks, against 
only 23% in Mtwara.  
Whatever the reasons are for the high prevalence of people with antimalarials in the blood, 
access to drugs does not seem to be a major issue in these communities, but rather 
appropriate case management to target those febrile patients that are sick with malaria. The 
important drug pressure across these three regions is worrying because the occurrence of a 
low drug level in blood induces strong selective pressure on parasites and causes the 
emergence of drug resistance [12,39].  
When using an objective endpoint such as the concentration of antimalarials in the blood, it 
appears that self-reporting of drug intake is unreliable, with only 28% concordance for 
individuals having detectable levels of antimalarials in their blood reporting the use of such 
treatments within the previous month, and 54% pretending having taken any drug actually 
having no residual antimalarials in their blood. Poor agreement between history taking and 
antimalarial concentration measurement has already been shown in two previous small-scale 
studies that were conducted among Tanzanian and Cambodian patients attending a health 
facility [49,50], and in a cross-sectional survey in Uganda [185].   
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Amongst the individuals who had detectable levels of antimalarials in their blood, 71% said 
they did not have fever in the previous two weeks and 6% said they had fever but did not seek 
care. Again, these results show that history taking is very unreliable and that all previous 
studies that described health seeking behaviour and drug consumption [3,42,177] should be 
taken with caution, as they leave aside a considerable part of the population using drugs. 
Although it has been shown that history validity can be improved [186], new technology 
platforms such as LC-MS/MS performed on DBS samples allow to move from subjective to 
objective and reproducible data. There is obviously a question of feasibility (ideally the DBS 
should be stored frozen) and cost (50 dollars for measurement of nine different antimalarials 
by LC-MS/MS in one DBS sample) to conduct large-scale surveys, but certainly such objective 
assessment could be used as a validation method for other more practical tools.  
Another main finding of this study is the poor diagnosis and treatment practices in case of 
febrile episode. Overall, only one third of the febrile individuals being tested for malaria at the 
place they sought care and about half being appropriately treated according to their 
diagnostic test result, or presumptively if no diagnostic tool was available. Presumptive 
treatment is thus still common, and  far from the goal set by the WHO of systematic testing 
of suspected malaria cases and treatment upon result [175]. The low testing rate is mainly due 
to the high proportion of individuals seeking care outside the health facilities where patients 
are usually not tested. Allowing drug retailers to perform malaria testing might be one way of 
reducing the numbers of antimalarials sells and consumption. In Tanzania, an ongoing 
research in which dispensers from ADDOs in intervention districts are trained to perform RDTs 
and treating with first-line treatment has already shown encouraging results with an increase 
from 0 to 65% of suspected malaria patients visiting a shop being tested [19].  
The proportion of febrile individuals appropriately tested for malaria was much higher in 
health facilities than in non-health facility antimalarial providers (70% vs 6.0%), but this 
difference was not much reflected in a better targeting of treatment to individuals with 
malaria. Indeed, the proportion of patients appropriately treated was only eight percentage 
point higher in health facilities than in non-health facility antimalarial providers [52.0% 
(129/248) vs 44.2% (169/382), p=0.04]. This can be partly explained by the fact that, according 
to antimalarial drugs detected in the blood of the interviewees, only half of the patients tested 
positive were treated. The same proportion of antimalarial drugs was detected in the blood of 
patients who were not tested.  
In the literature, a decrease by up to three-quarters in ACT prescription has been observed 
after mRDTs implementation, between 2006 and 2008 [26,187]. A recent systematic review 
including 14 studies showed that the overall compliance to positive and negative mRDT results 
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was 97% and 78% respectively and that lower levels of health care workers complied better 
that the more professional counterparts [188]. Our results are less encouraging since the fever 
cases were not always tested and appropriately treated. Studies rolled out in places where 
training has been done are more likely to detect a positive effect and a change observed at a 
given time point might not be sustainable. Besides, our findings add to previous household 
surveys conducted in the same regions three years before which showed no significant change 
in the proportion of febrile individuals obtaining an antimalarial at the population level 
[20,103]. This was explained by a reduction in the use of health facilities. Indeed, ADDOs are 
now recognized to be the principal source of medicines in Tanzania [189].  
Our results call for interventions to reinforce the whole system for a public health impact. 
Health facilities priorities should focus on improving systematic testing and treating all 
positive cases. As for non-health facility antimalarial providers, our findings support the 
suggestions already drawn from two recent trials that introducing mRDTs into regulated 
private sector settings can improve malaria testing and reduce over-treatment [19,190]. 
Testing and treating should also be encouraged at low level of health care, e.g. at the level of 
community health workers, as it has been proven to improve well-targeted ACT treatments in 
randomised cross-over trials in Africa [191,192].  
In addition, care should be taken when assessing appropriateness of treatment in the 
population. Our study observed a higher proportion of appropriate treatment when assessed 
by self-reported medical history than by antimalarials measured in the blood and there are 
several potential reasons to explain such discrepancies: in case of a positive test result, the 
treatment received may have not been an antimalarial or patient might have poorly adhered 
to their treatments [178,193,194]. In the case of a negative result, patients could have obtained 
a treatment from the informal sector and not reporting it.  
Exit interviews confirmed the findings of the household surveys. Only 58% of the patients 
tested positive by our field investigators prior leaving the health facilities had received 
treatment against malaria during their consultation. The most likely scenario is poor 
compliance by health professionals to an mRDT positive result and no presumptive treatment 
prescribed to fever cases not tested. In contrast, a rather small proportion of the patients 
tested negative received a treatment (11%), which indicates a good compliance to negative 
results. Such findings imply that if more febrile patients would be tested, the amount of 
unnecessary treatment distributed would decrease.  
Our study has several limitations. The history of fever recall was based on a two-week period 
in order to be able to compare with previous surveys in the same areas, but residual 
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antimalarial drugs can eventually be detected in the blood for up to four weeks. This could 
explain why a proportion (71%) of individuals who did not report a fever in the previous two 
weeks had detectable levels of antimalarials in the blood. However, as already mentioned 
before, history of drug intake was made on a four weeks period record in order to make the 
comparison between self-reported use and blood levels of antimalarials possible.  
The evaluation of diagnosis appropriateness from household surveys was based on self-
reported medical history only, and thus subjected to report bias. This limitation is nevertheless 
inherent to all studies of this kind, except for those that rely on direct observation of the 
consultation, which are subject to the Hawthorne effect though.  
Finally, our study did measure diagnosis and treatment practices in different settings (urban 
or rural) and different transmission areas, but only at one point in time.  
5.6. Conclusion  
Despite recent efforts that have been made to improve access to diagnostic tools and to 
reduce antimalarials overuse, there is still a considerable antimalarial drugs pressure at the 
population level. Improving rational use of drugs is necessary to prevent the development of 
resistance. The present findings indicate that the goal of the WHO guidelines of systematic 
diagnostic testing and treatment upon result is far from being reached, and that antimalarial 
treatments are not targeted to the individuals in need. As resources are invested into the 
development and implementation of new diagnostic tools and effective treatments, it is of 
paramount importance to make sure that those tools are used to their full potential, and 
properly enforced.  New health care interventions should not only be evaluated for their 
impact at the level of health facilities, but also at the level of the community. However, 
household surveys that collect information on health-seeking behaviour or practices through 
self-history are subject to important biases. Evaluation or monitoring tools that rely on 
objective measurements such as drug concentration in the blood should be favoured, if 
feasible. 
Acknowledgements 
We would like to thank the regional and district health officers and study participants. Many 
thanks to the field workers and drivers of the Ifakara Health Institute in Tanzania for their help 
in the data collection. Furthermore, thank you to Patrick Kachur and Catherine Goodman for 
their support in initiating the project, to Kristina Keitel, Christian Lengeler, Rebecca Thomson 
and Katia Bruxvoort for their advices and expertise during the field work and for Nicolas Maire 
and Aurelio Di Pasquale for their help on ODK programming. Financial support for this work 
CHAPTER V: APPROPRIATENESS OF MALARIA DIAGNOSIS AND TREATMENT  91 
 
 
was provided by grant No 320030 _149597 from the Swiss National Science Foundation and 
Blaise Genton was the Principal Investigator. 
Ethical approval  
This epidemiological study received approval from the Swiss Ethics Committees on research 
involving humans and from two responsible local authorities (Institutional review board of the 
Ifakara Research Institute and the National Institute for Medical Research in Tanzania). 
Interviews were conducted and capillary blood samples were obtained after receiving written 
informed consent in Kiswahili by the participants or their responsible caretaker.  
 
 
  
 
 
 
  
  
 
 
 
 
6. CHAPTER VI: PREDICTORS OF RESIDUAL 
ANTIMALARIALS IN THE BLOOD 
 
  
 
 
 
  
CHAPTER VI: PREDICTORS OF RESIDUAL ANTIMALARIALS IN THE BLOOD  95 
 
 
 
6. Predictors of residual antimalarial drugs in the blood in 
community surveys in Tanzania 
 
Authors:  Joanna Gallay1,2,3, Emilie Pothin1,2 ,Dominic Mosha4,  Erick Lutahakana4, Festo 
Mazuguni4, Martin Zuakulu4, Laurent Decosterd3, Blaise Genton1,2,5 
 
1. Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.  
2. University of Basel, Switzerland 
3. Division and Laboratory of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, 
University Hospital , Lausanne, Switzerland 
4. Ifakara Health Institute, Dar es Salaam, Tanzania. 
5. Division of Infectious Diseases and Department of Community Health, University Hospital, Lausanne, 
Switzerland 
 
 
 
 
 
 
 
 
 
This article has been published in Plos One (Sep 2018); 13(9):e0202745 
 
96      CHAPTER VI: PREDICTORS OF RESIDUAL ANTIMALARIAS IN THE BLOOD 
 
6.1. Abstract  
Background 
Understanding pattern of antimalarials use at large scale helps ensuring appropriate use of 
treatments and preventing the emergence and spread of resistant parasites. We estimated the 
proportion of individuals in community surveys with residual antimalarials in their blood and 
identified the factors associated with the presence of lumefantrine and/or desbutyl-
lumefantrine (LF/DLF) or sulfadoxine-pyrimethamine (SP).  
Methods 
A cross-sectional survey was conducted in 2015 in three regions of Tanzania with different 
levels of malaria endemicity. Interviews were conducted and blood samples were collected 
through household surveys for further antimalarial measurements using liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS). In addition, diagnosis 
and treatment availability were investigated through outlet surveys. Multilevel mixed effects 
logistic regression models were used to estimate odds ratios for having LF/DLF or SP in the 
blood.  
Results 
Amongst 6391 participants included in the analysis, 12.4% (792/6391) had LF/DLF and 8.0% 
(510/6391) SP in the blood. A multivariate analysis identified factors associated with higher 
odds of detecting LF/DLF in the blood; these include fever in the previous two weeks (OR=2.6, 
p<0.001), living in a district with higher malaria prevalence (OR=1.5, p<0.001) and living in a 
ward in which all visited Drug Stores had artemisinin-based combination therapies in stocks 
(OR=2.7, p=0.020). Participants in older age groups were less likely to have LF/DLF in the blood 
(OR=0.9, p<0.001). Odds of having SP in the blood were higher for pregnant women (OR=4.6, 
p<0.001), when living in Mwanza (OR=3.9, p<0.001 compared to Mbeya), for individuals that 
reported an episode of fever in the previous two weeks (OR=1.7, p<0.001) and for participants 
in older age groups (OR=1.2, p<0.001). 
Conclusion  
The most significant predictors identified were expected. History of fever in the past two weeks 
and young age were significant predictors of residual LF/DLF in the blood, which is 
encouraging. Antimalarial drug pressure was high in the population and hence the use of 
recommended first-line drugs in combination with malaria Rapid Diagnostics Tests should be 
promoted to ensure appropriateness of treatment.   
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6.2. Introduction  
Artemisinin-based combination therapies (ACTs) are the most potent weapon in treating 
falciparum malaria [12],  representing the second highest impact intervention on malaria 
control between 2000 and 2015 [195]. In response to the development of parasite resistance 
to conventional antimalarials such as chloroquine, the World Health Organisation (WHO) 
recommended ACTs as first-line therapy for uncomplicated malaria in 2006 [175] when the 
Ministry of Health and Social Welfare of Tanzania had already recommended artemether-
lumefantrine (Alu) as standard therapy in 2005 [17]. The use of antimalarials as combination 
therapy is yet clearly of benefit for the individuals [35], but artemisinin itself is rapidly 
eliminated while the “partner drugs” persist in the bloodstream as monotherapy for weeks 
due to their long half-lives [36]. Despite its poor efficacy and a high proportion of resistant 
parasites in Tanzania [196,197], sulfadoxine-pyrimethamine (SP) is still widely used as self-
medication outside of intermittent preventive treatment during pregnancy (IPTp) [198,199]. 
Both sulfadoxine and pyrimethamine have long half-lives. The extensive and often inadequate 
use of these long-acting compounds constitute a critical factor contributing to drug pressure 
[39], which in turn is a potent force selecting resistant parasites [34,40]. Thus, correct use of 
antimalarials is now one of the five goals and recommendations of WHO Global plan for 
artemisinin resistance containment [12]. Understanding the pattern of antimalarial drugs 
usage will help designing specific and targeted interventions aimed at reducing drug pressure 
and monitoring the implementation of diagnostic and treatment policies. 
Previous studies have explored the effect of environmental and behavioral factors on 
population drug use. Most of them relied on questionnaires [196,198,200,201] although there 
was no indication that information collected through self-reporting was reliable. With such 
methodology, uptake of antimalarials was reported to be low [40,47]. On the other hand, 
studies conducted during the chloroquine or SP eras [34,40,202,203] which used biochemical 
markers in addition to questionnaires showed high prevalence of individuals with detectable 
drug in urine or blood, although the tests used had a rather poor sensitivity. Two recent studies 
using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), a sensitive 
analytical method,  showed that  52% of the patients upon admission to a health facility in 
Cambodia [50] and 74% in Tanzania [49,50] had detectable antimalarials in their blood, 
although all of them stated that they had not taken any drug in the previous four weeks. These 
observations indicate frequent recourse to self-medication and poor reliability of self-
reporting when assessing drug use. Our study first aimed at evaluating the actual state of 
population drug pressure by estimating the proportion of individuals in community surveys 
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with residual antimalarials in their blood, and then at identifying the factors associated with 
the presence of lumefantrine (LF) or SP in the blood.  
6.3. Methods 
A cross-sectional investigation including household-based and drug outlet-based surveys was 
conducted concurrently. Detailed study setting, population and sampling have been described 
elsewhere (CHAPTER V) and can be summarized as follows.    
6.3.1. Study setting and population 
Surveys were conducted in three regions of Tanzania with different levels of malaria 
endemicity, i.e moderately high for Mtwara and Mwanza (17.4% and 16.1% respectively) and 
low for Mbeya (2.3%) [20]. Our study took place from May to August 2015 following the rainy 
season. In this country where the population is predominantly rural, over 95% of inhabitants 
of mainland Tanzania are at risk of malaria [1]. Alu is free of charge in public health facilities 
(HFs) for under five children, pregnant women, elderly and those who cannot afford to pay 
[20]. Although no-longer indicated for malaria case management, SP is still widely available 
both in the private and public sector, according to recent outlet surveys [176].  
6.3.2. Study sampling and data collection 
Tanzania has four different administrative levels: regions, divisions, districts and wards (which 
include five to seven villages). In each region, one urban and two rural districts were selected. 
Three wards per district, four streets or sub villages per ward, 20 household per sub 
village/street and up to six individuals per household were randomly selected. The 
questionnaire in Swahili was divided into 3 parts: i) household-related questions on indoor 
residual spraying (IRS), time to the closest HF and closest drug retailer; ii) demographic 
information, use of bed nets, pregnancy and history of fever in the previous two weeks; iii) 
information on health seeking behaviour. Capillary blood was collected from all participants 
for malaria Rapid Diagnostics Tests (mRDTs) analysis (ParaHIT-f test, Span diagnostic Ltd, 
Surat, India, detecting HRP-2 antigens) and applied on filter paper cards (FTA DMPK-B cards, 
Whatman, GE Healthcare) for further analysis of seven antimalarials and two metabolites by 
liquid chromatography coupled to tandem mass-spectrometry (LC-MS/MS) in the dried blood 
spots (DBS) samples [131,204]. The drug outlet surveys included all HFs (small district 
hospitals, public and private health centres, dispensaries) and drug stores [pharmacies, 
registered accredited drug dispensing outlets (ADDOs) and non-registered drug retailers, 
general stores and kiosks] surrounding the selected villages. Diagnostic tools (mRDTs and 
microscope) and antimalarials in stocks at the time of the visit were recorded.  
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6.3.3. Data management and statistical analysis 
The Open Data Kit collection tool (ODK) programmed on electronic tablets was used to collect 
the data and record Global Positioning System coordinates of each household and drug outlet 
visited. Data was stored on the ODK Aggregate data repository at the end of each survey day. 
R (version 3.4.0) was used for data cleaning and management and to produce logistic 
regressions as well as forest plots using the lme4 and sjPlot packages.  
6.3.4. Variable definitions  
Individuals were considered having an antimalarial in the blood if the concentrations 
measured in their corresponding DBS sample were equal or higher than the lower limit of 
quantification (LOQ) (CHAPTER IV). Age was categorized as presented in Table 6.1, based on 
the age distribution of the sampled population. Mean malaria endemicity was classified 
according to the most recent epidemiological profile of mainland Tanzania from the last 
Malaria Indicator Survey [18]. The following variables were used as binary variables: history of 
fever (in the two weeks prior to the survey), mRDT result (performed on the day of the survey), 
bednet use (the previous night), IRS (the previous year), pregnancy (at the time of the survey) 
and living in an urban or rural district. Participants were asked to estimate the time to reach 
the closest HF or drug store (DS) using the mode of transport they would normally use. Outlets 
were considered to have mRDTs and antimalarials in stock if, at least one non-expired test and 
respectively one complete non-expired treatment of any antimalarial for any age/weight 
group was observed.  
6.3.5. Multilevel mixed effects logistic regression analysis 
The presence of lumefantrine and/or desbutyl-lumefantrine (LF/DLF) and the presence of 
sulfadoxine and/or pyrimethamine (SP) were analyzed as outcome variables. A bivariate 
analysis was first performed to select variables based on the p-value of the log-likelihood ratio 
tests, with a cut-off of 0.2 [205]. Multilevel mixed effects logistic regression models were then 
performed by a backward step-by-step procedure. Independent variables and their 
interactions were retained when significance level was ≤0.05 and if they showed a model fit 
improvement [reduction in the Akaike Information Criteria (AIC) value of the model]. 
According to sampling design, regions, district and wards were included as nested random 
effects. 
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6.4. Results  
In total, 6485 participants were included in the household surveys but 94 were excluded of the 
present analysis because their DBS sample was not found or mislabelled. On average, 237 
individuals were interviewed in each ward, ranging from 166 to 380. The outlet surveys 
included 2 hospitals, 19 health centres, 39 dispensaries, 78 ADDOs, 57 DSs, 9 pharmacies and 
4 general stores or kiosks. 
6.4.1. Site and study participants description 
Females were 55.9% (3573/6391) while males were 43.8% (2802/6391). The median age was 
17 years and ranged from three months, one of the inclusion criteria, to 100 years. Overall, 
4421 participants were sampled in regions of high endemicity (2304 in Mwanza and 2117 in 
Mtwara) and 1970 in Mbeya, the region of low endemicity. Majority of the participants lived 
in rural districts [65.8% (4206/6391)]. Summary statistics for all assessed variables are shown 
in Table 6.1. 
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Table 6-1: Sample characteristics of included individuals and strength of association between variables 
and presence of LF/DLF (A) and presence of SP (B) in the blood. In the bivariate analysis, p-values are 
based on log-likelihood ratio tests. Variables with more than two categories were considered as ordinal, 
except for the regions.  Net use was defined as use in the previous night and PfPR2-10 as malaria endemicity.  
A)   
 
Total 
participants 
Participants with LF/DLF in the blood 
N (%) N (%) 95% CI 
 Bivariate analysis  Multivariate analysis 
 ORs p-value  ORs p-value 
Total 6391 (100.0) 792 (12.4) 11.7-13.1  - -  - - 
Sex          
Male 2802 (43.8) 350 (12.5) 11.5-13.5  0.97 0.673  - - 
Female 3573 (55.9) 441 (12.3) 11.4-13.2       
Missing 16 (0.3) - -       
Age          
0-4 years 1135 (18.1) 157 (13.8) 12.1-15.5  0.92 <0.001  0.92 <0.001 
5-9 years 996(15.8) 170 (17.1) 15.1-19.0       
10-14 years 765 (12.2) 111 (14.5) 12.4-16.6       
15-24 years 973 (15.5) 83 (8.5) 7.1-10.0       
25-44 years 1422 (22.6) 129 (9.1) 7.8-10.3       
45-59 years 552 (8.8) 79 (14.3) 11.9-16.8       
60-100 years 445 (7.1) 49 (11.0) 8.6-13.5       
Missing 103 (1.6) - -       
Pregnant          
Yes 104 (1.6) 10 (9.7) 4.9-14.5  0.71 0.297  - - 
No  1569 (24.6) 135 (8.7) 7.5-9.9       
Not applicable 4718 (73.8) - -       
Had a fever in the previous 2 
weeks 
 
 
 
  
 
   
Yes  1021 (16.0) 247 (24.2) 22.0-26.4  2.70 <0.001  2.62 <0.001 
No  5364 (83.9) 544 (10.1) 9.5-10.8       
Missing 6 (0.1) - -       
mRDT result          
Positive  1117 (17.5) 222 (19.9) 17.9-21.8  1.25 0.023  1.14 0.183 
Negative  5272 (82.5) 570 (10.8) 10.1-11.5       
Missing 2 (0.0) - -       
Net use           
Yes 4180 (65.4) 555 (13.2) 12.4-14.1  1.36 <0.001  1.30 0.004 
No 2211 (34.6) 238 (10.8) 9.7-11.8       
Missing 0 (0.0) - -       
IRS in the previous year          
Yes 1073 (16.8) 147 (13.7) 12.0-15.4  0.99 0.802  - - 
No 5316 (83.2) 645 (12.1) 11.4-12.9       
Missing 2 (0.0) - -       
Area          
Urban 2185 (34.2) 172 (7.9) 6.9-8.8  1.59 0.359  - - 
Rural  4206 (65.8) 620 (14.7) 13.8-15.7       
Missing  0 (0.0) - -       
Region           
Mbeya (reference) 1970 (30.8) 151 (7.7) 6.7-8.6  - -  - - 
Mwanza 2304 (36.1) 338 (14.7) 13.5-15.9  2.15 0.137  - - 
Mtwara 2117 (33.1) 303 (14.3) 13.1-15.6  2.49 0.075  - - 
Missing  0 (0.0) - -       
PfPR2-10 of the ward          
0 < 1% 1421 (22.2) 244 (17.2) 15.5-18.8  0.97 0.655  - - 
1 - < 5% 0 (0.0) - -       
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5 - < 10% 1453 (22.7) 202 (13.9) 12.4-15.4       
10 - < 50% 2062 (32.3) 183 (8.9) 7.8-9.9       
> 50% 1455 (22.8) 163 (11.2) 9.8-12.6       
Missing 0 (0.0) - -       
PfPR2-10 of the district          
0 < 1% 1244 (19.5) 48 (3.9) 3.0-4.8  1.53 0.002  1.52 <0.001 
1 - < 5% 0 (0.0) - -       
5 - < 10% 1470 (23.0) 138 (9.4) 8.1-10.6       
10 - < 50% 2259 (35.3) 343 (15.2) 13.9-16.4       
> 50% 1418 (22.2) 263 (18.6) 16.8-20.2       
Missing 0 (0.0) - -       
Time to the closest HF*          
<15 min 2134 (33.4) 276 (12.9) 11.7-14.1  0.85 0.011  0.84 0.007 
15 min to 1h 3483 (54.5) 430 (12.3) 11.4-13.3       
1h to 2h 564 (8.8) 57 (10.1) 8.0-12.2       
> 2h 167 (2.6) 26 (15.6) 10.9-20.2       
Don’t know 43 (0.7) - -       
Time to the closest DS**          
<15 min 2911 (45.5) 331 (10.7) 9.7-11.6  1.05 0.385  - - 
15 min to 1h 2599 (40.7) 354 (13.6) 12.5-14.7       
1h to 2h 461 (7.2) 60 (13.0) 10.4-15.6       
> 2h 63 (1.0) 9 (14.3) 7.0-21.5       
Don’t know 357 (5.6) - -       
ACTs in stocks in all the visited 
HF of the ward 
 
 
 
  
 
   
Yes 6391 (100.0) 792 (12.4) 11.7-13.1  - -  - - 
No  0 (0.0) - -       
Missing  0 (0.0) - -       
AM*** in stocks in all the visited 
HF of the ward 
 
 
 
  
 
   
Yes 6391 (100.0) 792 (12.4) 11.7-13.1  - -  - - 
No  0 (0.0) - -       
Missing  0 (0.0) - -       
mRDTs in stocks in all the visited 
HF of the ward 
 
 
 
  
 
   
Yes 4986 (78.0) 534 (10.7) 10.0-11.4  0.68 0.139  - - 
No  1405 (22.0) 258 (18.4) 16.7-20.1       
Missing 0 (0.0) - -       
ACTs in stocks in all the visited 
DS of the ward 
 
 
 
  
 
   
Yes 5528 (86.5) 667 (12.1) 11.3-12.8  2.88 0.008  2.69 0.020 
No  399 (6.2) 16 (4.0) 2.4-5.6       
Missing 464 (7.3) - -       
AM in stocks in all the visited DS 
of the ward 
 
 
 
  
 
   
Yes 5694 (8.9) 669 (11.7) 11.0-12.4  2.53 0.039  - - 
No  233 (3.6) 14 (6.0) 3.4-8.6       
Missing 464 (7.3) - -       
mRDTs in stocks in all the visited 
DS of the ward 
 
 
 
  
 
   
Yes 713 (11.2) 56 (7.9) 6.2-9.5  0.73 0.126  - - 
No  5217 (81.6) 627 (12.0) 11.3-12.8       
Missing  464 (7.3) - -       
*HF = Health Facility , **DS = Drug Store, ***AM = antimalarial drug 
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B)  
 
Total 
participants 
Participants with SP in the blood 
N (%) N (%) 95% CI 
 Bivariate analysis  Multivariate 
analysis 
 ORs p-value  ORs p-value 
Total 6391 (100.0) 510 (8.0) 7.4-8.5 -  -    
Sex          
Male 2802 (43.8) 200 (7.1) 6.3-7.9  0.97 0.036  - - 
Female 3573 (55.9) 310 (8.7) 7.9-9.4       
Missing 16 (0.3) - -       
Age          
0-4 years 1135 (18.1) 67 (5.9) 4.7-7.1  1.21 <0.001  1.18 <0.001 
5-9 years 996(15.8) 43 (4.3) 3.3-5.4       
10-14 years 765 (12.2) 41 (5.4) 4.0-6.7       
15-24 years 973 (15.5) 83 (8.5) 7.1-10.0       
25-44 years 1422 (22.6) 168 (11.8) 10.4-13.2       
45-59 years 552 (8.8) 62 (11.2) 9.0-13.4       
60-100 years 445 (7.1) 39 (8.8) 6.6-11.0       
Missing 103 (1.6) - -       
Pregnant          
Yes 104 (1.6) 28 (27.2) 20.0-34.4  4.91 <0.001  4.60 <0.001 
No  1569 (24.6) 166 (10.7) 9.4-12.0       
Not applicable 4718 (73.8) - -       
Had a fever in the previous 2 
weeks 
 
   
 
 
   
Yes  1021 (16.0) 127 (12.4) 10.7-14.1  1.58 <0.001  1.71 <0.001 
No  5364 (83.9) 383 (7.1) 6.6-7.7       
Missing 6 (0.1) - -       
mRDT result          
Positive  1117 (17.5) 26 (2.3) 1.6-3.1  0.26 <0.001  0.28 <0.001 
Negative  5272 (82.5) 484 (9.2) 8.5-9.8       
Missing 2 (0.0) - -       
Net use           
Yes 4180 (65.4) 356 (8.5) 7.8-9.2  1.07 0.541  - - 
No 2211 (34.6) 154 (7.0) 6.1-7.9       
Missing 0 (0.0) - -       
IRS in the previous year          
Yes 1073 (16.8) 82 (7.6) 6.3-9.0  0.44 <0.001  0.46 <0.001 
No 5316 (83.2) 428 (8.0) 7.4-8.7       
Missing 2 (0.0) - -       
Area          
Urban 2185 (34.2) 224 (10.2) 9.2-11.3  0.57 0.145  - - 
Rural  4206 (65.8) 286 (6.8) 6.2-7.4       
Missing  0 (0.0) - -       
Region           
Mbeya 1970 (30.8) 134 (6.8) 5.9-7.7       
Mwanza 2304 (36.1) 281 (12.2) 11.1-13.3  1.59 0.241  3.92 <0.001 
Mtwara 2117 (33.1) 95 (4.5) 3.7-5.2  0.56 0.156  1.02 0.942 
Missing  0 (0.0) - -       
PfPR2-10 of the ward          
0 < 1% 1421 (22.2) 131 (9.2) 8.0-10.5  0.89 0.102  - - 
1 - < 5% 0 (0.0) - -       
5 - < 10% 1453 (22.7) 107 (7.4) 6.2-8.5       
10 - < 50% 2062 (32.3) 169 (8.2) 7.2-9.2       
> 50% 1455 (22.8) 103 (7.1) 6.0-8.2       
Missing 0 (0.0) - -       
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PfPR2-10 of the district          
0 < 1% 1244 (19.5) 96 (7.7) 6.5-9.0  0.73 0.044  0.77 0.010 
1 - < 5% 0 (0.0) - -       
5 - < 10% 1470 (23.0) 175 (11.9) 10.5-13.3       
10 - < 50% 2259 (35.3) 191 (8.5) 7.5-9.4       
> 50% 1418 (22.2) 48 (3.4) 2.6-4.2       
Missing 0 (0.0) - -   -    
Time to the closest HF*          
<15 min 2134 (33.4) 194 (9.1) 8.1-10.1  0.83 0.003  0.85 0.031 
15 min to 1h 3483 (54.5) 279 (8.0) 7.2-8.8       
1h to 2h 564 (8.8) 27 (4.8) 3.3-6.3       
> 2h 167 (2.6) 8 (4.8) 2.1-7.5       
Don’t know 43 (0.7) - -       
Time to the closest DS**          
<15 min 2911 (45.5) 264 (9.1) 8.2-10.0  0.89 0.105  - - 
15 min to 1h 2599 (40.7) 200 (7.7) 6.8-8.6       
1h to 2h 461 (7.2) 36 (7.8) 5.7-9.9       
> 2h 63 (1.0) 3 (4.8) 0.3-9.2       
Don’t know 357 (5.6) - -       
ACTs in stocks in all the visited 
HF* of the ward 
 
   
 
 
   
Yes 6391 (100.0) 510 (8.0) 7.4-8.5  - -  - - 
No  0 (0.0) - -       
Missing  0 (0.0) - -       
AM***  in stocks in all the visited 
HF of the ward 
 
   
 
 
   
Yes 6391 (100.0) 510 (8.0) 7.4-8.5  - -  - - 
No  0 (0.0) - -       
Missing  0 (0.0) - -       
mRDTs in stocks in all the 
visited HF* of the ward 
 
   
 
 
   
Yes 4986 (78.0) 454 (9.1) 8.4-9.8  1.48 0.238  - - 
No  1405 (22.0) 56 (4.0) 3.1-4.8       
Missing 0 (0.0) - -       
ACTs in stocks in all the visited 
DS of the ward 
 
   
 
 
   
Yes 5528 (86.5) 467 (8.4) 7.8-9.1  1.27 0.839  - - 
No  399 (6.2) 17 (4.3) 2.6-5.9       
Missing 464 (7.3) - -       
AM in stocks in all the visited 
DS** of the ward 
 
   
 
 
   
Yes 5694 (8.9) 479 (8.4) 7.8-9.0  1.39 0.875  - - 
No  233 (3.6) 5 (2.1) 0.6-3.7       
Missing 464 (7.3) - -       
mRDTs in stocks in all the 
visited DS** of the ward 
 
   
 
 
   
Yes 713 (11.2) 96 (13.5) 11.4-15.6  1.73 0.223  - - 
No  5217 (81.6) 388 (7.4) 6.8-8.0       
Missing  464 (7.3) - -       
*HF = Health Facility , **DS = Drug Store, ***AM = antimalarial drug 
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6.4.2. Prevalence of antimalarials in the blood of the surveyed population 
Antimalarial drugs were present in the blood of 20.8% (1330/6391) (95%CI: 20.0-21.6) of 
individuals in total: 53.4% (710/1330) had lumefantrine (LF), 14.2% (189/1330) desbutyl-
lumefantrine (DLF), 20.5% (272/1330) sulfadoxine (SD), 26.5% (352/1330) pyrimethamine (PM), 
1.9% (26/1330) quinine (Q), 0.6% (8/1330) mefloquine (MF), 0.2% (3/1330) chloroquine (CQ), 
0.1% (2/1330) amodiaquine (AQ) and 6.7% (86/1330) N-desethyl-amodiaquine (DAQ). 
Additionally, 59.5% (792/1330) of individuals had LF and/or DLF (107 individuals had both and 
685 had one or the other) and 38.3% (510/1330) SP. When considering parent drug and 
metabolite or combined treatment as one drug (LF/DLF, AQ/DAQ and SP), 6.6% (88) of the 
1330 participants with residual drug concentrations in the blood had more than one 
antimalarial in the blood: 84 individuals had two different drugs, 2 had three drugs and 2 had 
five drugs. The proportions of participants with each type of antimalarial in their blood per 
region are detailed in Figure 6.1. In Mtwara, the proportion of individuals with LF/DLF in their 
blood [74.1% (303/409)] was significantly higher than in Mwanza [50.9% (338/664), p<0.001] 
and Mbeya [54.5% (151/277), p<0.001]. Inversely, the proportion of individuals with SP in their 
blood was significantly higher in Mwanza [42.3% (281/664), p<0.001] and Mbeya [48.4% 
(134/277), p<0.001] than in Mtwara [23.2% (95/409)]. 
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Figure 6-1: Percentage of participants with residual antimalarial concentrations in each study region. 
LF, lumefantrine; DLF, desbutyl-lumefantrine; SD, sulfadoxine; PM, pyrimethamine; MF, mefloquine; Q, 
quinine; CQ, chloroquine; AQ, amodiaquine; DAQ, N-desethyl-amodiaquine.  
 
6.4.3. Variables associated with the presence of antimalarials 
The full list of variables and interaction terms investigated in the multivariate logistic 
regression model to assess their association with LF/DLF or SP in the blood are summarized 
in Table 6.2, while the results of the bivariate and multivariate analysis can be found in Table 
6.1. In the multivariate analysis, before including interaction terms (Figure 6.2), an increasing 
age (OR=0.9, p<0.001) and living further away from a HF (OR=0.8, p=0.007) were associated 
with lower odds of detecting LF/DLF. Having had a fever in the previous two weeks (OR=2.6, 
p<0.001), living in a district with higher malaria prevalence (OR=1.5, p<0.001), sleeping under 
a bed net (OR=1.3, p=0.004) and living in a ward in which all visited DSs had ACTs in stocks 
(OR=2.7, p=0.020) were associated with higher odds of having DLF/LF in the blood. A 
statistically significant interaction between age and mRDT result (p<0.001) (Table 6.3) was 
noted and showed that increasing age was associated with lower odds of having LF/DLF in the 
blood only for the individuals tested positive by mRDT. A significant interaction between 
district parasite prevalence and fever (p<0.001) also showed that the likelihood of having 
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LF/DLF in the blood according to fever was higher at low endemicity than at high endemicity. 
More details on interactions are provided in Table 6.3. 
Table 6-2: Multivariate logistic regression models used in the present analysis. 
 LF/DLF Model SP Model 
Outcome 
Presence of lumefantrine and/or desbutyl-
lumefantrine in the blood 
Presence of sulfadoxine and/or 
pyrimethamine in the blood 
Regions All All 
Number of observations 6279 6278 
Variables   
 Included Age;  fever in the previous 2 weeks; mRDT 
result; net use; PfPr of the district; time to the 
closest HF; ACTs in stocks in DS 
Age , pregnant, fever in the previous 2 weeks, 
mRDT result, IRS in the previous year, region, 
time to the closest HF 
  Excluded Sex; pregnant; IRS in the previous year; area; 
region; PfPr of the ward; time to the closest DS; 
ACTs, AM, mRDTs in stocks in HF; AM, mRDTs 
in stocks in DS 
Sex; net use; area; PfPr of the district and of the 
ward; time to the closest DS; ACTs, AM, mRDTs 
in stocks in HF; AM, ACTs, mRDTs in stocks in 
DS 
Nested random effects Regions/districts/wards Regions/districts/wards 
Interaction terms 
included 
Age*mRDT result; PfPr of the district* fever in 
the previous 2 weeks 
Region* pregnant; Region*time to the closest 
HF 
Being pregnant (OR=4.6, p<0.001), living in Mwanza (OR=3.9, p<0.001 compared to Mbeya), 
having had a fever in the previous two weeks (OR=1.7, p<0.001) and increasing age (OR=1.2, 
p<0.001) were associated with higher odds having SP in the blood. Being tested positive by 
mRDT (OR=0.3, p<0.001), living in a house that had been sprayed by IRS in the previous year 
(OR=0.46, p<0.001), living in a district with higher malaria prevalence (OR=0.8, p=0.010) and 
living further from a HF (OR=0.8, p=0.031) were also associated with lower odds of having SP 
in the blood. Considering the interaction between region and pregnancy (p=0.002) showed 
that the likelihood of having SP in the blood when pregnant was much higher in Mbeya and 
Mtwara than in Mwanza (Table 6.3). The significant interaction between region and time to 
the closest HF (p=0.002) revealed that individuals living further from a HF were less likely to 
have SP in their blood in Mwanza only.  
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Figure 6-2: Multivariate analysis of the determinants for the presence of LF/DLF (A) and SP (B) in the 
blood of the surveyed individuals.  Lines width corresponds to 95% CI bounds and the number above each 
line correspond to the association’s OR. * indicate the strength of the significance (levels of significance: *= 
p<0.05, ** = p<0.01, *** = p<0.001) obtained from the multivariate analysis.   
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Table 6-3: Odds ratios of having LF/DLF or SP in the blood estimated by multivariate logistic 
regression including interaction terms.  These tables only present the variables included in the final 
adjusted models.  
Participants with LF/DLF in the blood 
 Multivariate analysis 
 ORs p-value 
Variables   
Age 0.99 0.560 
Had a fever in the previous 2 weeks 17.29 <0.001 
mRDT result 3.65 <0.001 
Net use 1.31 0.003 
PfPR2-10 of the district 2.01 <0.001 
Time to the closest HF 0.84 0.006 
ACTs in stocks in all the visited DS of the ward 2.52 0.029 
   
Interactions terms   
Age*mRDT result 0.68 <0.001 
PfPR2-10  of the district*fever in the previous 2 weeks 0.75 <0.001 
Participants with SP in the blood 
 Multivariate analysis 
 ORs p-value 
Variables   
Age 1.18 <0.001 
Pregnant 12.61 <0.001 
Had a fever in the previous 2 weeks 1.70 <0.001 
mRDT result 0.29 <0.001 
IRS in the previous year 2.17 <0.001 
Region   
Mwanza  11.30 <0.001 
Mtwara 1.68 0.323 
PfPR2-10 of the district 0.77 0.013 
Time to the closest HF 1.20 0.211 
   
Interactions terms   
Mwanza*Pregnant 0.16 0.003 
Mtwara*Pregnant 0.74 0.656 
Mwanza*Time to the closest HF 0.57 0.002 
Mtwara*Time to the closest HF 0.76 0.223 
Table explanation: when including a statistically significant interaction between age and mRDT result (p<0.001), 
odds of having LF/DLF in the blood decreased with increasing age, but only for the individuals tested positive 
(OR=0.67 for those tested positive and OR=0.99 for those tested negative). Participants with a positive mRDT result 
were more likely to have LF/DLF in the blood (OR=3.6, p<0.001), but ORs decreased when age increased (OR=2.4). 
After including an interaction between district parasite prevalence and fever (p<0.001), the OR of having LF/DLF in 
the blood according to fever were higher at low endemicity (OR=8.0) than at high endemicity (OR=6.0). Participants 
were more likely to have LF/DLF in the blood when living in a district of higher endemicity, especially if they did 
not have a fever (OR=1.6 for those who did not have a fever and OR=1.2 for those who had a fever).   
An interaction between region and pregnancy (p=0.002) showed that pregnant women were more likely to have 
SP in their blood, especially if they lived in Mbeya and Mtwara region (OR=12.7 in Mbeya, OR=9.5 in Mtwara and 
OR=1.8 in Mwanza). Odds of having SP in the blood were higher when living in Mwanza, but to a lesser extent for 
pregnant women (OR=1.8 for pregnant women and OR=11.2 for other participants). An interaction between region 
and time to the closest HF  (p=0.002) revealed that odds of having SP in the blood significantly decreased when 
living further from a HF, but only for those living in Mwanza (OR=0.7). This association was not significant when 
living in Mbeya (OR=1.2, p=0.211) or Mtwara (OR=0.9, p=0.223). Furthermore, participants living in Mwanza were 
more likely to have SP in the blood, especially when living close to a HF (OR=11.2 when living close to a HF and 
OR=6.4 with increasing distance).  
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6.5.   Discussion  
Knowing how antimalarial medication circulates in the population and what the most 
important drivers of antimalarial consumption are may help to improve treatment 
appropriateness and prevent the emergence and spread of resistant parasites. To our 
knowledge, this is the first study assessing drug consumption by means of antimalarial blood 
concentrations including such a large sample size [34,40,202].  
Overall, 20.8% of the study participants had antimalarials in the blood. LF/DLF composed more 
than half (59.5%) of the drugs detected in our sampled population. Most of the factors 
significantly associated with the presence of LF/DLF in the blood were expected, including 
history of fever, which had the highest ORs. Indeed, when fever occurs, antimalarials and 
antibiotics are commonly used as presumptive treatment [34,47], with or without 
parasitological confirmation. However, odds of having LF/DLF in the blood according to fever 
were modulated by district parasite prevalence and were found to be higher at low endemicity. 
This could be explained by the fact that districts with highest malaria endemicity are also the 
most rural. Shortage of drugs and long waiting time at HFs due to disease burden, long 
distance to HFs and inability to pay for health care are factors discouraging people to seek 
treatment in case of fever and which might not apply in urban districts where inhabitants are 
wealthier and access to care is less of a concern [199,206,207]. The association between 
younger age and the presence of LF/DF in the blood adds to previous studies reporting that 
small children are more likely to be taken to the HF and being treated with ACTs 
[34,201,202,206,207]. The interaction between age and mRDT result revealed that odds of 
having LF/DLF in the blood in case of positive mRDT decreased when age increased. This 
supports previous observations  that children are better cared than older people, which is 
encouraging since children are the most vulnerable population [208]. The effect of the distance 
to HF and drug stocks in DSs on the presence of LF/DLF confirms that access to treatment 
(including distance to health care provider and treatment availability) leads to more drug 
consumption, and hence  drug pressure [34,198,209]. In our data, distance to DS did not play 
a role on pattern of drug use, probably because all households were located within a short 
radius of DSs. Such leveling effect has previously been reported in the literature [198]. We 
could not detect an effect of drugs availability in HFs on antimalarial use since all HFs visited 
during the survey had ACTs in stock. However, the significant effect of stocks of ACTs in DSs 
shows the importance of these providers, as often reported in the literature ([189], CHAPTER 
V).     
SP accounted for 38.3% of all antimalarials detected although it has been shown to have low 
therapeutic value in Tanzania [17,210], and that SP super-resistant haplotypes are widespread 
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throughout the country [197]. SP had been officially abandoned as first line treatment in 2006 
in Tanzania [17] but is still present in HFs for IPTp [17]. Amongst all individuals, 8.0% 
(510/6391) had SP in the blood. According to 2015-16 DHS surveys [3], 8.6% of women aged 
between 15-49 years are pregnant on average. Considering that women aged between 15-49 
years represent around 25.0% of the total population [104], one would expect around 2.0% of 
the participants to have SP in their blood, much lower than the proportion measured in our 
study. As mentioned before, this large discrepancy goes in line with previous studies reporting 
the common use of SP as self-medication [196,199,211]. Measuring SP in the blood provides 
interesting insight on how these treatments are used in different regions of the country and 
by different population groups. For example, in the univariate analysis, female were more likely 
to have SP in the blood.  However, this association was no longer significant when adjusting 
for pregnancy in the multivariate analysis as previously reported in the literature 
[34,40,49,201]. Indeed, it was pregnancy that was a strong predictor of the presence of SP in 
the blood, which reflects adherence to IPTp programs [17]. This association was nevertheless 
mitigated in Mwanza, the reason possibly being that in Mbeya and Mtwara the use of SP is 
more restricted to IPTp while in Mwanza, treating malaria with SP is more common practice. 
This hypothesis is reinforced by the fact that Mwanza was the region with the highest 
proportion of individuals with SP in the blood, and the only region for which distance to HF 
had significant influence on the presence of SP in the blood. Age was also significantly 
associated with the presence of SP in the blood but contrary to DLF/LF, residual levels of SP 
were more likely to occur in older people, who have more often recourse to self-medication 
[212]. These results tend to show that compliance to standard malaria treatment 
recommendations is lower in Mwanza and in adults.   
Almost all antimalarials detected in the studied population were part of the recommended 
treatments in Tanzania, which is encouraging. Beside LF/DLF and SP, which were the most 
prevalent, 123 individuals (9.3% of all antimalarials detected) were found with quinine, 
mefloquine, amodiaquine or its metabolite N-desethyl-amodiaquine (which were more 
prevalent due to amodiaquine’s short half-life of 3.9h when used in ACTs [213]). Quinine is the 
drug of choice for treatment of severe malaria and second line drug in case of treatment failure 
with Alu. Amodiaquine and mefloquine can both be found Tanzania in combination with 
artesunate as a viable option for treating uncomplicated malaria [17]. Three individuals had 
chloroquine in their blood although it had been banned from the therapeutic armamentarium 
in 2001.  
Previous studies conducted in Tanzania reported that around 2.0% of the fever in low and 8-
20% in highly endemic settings ([214,215][25] Boillat et al, unpublished) are due to malaria. In 
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our study, 1021 individuals reported a fever in the previous two weeks (Table 6.1), and 630 of 
them said they sought care because of their fever (CHAPTER V). Considering that, on average, 
10.0% of fevers are due to malaria according to literature, 63 individuals should have received 
an antimalarial. This number can be doubled because LF can be detected in DBS samples for 
up to one month (unpublished data) and history of fever recall was based on a two-week 
period. These estimations should have resulted in a prevalence of 19.7% (1260/6391) of the 
total surveyed population (providing all participants who sought care in the previous month 
were treated) having LF detected in their blood if none had a diagnostic test done and 2.0% 
(126/6391) if all had been tested and treated upon result. Together with the 2.0% of the 
population constituted by pregnant women receiving SP through IPTp, we would expect 4.0% 
of the participants to have an antimalarial in the blood, which is far from what we measured 
(20.8%). This highlights the urgent need to implement interventions aimed at decreasing drug 
pressure, notably encourage the use of mRDTs to target treatments to individuals with malaria 
only.  
Our study’s main limitation resides in the fact that we did not collect all possible information 
on potential factors influencing drug use. Socio-economic determinants, knowledge and 
attitude on malaria management might have been of interest, although differences in wealth 
might not have been much different, at least in rural areas.  
6.6. Conclusion  
Understanding pattern of antimalarial drug use has implication in malaria control (access to 
care as well as diagnostic and treatment policies implementation) and surveillance (parasite 
resistance). The most significant predictors identified were encouraging since they implied 
that people took a drug when they had a fever and that children were treated with standard 
first line treatment, i.e. artemether-lumefantrine. However, the long-standing belief that access 
to treatment should be increased might need to be revisited [216], as proven by the number 
of people having drugs in their blood and the good availability of drugs in the health facilities 
and drug stores. Efforts need rather to be focused on the appropriate use of these drugs, 
namely to target antimalarial treatment to those who have malaria, with the appropriate 
dosage and correct adherence, and to recommend the use first-line efficacious drugs in adults 
[217]. This study has shown that drug pressure was highest in districts of high transmission 
and in most accessible locations. This observation calls for interventions to be targeted to such 
areas since they constitute favorable conditions for development and spread of resistant 
strains.  
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7.1. Abstract  
Background 
Artemisinin-based combination therapies treatment failures have already been observed due 
to the presence of partner-drug resistance. We investigated whether the presence of residual 
lumefantrine (LF) or sulfadoxine-pyrimethamine (SP) blood levels in individuals sampled in the 
community predicted the presence of P. falciparum harbouring molecular markers of 
resistance. 
Methods 
Community-based cross-sectional surveys took place in three regions of Tanzania with 
different levels of malaria endemicity. Dried blood spot samples were collected for analysis of 
antimalarials and specific mutations known to be associated with LF or SP resistance.  
Results 
Individuals with high LF blood concentrations were more likely to have wild-type parasites 
(OR=4.80, 95%CI: 1.57-14.70) and a recent episode of fever (OR=2.76, 95% CI: 1.42-5.34) while 
those with low LF concentration were more likely to have parasites harbouring the pfmdr1 
N86/184F haplotype (OR=4.80, 95%CI: 1.57-14.70) and less likely to have fever (OR=0.36, 95% 
CI: 0.19-0.70). Low SP concentrations were associated with higher probability of carrying 
parasites harboring the pfdhfr/pfdhps quintuple or sextuple mutations compared to higher 
concentrations (OR=19.63, 95%CI: 1.44-268.25).  
Conclusion  
Our data provide evidence that low LF and SP concentrations in the blood of individuals 
surveyed in the community was associated with the presence of parasites habouring drug 
resistance markers.  
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7.2. Introduction  
Global malaria control and elimination highly depend on the sustained efficacy of artemisinin-
based combination therapies (ACTs) [10]. Due to its short half-life, artemisinin is rapidly 
cleared from the bloodstream. The partner drug (with longer half-life) persists as a vulnerable 
monotherapy for weeks after treatment, particularly at sub-therapeutic concentrations, 
selecting for newly acquired tolerant parasites [36,96]. This constitutes the main weakness of 
current ACTs and treatment failures have already occurred in the absence of artemisinin 
resistance, mainly due to partner drug resistance [218,219].  
In Tanzania, sulfadoxine-pyrimethamine (SP) was introduced as first-line treatment for 
uncomplicated falciparum malaria in 2001 and replaced in 2006 by artemether-lumefantrine 
(ALu) due to widespread resistance and high rate of treatment failure [17,101,220,221]. In 
patients, parasites harboring multiple copies or the N86/184F haplotype of the pfmdr1 gene 
are selected by ALu treatment and can withstand high lumefantrine (LF) concentrations 
[37,96,97,222,223]. In 2010-11 in Tanzania, the prevalence of the pfmdr1 haplotype claimed 
to be associated with LF tolerance ranged from 17 to 26% [223]. Regarding SP, the 
combination of the pfdhfr triple mutations (51I/59R/108N) with the pfdhps double mutations 
(437G/540E) confers high-level resistance [197,221]. Recently, these super-resistant 
haplotypes have been reported to be widespread throughout Tanzania [197].  
The influence of LF concentrations on the selection of tolerant parasites has been observed in 
clinical trials settings [37,97,224,225]. However, there is little direct evidence that drug pressure 
in the community leads to the emergence of parasite resistance. Previous studies [39,69] 
showed that in areas of low transmission, drug pressure was the critical factor for parasite 
resistance, which was not the case in high transmission places. These results illustrate the 
complex interplay between parasite prevalence, immunity and drug pressure and call for more 
research using sensitive and reliable methods for drug pressure assessment and integrating 
various determinants. The aim of our study was to investigate whether the presence of residual 
LF or SP in the blood of individuals sampled in the community predicted the presence of 
Plasmodium falciparum harbouring molecular markers of resistance.  
7.3. Methods 
7.3.1. Study area and population 
A community-based cross-sectional survey was conducted in three regions of Tanzania from 
May to August 2015, following the rainy season. The regions represented heterogeneous 
malaria endemicity, i.e moderately high for Mtwara and Mwanza (17.4% and 16.1% 
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respectively) and low for Mbeya (2.3%) [20]. Over 95% of inhabitants of mainland Tanzania are 
at risk of malaria and the population is predominantly rural [1]. Detailed study setting, 
population and sampling have been described elsewhere (CHAPTER V).  
7.3.2. Study sampling and data collection.  
Tanzania has four different administrative levels: regions, divisions, districts and wards. In each 
region, one urban and two rural districts were selected. Random selection was then carried 
out as follow: three wards per district, four streets or sub villages per ward, 20 household per 
sub village/street and up to six individuals per household. All consenting individuals were 
eligible to participate with the exception of those under three months of age or with a severe 
illness requiring immediate referral. Interviews were conducted in Swahili and capillary blood 
was collected from all participants. The Open Data Kit collection tool (ODK) programmed on 
electronic tablets was used to collect the data.  
7.3.3. Laboratory procedures 
One drop of capillary blood was used for mRDTs analysis (ParaHIT-f test, Span diagnostic Ltd, 
Surat, India, detecting HRP-2 antigens) and four applied on filter paper cards (FTA DMPK-B 
cards, Whatman, GE Healthcare).  Concentrations of seven antimalarials and two metabolites 
[amodiaquine (AQ), N-desethyl-amodiaquine (DAQ), lumefantrine (LF), desbutyl-lumefantrine 
(DLF), mefloquine (MF), chloroquine (CQ), quinine (Q), sulfadoxine (SD) and pyrimethamine 
(PM)] were further measured in the dried blood spot (DBS) samples using a validated liquid-
chromatography coupled to tandem mass-sprectrometry (LC-MS/MS) methodology ([131], 
CHAPTER IV). Artemisinin compounds were not analysed due their very short half-life and their 
rapid degradation when using the current sampling procedure. The P.falciparum DNA was 
extracted from the same DBS samples and amplified by polymerase chain reaction assay (PCR). 
Sequencing was then used for the assessment of Single Nucleotide Polymorphisms (SNPs) 
related to parasites drugs resistances. The SNPs analysed were the pfmdr1 mutations N86Y 
and Y184F, pfcrt mutations C72S, M74I, N75E and K76T/I/N, pfdhfr mutations A16V/S, N51I, 
C59R, S108N/T and I164L and pfdhps mutations S436A/F, A437G, K540E, A581G and A613T/S. 
The number of copy of the pfmdr1 gene was also assessed by real-time PCR.  
7.3.4. Data analysis  
R (version 3.4.0) was used for data analysis to produce summary statistics, logistic regressions 
and plots using the lme4 and ggplot2 packages.  
Drug concentrations were categorised as presented in Table 7.1. A meta-analysis  showed that 
LF plasma concentration >200 ng/ml at day 7 were associated with >98% cure rates and that 
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lower concentrations constituted favourable conditions for the development of resistance [38]. 
Taking into account the ratio between LF DBS and plasma concentrations (CHAPTER IV) of 
approximately 0.5, a cut-off concentration of 100 ng/ml was chosen in our analysis to 
distinguish between low and high concentrations. Since there is no accurate estimate of in-
vivo minimal inhibitory concentration of sulfadoxine (SD) and pyrimethamine (PM) [226], the 
median concentration measured in our study sample was thus chosen as cut-off concentration 
(700 ng/ml for SD and 10 ng/ml for PM). Individuals were considered to have an antimalarial 
in the blood if the concentration measured in their corresponding DBS sample was equal or 
higher than the lower limit of quantification (LOQ) of the analytical method (CHAPTER IV).  
For molecular markers, individuals carrying mixed infections (wild and mutant types) were 
analysed as harbouring the polymorphism associated with ALu or SP tolerance. Parasites with 
more than 1.5 copies of the pfmdr1 gene were considered as having multiple copies [227] 
(with no distinction between 2 copies and more, as it has been described not to influence the 
parasites’ susceptibility to LF [225]).  
Age was categorized based on the age distribution of our sampled population. Mean malaria 
endemicity of the district was classified according to the categories used in the most recent 
epidemiological profile of mainland Tanzania [18]. Variables with more than two categories 
were considered as ordinal, except for the drug concentrations and the regions.  
Odd Ratios (OR) for the association between molecular markers of LF and SP 
tolerance/resistance in the blood of individuals and the presence of lumefantrine and/or 
desbutyl-lumefantrine (LF/DLF) and SP in the blood, or the presence of low drug 
concentrations were first estimated using bivariate analysis. Then, ORs for the association 
between molecular markers of LF and SP tolerance/resistance and the presence of drug in the 
blood at low concentrations were estimated by multivariate mixed effect logistic regression. 
ORs were adjusted for all variables that had an influence on the presence of molecular markers 
of resistance [previously selected by bivariate analysis with a significance level <0.20 and if 
they showed a model fit improvement (reduction in the Akaike Information Criteria value of 
the model)]. Regions, district and wards were included as nested random effects.  
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Table 7-1: Characteristics of individuals carrying parasites in which A) pfmdr1  gene and B) pfdhfr and 
pfdhps were genotyped and strength of association between variables and presence of mutations 
assessed by bivariate and multivariate analysis. Variables with more than two categories were considered 
as ordinal, except for the drug concentrations and the regions. PfPR2-10 was defined as malaria endemicity.  
A) 
 
Total 
participants 
Participants carrying parasites harboring the pfmdr1  N86/184F mutant haplotype 
N (%) N (%) 95% CI 
 Bivariate analysis  Multivariate analysis 
 ORs 95% CI  ORs 95% CI 
Total 683 (100.0) 444 (65.0) 11.7-13.1  - -  - - 
LF blood 
concentration 
categories  
         
>100 ng/ml 20 (2.9) 6 (30.0) 13.1-46.8  Reference   Reference   
20-100 ng/ml 52 (7.6) 35 (67.3) 56.6-78.0  4.52 1.46-14.02*  4.27 1.35-13.48* 
<Limit of 
quantificationa)  
611 (89.5) 403 (65.9) 62.8-69.1  4.22 1.58-11.29**  4.38 1.58-12.10** 
Missing 0 (0.0) 0 (0.0) -       
Age          
0-4 years 109 (16.0) 67 (61.5) 53.8-69.1  0.93 0.84-1.03*  0.89 0.80-0.99* 
5-9 years 155 (22.7) 106 (67.9) 61.8-74.1       
10-14 years 152 (22.3) 110 (72.4) 66.4-78.3       
15-24 years 106 (15.5) 68 (64.1) 56.5-71.8       
25-44 years 104 (15.2) 62 (59.6) 51.7-67.5       
45-59 years 37 (5.4) 21 (56.8) 43.4-70.1       
60-100 years 19 (2.8) 10 (52.6) 33.8-71.5       
Missing 1 (0.1) 0  (0.0) -       
Had a fever in the 
previous 2 weeks 
         
Yes 188 (27.6) 106 (56.1) 50.1-62.0  0.57 0.40-0.82**  0.58 0.40-0.84** 
No 497 (72.4) 338 (68.4) 65.0-71.9       
Missing 0 (0.0) 0 (0.0) -       
IRS in the previous 
year 
         
Yes 143 (21.0) 82 (57.3) 50.5-64.1  0.68 0.45-1.03  0.68 0.45-1.03 
No 539 (79.0) 362 (67.0) 63.7-70.4       
Missing 0 (0.0) 0  (0.0) -       
PfPR2-10 of the 
district 
         
0 < 1% 5 (0.7) 3 (60.0) 24.0-96.0  1.21 0.93-1.58  1.18 0.91-1.52 
1 - < 5% 0 (0.0) 0 (0.0) -       
5 - < 10% 56 (8.2) 31 (55.4) 44.4-66.3       
10 - < 50% 288 (42.2) 186 (64.6) 59.9-69.2       
> 50% 334 (48.9) 224 (67.1) 62.8-71.3       
Missing 0 (0.0) 0  (0.0) -       
a) Limit of quantification of LF = 20 ng/ml 
Significance: * =p<0.05; **=p<0.01 
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B) 
 
Total 
participants 
Participants carrying parasites harboring the pfdhfr/pfdhps quintuple 
mutation 
N (%) N (%) 95% CI 
 Bivariate analysis  Multivariate analysis 
 ORs 95% CI  ORs 95% CI 
Total 605 (100.0) 452 (74.7) 71.8-77.6  - -  - - 
SP blood 
concentration 
categories 
         
>700 ng/ml of SD 
and/or 10 ng/ml of PM  
7 (1.2) 3 (42.9) 12.1-73.6  Reference    Reference   
20-700 ng/ml of SD 
and/or 2-10 ng/ml of 
PM  
13 (2.1) 12 (92.3) 80.1-104.5  19.63 1.44-268.25*  19.86 1.44-273.97* 
<Limit of quantification 
of SD and PMa)  
583 (96.4) 436 (74.8) 71.8-77.7  4.67 0.94-23.33  4.75 0.95-23.81 
Missing 2 (0.3) 0 (0.0)        
Region           
Mwanza (reference) 303 (50.1) 262 (86.5) 83.2-89.7       
Mtwara 259 (42.8) 155 (59.8) 54.8-64.9  0.22 0.14-0.33  0.22 0.14-0.32*** 
Mbeya  43 (7.1) 35 (83.4) 76.3-94.4  0.89 0.35-2.24  0.90 0.35-2.29 
Missing  0 (0.0) 0 (0.0) -       
a) Limits of quantification = 20 ng/ml for SD and 2 ng/ml for PM  
Significance: * = p<0.05; ** = p<0.01, ***=p<0.001     
7.4. Results  
7.4.1. Concentrations of antimalarials measured in the surveyed population 
Antimalarials were present in the blood of 20.8% (1330/6391) (95%CI: 20.0-21.6) of 
participants. The concentration range detected in the 1330 individuals were 6–2165 ng/ml 
(median=24) for DAQ, 20–8202 ng/ml (median=133) for Q, 20–82046 ng/ml (median=693) for 
SD, 2–458 ng/ml (median=10) for PM, 4–214 ng/ml (median=15) for MF, 20–436 ng/ml 
(median=30) for DLF and 20–4459 ng/ml (median=43) for LF (Figure 7.1; only 2 and 3 
individuals had AQ and CQ in the blood, respectively, these results are thus not shown).   
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Figure 7-1: Concentrations distributions of each antimalarial, detected in 1330 DBS samples collected 
in the household survey. The number of samples, median concentration, interquartile ranges, lowers and 
upper adjacent values and outlier values are shown for each antimalarial. Two and three individuals had 
detectable levels of amodiaquine and chloroquine respectively, hence these drugs are not represented on 
this figure.  
 
7.4.2. Relation of prevalence of antimalarials to prevalence of molecular markers of 
resistance  
Amongst the 6485 participants in the household surveys, 17.5% (1136) were tested positive 
for malaria. The molecular markers analysis was performed in a sub-sample of 683 positive 
individuals randomly selected from the three regions. Amongst those, 682, 589, 614 and 616 
were successfully genotyped for SNPs on the pfmdr1, pfcrt, pfdhfr and pfdhps genes, 
respectively and 635 for the copy number of the pfmdr1 gene.   
The N86/184F haplotype (formed by a mutation on the Y184F codon) and multiple copies of 
the pfmdr1 gene were harbored by 65.1% (444/682) and 8.8% (56/635) of genotyped samples, 
respectively. LF/DLF was detected in 12.5% (85/682) of the samples for which the pfmdr1 
86/184 haplotype was assessed and in 12.4% (79/635) of the samples analyzed for pfmdr1 the 
copy number. Amongst the samples harboring the N86/184F haplotype and multiple copies 
of the gene, 10.8% (48/444) and 7.1% (4/56) had detectable levels of LF/DLF, respectively 
(Table 7.2). Having LF in the blood was not associated with higher odds of carrying a parasite 
with the mutant N86/184F haplotype (OR=0.64, 95%CI: 0.40-1.01) or an increased copy 
number of the pfmdr1 gene (OR=0.52, 95%CI: 0.18-1.47). The wild type pfcrt 76K allele was 
present in 85.4% (502/588) of the genotyped isolates. Since this wild type allele is ubiquitous 
in Tanzania [228], it was excluded from the present analysis.  
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Table 7-2: Distribution of pfmdr1 single nucleotide polymorphisms (N86Y, Y184F) and pfmdr1 
multiple copies according to the presence of lumefantrine and/or desbutyl-lumefantrine (LF/DLF) in 
the blood of the individuals carrying the parasites. P-values were measured using Pearson Chi-square 
test. Bold underline indicates the amino acid changes.  
 Pfmdr1  polymorphisms Pfmdr1  copy number 
N86/Y184 
(Wild type) 
N86/184F 
(Mutant) OR 
95% CI 
(p-value) 
86Y/Y184 
(Mutant) 
86Y/184F 
(Mutant) 
N copy=1 
(Wild type) 
N 
copy>1 
(Mutant) 
OR 
95% CI 
(p-value) 
 N (%) N (%) N (%) N (%) N (%) N (%) 
Total  232 (34.0) 444 (65.1)   5 (0.7) 1 (0.2) 556 (87.6) 79 (12.4)   
LF/DLF in  
the blood  
          
Yes 37 (15.9) 48 (10.8) 0.64 0.40-1.01 
(0.073) 
0 (0.0) 0 (0.0) 52 (9.4) 4 (5.1) 0.52 0.18-1.47 
(0.216) 
No  195 (84.1) 396 (89.2)   5 (100.0) 1 (100.0) 504 (90.6) 75 (94.9)   
 
The pfdhfr/pfphps quintuple or sextuple mutations (formed by the triple pfdhfr 51I/59R/108N 
mutations combined with pfdhps 437G/540E double or 437G/540E/581G triple mutations) 
harbored by 74.5% (451/605) of genotyped samples. SP was detected in 3.3% (20/605) of the 
samples genotyped for the pfdhfr/pfdhps haplotype and in 3.3% (15/452) of those harboring 
the quintuple or sextuple mutations. Having SP in the blood was not significantly associated 
with carrying a parasite with these mutations (OR=1.28, 95%CI: 0.42-3.92) (Table 7.3). 
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Table 7-3: Distribution of Pfdhfr (A16V/S, N51I, C59R, S108N/T, I164L) and pfdhps (S436A/F, A437G, 
K540E, A581G and A613T/S) single nucleotide polymorphisms according to the presence of 
sulfadoxine/pyrimethamine (SP) in the blood of the individuals carrying the parasites. P-values were 
measured using Pearson Chi-square test. Bold underline indicates the amino acid changes. 
 Pfdhfr polymorphisms Pfdhps polymorphisms Pfdhfr and Pfdhps polymorphisms 
Othera 
51I/59R/108N 
triple mutationb 
Otherc 
437G/540E double  
or 437G/540E/581G 
triple mutationsd 
Other 
Quintuple or 
sextuple 
mutationse 
OR 
95% CI 
 (p-value) 
 N (%) N (%) N (%) N (%) N (%)  
Total  87 (14.2) 527 (85.8) 87 (14.1) 529 (85.9) 154 (25.5) 451 (74.5)   
SP in the blood          
Yes 3 (3.4) 18 (3.4) 2 (2.3) 18 (3.4) 4 (2.6) 15 (3.3) 1.28 0.42-3.92 
(0.664) 
No  84 (96.6) 509 (96.6) 85 (97.7) 511 (96.6) 149 (96.7) 436 (96.7)   
a. including single (AICSI, ANCNI) and double mutations (AIRSI, AICNI, ANRNI) 
b. AIRNI 
c. including single (AAKAA, SGKAA, SAEAA) and double mutations (FAEAA) 
d. SGEAA, SGEGA, FGEGA, AGEAA, FGEAA, SGEAS or FGEAS 
e. pfdhfr AIRNI + pfdhps SGEAA, SGEGA, FGEGA, AGEAA, FGEAA, SGEAS or FGEAS 
 
7.4.3. Relation of pfmdr1, pfdhfr and pfdhps mutations to LF and SP concentration  
LF concentrations measured in the genotyped samples harboring the pfmdr1 mutant 
N86/184F haplotype were lower (median = 33.7 ng/ml) than those measured in samples 
harboring wild type (WT) haplotype (median=69.9) (Figure 7.2). Median LF concentrations did 
not differ significantly (p=0.074, measured using Mann-Whitney rank sum test) between both 
haplotypes but as shown in Figure 7.2 and 7.3, the distribution’s density at low concentrations 
was higher for the N86/184F haplotype than for the wild type. The association between 
pfmdr1 multiple copies and LF levels was not considered because only four samples harbored 
multiple copies of the pfmdr1 gene together with detectable LF levels. By bivariate analysis, 
having LF in the blood at concentrations <100 ng/ml was associated with higher probability 
of carrying a parasite with the pfmdr1 N86/184F haplotype compared to higher 
concentrations (OR=4.52, 95%CI: 1.46-14.02). Similar results (OR= 4.27, 95%CI: 1.35-13.48) 
were obtained when calculated by multivariate analysis after adjusting for other significant 
predictors (age, a febrile episode in the previous 2 weeks, IRS in the previous year and district 
malaria prevalence) (Table 7.1). As illustrated in Figure 7.3, individuals with high LF blood 
concentrations (>100 ng/ml) were more likely to have WT parasites (OR=4.80, 95%CI: 1.57-
14.70) and a recent episode of fever (OR=2.76, 95% CI: 1.42-5.34) while those with low LF 
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concentration were more likely to have mutant parasites (OR=4.80, 95%CI: 1.57-14.70) and 
less likely to have fever (OR=0.36, 95% CI: 0.19-0.70).  
Concentrations of PM measured in the genotyped samples harboring the quintuple or 
sextuple mutations were significantly lower than those measured in samples harboring other 
SNPs (median = 131.0 ng/ml and 3.7 ng/ml respectively, p=0.034). Amongst the 10 genotyped 
samples with detectable SD concentrations, only one did not harbor quintuple mutations. By 
bivariate analysis, having SP in the blood at concentrations <700 ng/ml of SD and/or <10 
ng/ml of PM was associated with higher probability of carrying parasites harboring the 
pfdhfr/pfdhps quintuple or sextuple mutations compared to higher concentrations 
(OR=19.63, 95%CI: 1.44-268.25). Similar results (OR=19.86, 95%CI: 1.44-273.97) were obtained 
by multivariate analysis after adjusting for the regions (the only other significant predictor) 
(Table 7.1). No significant interactions were found in the final multivariate models. 
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Figure 7-2: Concentrations distributions of lumefantrine (LF), pyrimethamine (PM) and sulfadoxine 
(SD) measured in DBS samples of individuals carrying Plasmodium falciparum harbouring different 
single nucleotide polymorphisms (SNPs) of the pfmdr1 , pfdhfr and pfdhps genes, respectively. The 
box plots represent the median concentration, interquartile ranges, lower and upper adjacent values 
(excluding outlier values). The violin plots represent the total distribution of the data (including outliers), as 
well as the distribution’s density, using the width of the plots. Mann-Whitney rank sum test was used to 
compare median drug concentrations between SNPs. 
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Figure 7-3: Concentrations distributions of lumefantrine (LF) measured in DBS samples of individuals 
carrying Plasmodium falciparum harbouring different SNPs of the pfmdr1 gene, in relationship with 
fever. Individuals with LF concentrations >100 ng/ml were more likely to report a febrile episode in the 
previous two weeks (OR=2.76, p=0.003). *LOQ = limit of quantification of LF (20 ng/ml). 
 
7.5.   Discussion  
The present survey provides the first data on level of parasite resistance when in relation to 
residual concentrations of LF in individuals sampled in the community.  
ALu had officially replaced SP in 2006 in Tanzania. An increase from 8% to 33% in the 
occurrence of the pfmdr1 N86/184F combination from 2006 to 2010 has been reported, 
excluding mixed infections [221,229]. In the present study, this proportion was 44% (184/415). 
A study conducted between 2006 and 2011 in Tanzania reported that all samples had one 
copy of the pfmdr1 gene [222]. In our study, this figure was 12%. This increase reflects 
probably the intense use of ALu as first-line treatment in the last nine years and possibly the 
resulting drug pressure on the parasites in this country.   
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Unexpectedly, the pfmdr1 N86/184F haplotype was not more frequent in individuals with 
residual LF/DLF levels in their blood. A few studies conducted more than a decade ago 
investigated the association between CQ and SP blood levels and the presence of parasites 
harboring resistance markers in individuals sampled in the community [79,80,83,230,231]. 
They showed an association between the presence of drugs and the occurrence of the pfcrt 
76T mutation, but not with the pfmdr1 86Y mutation, although it was known to be selected 
by CQ treatments [232]. It is important to stress that the dynamic of resistance is not expected 
to be the same for monotherapies such as CQ and ACTs due to the presence of the artemisinin 
component during the first three days of treatment. Furthermore, these studies focused on 
children and pregnant women populations and do not allow to do a straightforward 
comparison with our data.  In the present survey, individuals harboring LF concentrations 
above 100 ng/ml were less likely to carry parasites including the pfmdr1 mutant N86/184F 
haplotype than those with low or no detectable LF levels. The tolerant parasites selection 
might result from two events: i) they are present during the primary infection and are selected 
by the treatment, ii) newly acquired tolerant parasites emerge from the liver and are exposed 
to sub-therapeutic drug levels from a previous treatment [35,39]. The latter is the main cause 
of resistance selection because the chances of partner drug mutation emerging from primary 
infections are low due to the artemisinin [233]. The selection of tolerant parasites is less likely 
to occur soon after ACT intake due to the presence of the two drugs at high concentrations. 
The problem arises if parasites exposure to treatment occurs later, when only the partner drug 
remains in the blood stream at sub-therapeutic level [12,226]. At this point, less susceptible 
parasites have a survival advantage which leads to their selection and spread of resistance 
[39]. This window of selection is one of the three key drivers of resistance [35,39]. Our findings 
are in line with a previous study suggesting that pfmdr1 N86 selection operates mainly during 
the elimination phase of LF, precisely 20-30 days after treatment initiation [96].  
By multivariate analysis, having had a fever in the previous two weeks and being of an older 
age were significantly associated with decreased risk of carrying a LF tolerant parasite. 
Individuals with fever were less likely to carry tolerant parasites because they were treated 
more recently (as witnessed by their high LF concentrations). The detected WT parasites are 
most likely those responsible for the primary infection recently treated and not killed yet. 
Moreover, WT parasites were exposed to a broader range of concentrations due to the higher 
absolute variability of the concentrations in the early phase of the treatment. Malaria disease 
severity is directly correlated with parasite density [234]. Tolerant parasites in non-febrile 
individuals might thus be low densities infections resulting from a previous treatment. The 
prevalence of resistance to LF being a function of age has already been observed suggesting 
that acquired immunity played a critical role in the clearance of mutant parasites [226,230,235]. 
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According to previous studies, resistances are more likely to occur in high transmission areas 
[69,236], because people living in such areas are more likely to be infected at a time when 
residual drug levels are present in their blood [12,226] and because the resistant parasites are 
more likely to be transmitted. In our study, this tendency was observed for LF but was not 
significant. O’Meara et al. mathematical model showed that immunity (linked to age and 
transmission intensity), treatment rate, drug decay kinetics and presumptive treatment rate 
are important factors in the spread of resistance, findings also supported by our data [235]. 
Their model concluded that the spread of partial resistance was driven by drug treatment of 
uninfected, non-immune individuals. 
Many individuals with no LF detectable in their blood carried parasites with the mutant pfmdr1 
N86/184F haplotype.  Previous study showed a strong selection of N86/184F persisting for 
about two months after a single treatment with ALu [237] and that P.falciparum can persist at 
low densities in a host for months after treatment [238]. It is thus conceivable that the tolerant 
parasites selected by previous treatment or by exposure to sub-therapeutic levels of LF in case 
of re-infection would remain in the bloodstream for a considerable period, even when drug 
levels have become undetectable. Since individuals were considered to have an antimalarial 
in their blood if a concentration equal or higher than the analytical method’s LOQ was 
measured, one could also argue that parasites were in presence of low LF levels which could 
not be detected but could still have an effect on tolerance selection.  Furthermore PCR 
positivity can persist several weeks after treatment even if parasites are dead [239].  
Our findings have several implications. First based on the literature, it is unclear whether ALu 
therapies can reliably eradicate parasites carrying the N86/184F mutation [240]. The present 
study is reassuring on that matter since no mutations were found at high concentrations, 
implying that the artemether component or the synergies between the two drugs clear the 
mutant parasites effectively.    
Then, the median concentrations measured in our sampled population for each drug were 
very low and are typically expected to be encountered from two (for LF and PM) to six (for SD) 
weeks after treatment intake [170,171,241–251]. Such concentrations are favorable conditions 
for tolerance/resistance selection. Studies reported that parasites with the N86/186F 
haplotype were able to withstand estimated LF concentrations two-fold higher than the 
N86/Y186 haplotype [97] and that they could re-infect at higher concentrations than WT [37], 
implying that they can spread more easily [240], with increased risk of recrudescence after ALu 
treatment [97]. According to authors, some parasites carrying the pfmdr1 N86/184F haplotype 
were able to grow at estimated LF blood concentrations of 500nM (=264 ng/ml). The latter 
concentration is higher than 87% (620/710) of those measured in our study sample. In our 
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analysis, 73% (521/710) of the concentrations measured in our study sample were below the 
100 ng/ml threshold.  
In 2010-2011, the prevalence of pfdhfr/pfdhps quintuple mutations in Tanzania was on 
average 77% [252]. In our study, this figure was 75% showing that continuous use of SP 
maintains the selection of resistance (although not recommended anymore outside of IPTp 
programs [17]. Similarly to LF, low SP concentrations were associated with carrying resistant 
parasites. This association was not very strong due to the fact that only 20 individuals had 
parasites and SP in their blood and that the quintuple mutation in Tanzanian parasite 
population has been high for many years [252]. Furthermore, there was a significantly lower 
proportion of SP resistant strains in Mtwara compared to Mwanza and Mbeya, already noticed 
in 2010-2011 [252], which cannot be explained by drug use nor transmission intensity, because 
as previously reported (CHAPTER V), Mtwara was not the region with the lowest proportion of 
individuals with antimalarials in their blood nor the lowest malaria endemicity. Kavishe et al. 
[197] speculated that factors related to population movement and cross-border spread of 
resistance could contribute to these differences.   
Our study has several limitations. First, the final sample size was rather small due to the fact 
that only few people had LF together with parasites harboring multiple copies of pfmdr1 in 
their blood or SP together with parasites. Then, it was impossible due to study design to know 
if the parasites were remaining from a previously treated infection or if they originated from 
a new infection. This information would have helped interpreting the role of LF levels on 
tolerance selection. Finally, due to their high prevalence, mixed infections were excluded from 
the analysis. We postulated that individuals carrying a mixed infection were carrying the 
polymorphism associated with ALu tolerance. This assumption is debatable but the same 
magnitude of the effect was observed when analyzing mixed infections as a third distinct 
group.  
7.6. Conclusion  
We demonstrated that the presence of low LF concentrations in the blood of individuals 
surveyed in the community was associated with the presence of parasites habouring markers 
of drug resistance. This proves in vivo the direct correlation between residual antimicrobial 
drug and occurrence of resistance. These results highlight the fact that the selection of 
resistant parasites is expected to remain as long as the population is treated by artemisinins 
combined with long half-life parent compounds. In this context, the argument that long half-
life antimalarials confer protective efficacy a few days after treatment should be weighed 
against the increased risk of mutant parasites selection. The latter is of particular concern 
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because the prevalence of resistant parasites was already high in our survey and seemed to 
be increasing since ALu introduction, in 2006 [6]. Although the latest data still show good 
treatment efficacy of ALu in Tanzania [253], a better targeted use of antimalarials in favor of 
parasitologically confirmed malaria cases only should be strongly promoted [235].  Our data 
support the current view that combinations should ideally include drugs with close half-lives 
[240]. Lately, the possibility of using triple combination therapy to prevent resistance has been 
investigated with encouraging results [254].  
Acknowledgements 
We would like to thank the regional and district medical officers as well as study participants. 
Many thanks to the field workers and drivers of the Ifakara Health Institute in Tanzania for 
their help in data collection. Furthermore, thank you to Patrick Kachur and Catherine Goodman 
for their support for project initiation, to Kristina Keitel, Rebecca Thomson and Katia Bruxvoort 
for their advices and expertise during the field work and for Nicolas Maire and Aurelio Di 
Pasquale for their help on ODK programming. Financial support for this work was provided by 
grant No 320030 _149597 from the Swiss National Science Foundation to Blaise Genton as 
Principal Investigator.
  
 
 
  
 
 
 
 
8. CHAPTER VIII: GENERAL DISCUSSION 
 
  
 
 
 
CHAPTER VIII: GENERAL DISCUSSION  137 
 
 
The main purpose of this thesis was to evaluate the usefulness of measuring concentrations 
of antimalarial drugs in the blood to assess drug pressure in the general population and to 
understand how levels of residual antimalarial drugs in community surveys interrelate with 
malaria prevalence, access to care, diagnosis and treatment practices as well as drug 
resistance. We drew on previous evidence that the use of drugs cannot be accurately reflected 
by self-report [49,50], suggesting that methodologies relying on objective and standardized 
endpoints should be used, or at least added, to monitor interventions aimed at improving 
access and rational use of drugs in Tanzania [26,27].  
First, it was important to measure antimalarials using sensitive analytical methodology 
adapted to field conditions. For this purpose, we developed a LC-MS/MS assay for the 
simultaneous analysis of the main antimalarial drugs used in combination with artemisinin 
derivatives in Tanzania in dried blood spots (DBS) samples (CHAPTER IV). The proposed assay 
was found to be suitable for the analysis of residual antimalarials in DBS samples collected at 
large scale thanks to the high sensitivity achieved, the convenience of a single extraction 
procedure and a good stability of the compounds in the DBS samples.  
The developed assay was applied within the frame of a PK study including 16 healthy 
volunteers who received a single adult dose of ALu. LF concentrations in plasma and in DBS 
were highly correlated at all time points (R=0.97) (CHAPTER IVa) and lumefantrine (LF) half-
life calculated from plasma and DBS measurements was similar (101.9 hours in plasma versus 
103.6 hours in DBS) (CHAPTER IVb). This confirmed that LF concentrations determined in DBS 
could be used as surrogate to plasma concentrations.  
The analytical method was then used for measuring residual antimalarial drugs concentrations 
in 6485 DBS samples collected in a cross-sectional survey rolled-out in three regions of 
Tanzania with different levels of malaria endemicity (CHAPTER V). This study showed that 
amongst 6391 participants included in the antimalarial analysis, close to one fifth (20.8%) had 
antimalarials detected in their blood. There was no relationship between the level of malaria 
transmission and the proportion of drug circulating in the blood of the population at regional 
level. According to antimalarials measurement, self-reporting of drug intake appeared to be 
unreliable and there was room for improvement with regard to diagnosis and treatment 
practices in case of febrile episode. Indeed, 31% of the individuals with fevers seeking care 
were appropriately tested and 50% appropriately treated for malaria.  
Understanding patterns of antimalarial drugs use might help to improve treatment 
appropriateness and decreasing drug pressure. This was addressed in CHAPTER VI where we 
used a multivariate analysis to determine the factors associated with the presence of 
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lumefantrine and/or desbutyl-lumefantrine (LF/DLF) or sulfadoxine-pyrimethamine (SP) in the 
blood, which were the antimalarials identified as most frequently used in our surveyed 
population.  
Finally, the main consequence of drug pressure is the emergence of parasite resistance. In this 
context, we investigated in CHAPTER VII whether the presence of residual LF or SP in the blood 
of individuals sampled in the community predicted the presence of Plasmodium falciparum 
harbouring molecular markers of resistance. We found that having LF or SP in the blood was 
not associated with higher odds of carrying a parasite harboring mutations known to reduce 
parasites susceptibility. However, by multivariate analysis, having LF or SP in the blood at low 
concentrations was significantly associated with higher probability of carrying a mutant 
parasite.  
All these aspects provide a unique perspective on drug pressure and its relation to diagnosis 
and treatment environment and drug resistance in settings with different levels of malaria 
endemicity. In this section we will discuss questions, challenges and limitations that have 
arisen throughout the project. We will present the implications of our research findings and 
how they can be further implemented by addressing the following points:  
 Determination of antimalarials concentrations in DBS   
 Drug measurements: gold standard to evaluate new diagnosis and treatment 
strategies and their impact on drug pressure?  
 Challenges in improving malaria case management at population level  
 Residual antimalarials: implications for parasites resistance and case management  
 
  
 
Table 8-1: Contribution of each chapter of the thesis to innovation, validation and application  
Chapter title Related objectives Innovation Validation Application 
IVa) LC-MS/MS method for the simultaneous 
analysis of 7 antimalarials and two active 
metabolites in dried blood spots for 
applications in field trials: analytical and 
clinical validation 
IVb) Lumefantrine pharmacokinetic using 
plasma and dried blood spots: a comparison 
in healthy volunteers 
To develop and validate a LC-MS/MS assay 
for the simultaneous analysis in dried blood 
spots (DBS) of the main antimalarial drugs 
used in combination with artemisinin 
derivatives in Tanzania. 
Development of a methodology for 
antimalarial drugs blood 
measurement using a new sampling 
approach. 
First validation of DBS sampling 
versus plasma sampling of an 
antimalarial using population 
pharmacokinetics approach. 
The methodology could be used to assess DBS 
drug concentrations in the frame of an 
epidemiological cross-sectional study and an 
efficacy study. 
V) Appropriateness of malaria diagnosis and 
treatment of fever episodes according to 
patient history and antimalarial blood 
measurement: a cross-sectional survey from 
Tanzania 
 
To measure blood levels of residual 
antimalarial drugs (primarily LF and SP) in 
representative samples of people in malaria 
endemic areas and to compare these results 
with self-reported history of drug use.  
To use antimalarials blood measurements in 
community surveys to assess diagnosis and 
treatment appropriateness in case of fever 
episode at population level. 
New approach to assess 
appropriateness of case 
managements instead of self-
reported history. 
- 
Drug measurements could complement or 
replace traditional survey methods to assess 
drug use and case managements.  
Results could be used by health authorities to 
develop interventions aimed at improving 
diagnosis and treatment appropriateness.  
VI) Predictors of residual antimalarial drugs in 
the blood in community surveys in Tanzania 
 
To use antimalarials blood measurements in 
community surveys to evaluate the actual 
state of population drug pressure and to 
identify the factors associated with the 
presence of LF or SP in the blood. 
New approach to assess drug 
pressure at population level and to 
determine factors associated with the 
use of LF and SP. 
First report exploring factors 
associated with LF in the blood.   
- 
Results could be used by health authorities to 
plan targeted interventions aimed at decreasing 
antimalarial drugs pressure at population level.  
The methodology could be used as a new 
approach to assess treatment policies 
implementation.  
VII) Do residual antimalarials in the blood of 
individuals sampled in the community predict 
the presence of resistant parasites? A cross-
sectional survey in Tanzania 
 
To investigate whether the presence of 
residual LF or SP in the blood of individuals 
sampled in the community predicts the 
presence of Plasmodium falciparum 
harbouring molecular markers of resistance.   
First results of the effect of LF blood 
concentrations in the blood of 
individuals surveyed in the 
community on the selection of 
P.falciparum harbouring resistance 
markers.  
Provides in vivo proofs of the direct 
correlation between residual 
antimicrobial drug and occurrence of 
resistance, already observed in 
clinical trials settings.  
These results could be used by health 
authorities to develop interventions aimed at 
promoting better targeted use of antimalarials.  
Antimalarial drugs combinations should include 
drugs with close half-lives.  
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8.1. Determination of antimalarials concentrations in DBS   
The building block of this thesis was to develop an analytical assay meeting the specific needs 
required by field epidemiological studies (CHAPTER IVa). Our study design necessitated that 
the analytical method could offer the convenience of a single extraction procedure and a 
single analysis of several drugs from different classes, in order to be applied to a large number 
of samples. The one step extraction and multiplex analysis also resulted in decreasing 
analytical costs.  
The assay was sensitive enough to reach lower concentrations than in previously published 
methods [113] [2 ng/ml (sulfadoxine) and 20 ng/ml (chloroquine, quinine, pyrimethamine, 
mefloquine, LF and DLF)], which was necessary due to the fact that the concentrations 
measured in the samples were mainly low residual concentrations. Most of the concentrations 
detected in the DBS samples collected in Tanzania were close to the method’s limit of 
quantification (LOQ). A higher sensitivity of the method could have enabled to better 
discriminate individuals with very low residual concentrations from those without any drug in 
the blood, providing a more accurate picture of population drug use. But in order to achieve 
higher sensitivity, a last generation liquid-chromatography coupled to tandem mass-
spectrometry (LC-MS/MS) platform and a complex sample preparation would have been 
needed, resulting on an increase in time and costs. An analytical method needs to be chosen 
according to its intended use and in our case, the gain in sensitivity needed to be balanced 
against the increase in costs and analytical time. In order to assess drug pressure before and 
after intervention at larger scale, a simple and cheap method is adequate. In contrast, to assess 
drug pressure in a specific population or in the frame of pharmacokinetics studies, a more 
tedious and expensive but sensitive method should be chosen.   
The stability of antimalarials in DBS samples is a critical element. A benefit of the DBS sampling 
technology is the supposed analytes stabilisation after the blood spots have become dry [93]. 
In our case, the stability provided by the solid and dried form was sufficient to store the 
samples at room temperature for 24 hours, enough time to ship the samples to a laboratory 
or a health facility (HF) where they could be stored between -10 and -20°C.    
We noticed during the analytical method’s development the important influence of the 
haematocrit and volume of blood spotted on the results accuracy. While the latter can be 
easily addressed in field conditions by using glass capillaries of defined volume coated with 
heparin, the haematocrit effect is more difficult to handle. Recently, new devices have been 
developed to elude haematocrit and blood volume issues [255–258] but again, the relating 
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costs are important and some studies have reported an overestimate of analytes 
concentrations [256–259].   
The sensitive and rapid analytical developed (to be used in field conditions/remote settings) 
can detect LF concentrations for up to one month after treatment intake (CHAPTER IVb). The 
comparison between pharmacokinetic (PK) parameters of LF obtained from plasma and DBS 
measurements showed that DBS can be used as a confident surrogate to venous sampling 
(CHAPTER IVb). Our methodology could support an accurate interpretation of clinical trial 
outcome and could improve our understanding on the parasites phenotype associated with 
decreased susceptibility and its selection after treatment intake. However, regarding the other 
antimalarials, our study showed that a correlation between DBS and plasma is necessary due 
the fact that drugs distribution is not even in the different blood compartments and to the 
lack of PK/PD studies based on whole blood sampling (CHAPTER IVa).  
8.2. Drug measurements: gold standard to evaluate new diagnosis and treatment 
strategies and their impact on drug pressure?  
8.2.1. Comparison between traditional surveys and drug measurements  
Table 8.2 gathers the type of information obtained, the methods used and the limitation of 
“traditional surveys” (such as household surveys using questionnaires, HF and private 
medicines retails outlets surveys) and surveys using drug measurements.   
Measuring drug in the blood of the population allows moving from subjective to objective 
and reproductive data. Using drug measurements is reliable and reproducible, but this 
methodology lacks capturing information such as treatment seeking behavior and diagnosis. 
If it can identify accurately the type of antimalarials used in the population, the amount and 
exact timing of drug intake cannot be assessed. LF’s inter-individual variability in terms of 
absorption and half-life [168] brings variability on the number of days up to which LF can be 
detected in the blood (CHAPTER IVb).  
The limitations relating to the DBS sampling technology have been discussed before 
(CHAPTER VIII, section 8.1 ) and are few, thanks to the possibility of using capillary tubes to 
standardize the volume of capillary blood sampled and by the good stability of the drugs in 
DBS for 24 hours at room-temperature. The main question with regard to drug measurements 
at population level is whether it is easily implementable and affordable. The LC-MS/MS 
platform is expensive (approximately 50 dollars for measurement of nine different 
antimalarials in one DBS sample) and requires technicians specifically trained for the machine’s 
maintenance.   
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An alternative could be to use liquid chromatography coupled to UV detection (LC-UV) which 
requires less-skilled technologist and lower start-up costs [260]. The main drawbacks of LC-
UV is the loss of sensitivity and selectivity [261] which implies the need of an extensive sample 
clean-up and to restrict to a lower number of drugs analyzed simultaneously. If drug 
measurements are used to evaluate drug pressure before and after an intervention with the 
aim of assessing the impact of the intervention’s implementation, a less sensitive methodology 
can be used. This would decrease the power of the study but would still be able to catch the 
magnitude of the change in drug pressure. Moreover, some University laboratories in sub-
Saharan Africa (including Tanzania) are already well-equipped with facilities such as liquid or 
gas chromatography coupled to UV detection to perform biomedical analysis [262]. The use 
of already existing platforms could push forward local capacities and give opportunities to 
train local laboratory technicians and data analysts.  
Traditional survey methods such as HF and drug outlet surveys relying on exit interviews, 
recording of drug stocks and prescription rates have the advantages of providing information 
on the availability and quality of malaria rapid diagnostic tests (mRDTs) and drugs at different 
levels of the private and public health sector. Information collected can serve as baseline 
indicator in countries to scale up diagnostic tools and treatments availability [263]. To some 
extent, they also inform on diagnosis and prescription habits, guidelines compliance, 
knowledge and ability of health workers. They reflect the potential capacity of the health 
system.  
  
 
Table 8-2: Comparison between traditional surveys and surveys using drug blood measurements   
References Survey design 
Data collection 
methodology 
Information collected Limitations  
Traditional surveys 
[32,263–
269] 
- Health facility 
surveys (private 
and public sector) 
- Private medicine 
retails outlet 
surveys 
- Audit sheets (filled by 
direct observation or 
report from providers) 
- Patients exit 
interviews 
- Mystery shopper 
- Providers register 
books 
 
Diagnostic tools:  
- Stocks (number, brand, manufacturer) 
- Distribution (sold or used in the previous 7 days) 
- % of patients tested 
- Microscopy services available  
Antimalarials:  
- Prices, availability, market share, brand 
- % of patients tested, compliance to test result   
- % of patients prescribed (AM and ATB) 
- Formulation, brand  
Other: 
- % of patients referred 
- Knowledge and ability to test and appropriately 
treat patients  
- Safety disposal  
- No information on how mRDTs are being used 
- Providers often had a waiver to perform mRDTs under pilot study conditions  
- Providers report subjected to bias (stocks, pricing, sales)  
- Hawthorn effect  
- No certainty that patients ingested drugs  
- No information on the number of visits in private medicine outlets  difficult 
to assess the proportion of visitor receiving a drug 
- Do not include diagnosis-only service providers (private laboratories)  
- Recording errors   
- Time consuming for field workers  
- Cost burden  
- Intense training needed 
- Respondent fatigue  
[3,20,42,2
70,271] 
Household surveys  Questionnaires  - Treatment seeking behavior  
- % of people with fever obtaining an antimalarial 
or ACT (by treatment source)  
- Information on economic status, demographics, 
access to treatment, preferences  
 
- Unreliability of self-reported data (mRDTs, antimalarials prescription, treatment 
seeking behavior, antimalarial consumption)   
- Large sample size needed 
- Respondent fatigue 
- Time consuming for field workers  
- Cost burden  
- Lack of harmonization for history of fever recall (previous 48h versus previous 
2 weeks) 
- No certainty that patients ingested drugs 
Drug measurements  
-  Household surveys Dried blood spot 
samples 
- % of people with antimalarials in the blood 
- Type of antimalarials used in the population 
- Treatment seeking behavior  
- % of people with fever obtaining an antimalarial 
or ACT (by treatment source) 
 
- Unreliability of self-reported data (mRDTs, treatment seeking behavior)   
- Lack of harmonization for history of fever recall (previous 48h versus previous 
2 weeks) 
- Cost burden  
- Logistical needs required by sampling method  
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However, regarding coverage of appropriate antimalarials treatment at the community level, 
such design pain tackling the actual component of drug use. 
Demographic health surveys (DHS) and malaria indicator surveys (MIS) have been collecting 
information on intervention and malaria related outcomes in Tanzania since 2000 [272]. They 
have the advantage of informing on the final effect of an intervention at the community level, 
to help understand the context influencing treatment seeking behavior and drug use. They 
can also replace HF data relating to malaria prevalence in children under five and case 
management when they are not very reliable. Their main limitation is the unreliability of 
information ([40,69] and in CHAPTER V: only 28% concordance for individuals having 
detectable levels of antimalarials in their blood reporting the use of such treatments within 
the previous month). In fact, the need for developing more sensitive and specific methods to 
assess impact of interventions has already been expressed due to, for example, recall bias or 
omissions from the interviewees and gaps in disease identification due to non-specific 
symptoms [271].  
More generally, traditional surveys provide data available at national level, but they result in 
high costs and human resources burden and no data on quality of care are collected [271]. 
Also, due to the length of the survey, questionnaires in community surveys have mainly 
focused on children under five [3], leaving aside the adult population which is not similar 
regarding health seeking behavior and case management (CHAPTER VI, [34,198]).  
8.2.2. What method should be used?   
Household surveys are necessary because what is happening in the HF does not reflect the 
way the whole population is managed. Indeed, it is of paramount importance to assess the 
association between the implementation of an intervention and public health gain, and to 
ensure interventions reach those in need [266]. As shown in Figure 8.1, under real conditions, 
there is a measureable “effectiveness decay” resulting from the effect of diverse elements of 
the health system (including challenges in financing, procurement, work force, supply chain 
and adherence, change in care seeking behavior) [273].  
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Figure 8-1: Systems effectiveness framework showing how intervention’s efficacy (here ACTs) 
translates into effectiveness. Source: malERA Consultative Group on Health Systems and Operational 
Research [274]. 
Household surveys are one step further from outlet surveys and can measure the effectiveness 
of an intervention more than its efficacy [273,274]. If programs aim at improving rational use 
of drugs, then drug pressure and resistance should be the most valuable final outcomes, and 
should be measured in the community due to the potential influence of many actors within 
and outside the health system.  
The data need furthermore to be informative, practical in terms of collection and interpretation 
[273]. The “minimal needed data” is a balance between collectable and informative. Our study 
was a proof of concept and showed that reliable and informative data can be collected. Drug 
measurements could furthermore be integrated into existing intervention packages (for 
example, along with malaria prevalence assessment by mRDTs where capillary blood is 
collected anyways). 
Questionnaires are important to understand the context which has a major role in determining 
an implementation performance [266]. Blood measurement could be used to assess drug 
prevalence, concentrations (in relation to resistance) and the type of treatment while 
questionnaires can inform on the frequency of drug use and to describe the sociological and 
behavioral context in which drugs are used, whose importance is not to be disputed [40]. But 
thanks to the high quality of data provided by drug measurements, the sample size could be 
smaller. Moreover, there is a need to establish a tool for analyzing effectiveness decay and to 
understand and mitigate this effect [273]. Drug measurements, maybe performed on a sub-
sample of individuals, combined with questionnaires and HF surveys could be a tool to assess 
and understand this effectiveness decay.  
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8.3. Challenges in improving malaria case management at population level  
8.3.1. Importance of engaging the whole health system for a public health impact  
The final aim of implementing new case management is to improve not only short-term health 
outcomes but also long-term outcomes at individual and population level through rational 
use of drugs.   
As presented in CHAPTER V and VI, 20.8% of the surveyed population had antimalarials in the 
blood. This overall drug pressure reflects good drug coverage and access, even at community 
level, thanks to initiatives such as the Affordable Medicines Facility-malaria (AMFm) initiative 
that achieved access to affordable drugs in remote places [265]. Our study showed that fever 
was highly correlated to the use of antimalarials, meaning that there is still a strong belief that 
fevers are mainly due to malaria. As explained in CHAPTER VI, if all fever cases were treated 
with an antimalarial, this would lead to a proportion of 19.7% (close to the 20.8% mentioned 
above) of study participants having drugs in their blood, instead of the 2.0% corresponding 
to real febrile malaria cases [25,214,215]. These results are less encouraging than those of 
other studies [188] and showed that more than availability of diagnosis and treatment, the 
actual use and compliance of mRDTs is an issue. Indeed, all of the surveyed HF had 
antimalarials in stocks and 80% of them had mRDTs (CHAPTER V). However, there was no 
correlation between the availability of mRDTs in HF and the prevalence of individuals with 
antimalarials in the blood (CHAPTER VI). Availability or mRDTs alone is not sufficient to ensure 
the appropriate use of ACTs (either because mRDTs are not used or because of poor 
compliance to test results) [30,182].  
Systematic testing and treatment upon result will not be achieved as long as countries do not 
take a “total health system” approach to address the challenge of effective malaria case 
management, as recommended by the Global Fund [275]. Indeed, the poor diagnosis and 
treatment practices in case of febrile episode were mainly due to the high proportion of 
individuals seeking care outside HF (CHAPTER V and VI). This calls for a better understanding 
of drug and diagnosis coverage and quality in all provider types, and strategies designed to 
tackle these challenges, while considering the relationship between sectors.  
8.3.2. Target interventions: where and how?  
The cost of ignoring private (registered and unregistered) sector is high for public health but 
the choice of the appropriate approach to engage this sector is open to debate [276]. Lately, 
pilot programs have aimed at encouraging private providers to improve the quality and 
coverage of their care [276] but evidence of the benefit of such interventions to date is very 
mitigated.  
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Can we reduce antimalarial consumption by allowing drug retailers to perform malaria testing? 
A recent review assessing the implementation of mRDTs in private drug stores showed that 
although mRDTs were made available in the private medicine outlets, this was not sufficient 
to ensure their appropriate use [270]. Indeed, most of these studies showed increase testing 
and good compliance but most of them were pilot studies implemented at small scale, at one 
point in time, and were given a waiver to perform mRDTs [270]. Studies with more intensive 
interventions and supervision produced better results but uncertainties remain regarding the 
consistency of the observed effect in the long term and when scaled up at national level for 
the following reasons: i) simple interventions such as mRDTs requires complex supporting 
interventions [267] which have been proved not to be very successful at HF level, i) the 
regulatory framework prohibiting private providers to sell mRDTs makes the scaling up 
difficult [268] iii) a complete and successful training and supervision of all private drug retailers 
in a country is ambitious given the fact that some of them are not even registered [23]. Other 
challenges are the lack of referral system from private retailers to public facilities and the many 
rationales for providers to provide antimalarials to patient with a negative test such as fear for 
the patients that the disease worsens without antimalarial, patients demand, time consuming, 
or incentive to make sale although the test is negative [270].  
Although drugs are more expensive in drug stores than in HF [189], other reasons motivate 
people to seek care outside of HF, such as feeling quality of service is poor in HF or not wanting 
to wait, not wanting to pay for a consultation and drug stock outs [189]. These reasons were 
also frequently noticed during our fieldwork. Efforts should thus be invested in training more 
HF staff, frequently supervise them and encourage them to retain where they are needed [277]. 
Another reason for not seeking care in HF is their remoteness, especially in rural areas [278]. 
Training more community health workers in villages could address this issue and could not 
only improve well-targeted ACTs treatment at community level, but also create opportunities 
for improving management of non-malaria fever by referring patients to the HF, only when 
needed [191].  
Another important matter regarding case management is that even when appropriately tested 
in HF, half of the people tested positive did not have any antimalarial in the blood (CHAPTER 
V). It might be due to non-compliance of HF to positive results or non-adherence of patients 
to treatment. The latter raises a concern regarding resistance if people do not take the full 
course of their treatment and should also be addressed [194]. 
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8.4. Residual antimalarials: implications for parasites resistance and case 
management  
Pfmdr1, pfdhfr and pfdhps mutant isolates were frequent in the surveyed regions (CHAPTER 
VII). The use of antimalarials seems to be a factor contributing to the selection of resistant 
parasites in the host, but not in the way it was expected. Indeed, the presence of LF in itself in 
the blood was not associated with the presence of parasites harboring markers of drug 
resistance, but the presence of low LF concentrations did. Our results are consistent with 
previous studies that suggested the “window of selection” as a key driver of resistance [39]. 
According to Hasting and Ward [240] parasites carrying the pfmdr1 N86/184F mutation can 
infect a new host 17 days after treatment onset. The simulation performed using the PK model 
constructed in CHAPTER IVa showed that 50% of individuals had detectable residuals LF levels 
for up to 26 days, meaning that mutant parasites can be selected during a period of at least 9 
days. In Tanzania, in a settings of similar malaria endemicity as our study regions (21.0-24.6%), 
the average EIR (=average number of infectious mosquito bites [279]) was 1.1-1.3 per month 
in 2011 [280]. It implies that a person taking ALu has a chance of approximately 35% to be 
infected during that 9 days period of selection (chances being even higher during the peak of 
transmission after the rainy season). This constitutes the drawbacks of using drugs with long 
half-life such as LF and SP. The problem with shorter half-life compound is that they need to 
be given more frequently and for a longer period, which could decrease patients’ adherence 
[35].   
Another matter is that the presence of pfmdr1 N86/184F increases the chances of resistance 
in artemisinin to appear [240]. Indeed, parasites harboring the 86N allele are less sensitive to 
artemisinins in vitro [281,282] and infections with LF tolerant parasites imply that artemisinins 
act as monotherapy, hence contributing to selection pressure for artemisinin resistance [240].  
Our findings suggest that ALu is not robust enough to obviate the selection of mutant 
parasites and that a single treatment is sufficient for this selection to happen. This raises 
concerns about the speed with which the mutations are selected but also has implications in 
terms of case management. Indeed, a study suggested that patients presenting in a HF with a 
partner drug detected in their blood were 4 times more likely to fail subsequent treatment 
with the same ACT [283] and that they should then be treated with an alternate ACT. These 
data are consistent with the great number of ACT failure rate observed, regardless of whether 
artemisinin resistance was present [284]. This is explained by the fact that the artemisinin 
component is responsible for the rapid reduction in parasites load [35] which alleviates the 
symptoms while the partner drug ensures the successful therapeutic outcome, killing the 
remaining parasites (10-104) [14]. In ACTs, artemisinin is protected by the partner drug. If 
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artemisinin resistant parasites are present, they will be killed by the partner drug which makes 
the selection of artemisinin resistant parasites through ACTs unlikely. Despite the protective 
effect of the partner drug, artemisinin resistance has already emerged in South East Asia, which 
was attributed to the use of artemisinin-based monotherapies, substandard and counterfeit 
treatments [12]. In the reverse situation, resistance to partner drug can be selected during the 
selection window, leading to treatment failure [219].   
In 2002, Talisuna et al. [69] observed lower CQ use in high parasite prevalence sites and 
attributed it to the acquisition of partial immunity in high transmission areas, resulting in less 
clinical demonstration of the disease. In our study, the assumption that higher parasite 
prevalence leads to lower drug use through lower frequency of clinical malaria cases was valid 
for adults, who were more likely to use SP (CHAPTER VI). However, in children who are more 
prompt to clinical malaria, the opposite trend was observed: LF prevalence increased with 
malaria endemicity. Moreover, due to their poor immunity, they are more at risk of selecting 
resistance [226,230,235]. Special attention should thus be given to increase appropriate case 
management in children, not only for a positive clinical outcome, but also to control the spread 
of resistance. Indeed, in high transmission areas where resistance can spread faster, their 
immunity is not sufficient to stop infection to evolve in clinical malaria and to stop the 
selection of resistant parasites. Moreover, as shown in CHAPTER VI, drug pressure is higher in 
highly endemic districts and in the most accessible locations. Interventions aimed at improving 
case management should be prioritized in these areas because they constitute favorable 
conditions for development and spread of resistance.  
  
 
 
  
  
 
 
 
 
9. CHAPTER IX: RECOMMENDATIONS AND CONCLUSION 
 
CHAPTER IX: RECOMMENDATIONS AND CONCLUSION  153 
 
 
9.1. Recommendations  
9.1.1. Implications of the research findings into policy and actions 
Tanzania mainland’s goal was to reduce the average country malaria prevalence to less than 
1% by 2020 [1]. However, this country particularly leans on case management and long lasting 
insecticidal nets (LLINs), which are both threatened by resistance. There is an urgent need to 
make rational use of drug a real and sustainable objective. Investments are put in researching 
for new diagnostic tools and drugs (20% of the annual malaria research and development 
funding [285]), while those existing are not used to their full potential.  
Based on our findings, we can draw the following recommendations for health authorities and 
policy makers in Tanzania:   
 
 Use drug measurements to assess impact of interventions and programs  
Measuring drugs in the frame of population-based and school-based surveys can, combined 
with questionnaires limited to a few questions:  
- help understand the most important drivers of antimalarials consumption 
- help targeting interventions in the locations where medicine use appears inappropriate 
[286]  
- assess whether programs such as Intermittent Preventive Treatment of malaria in 
pregnancy (IPTp) are correctly implemented (when used in population-based surveys) 
- assist in decision-making to implement specific interventions and be used as outcome 
indicator [287] to further assess the success and impact of the implementation 
- combination of available technologies such as high performance platforms (LC-MS or 
LC-UV) with mapping and modeling [288] can enable the collection of the minimal 
needed data of good quality [285] and predict data where they do not exist. 
 
 Use drug measurements to assess impact of interventions and programs  
 Strengthen drug policy outside health facilities 
 Target interventions towards high risks areas 
 Target children at high endemicity and adults at low endemicity   
 Prioritize health workers training  
 Use of local capacities  
 Increase consumer awareness 
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 Strengthen drug policy outside health facilities 
The high prevalence of lumefantrine (LF) levels (more particularly at sub-therapeutic levels) 
and of the relating mutant parasites in the studied population challenges the rationale of 
increasing access to highly effective treatment such as ALu through private sector, without 
suitable use of diagnostic tools. More restrictive rules should be introduced to drug vendors, 
such as forbidding the sale of ACTs without prescription or without positive mRDT result. This 
should be done along with increased mRDTs roll-out with proper training and supervision.  
Then, the relatively high proportion of adults self-treated with SP calls for a special attention 
on reinforcing the use of first line treatments, in Mwanza particularly. The supply of 
sulfadoxine-pyrimethamine (SP) outside health-facilities (HFs) for specific programs such as 
IPTp and IPTi should be forbidden due to the poor efficacy of this treatment.  
 Target interventions towards high risks areas  
By measuring antimalarials in the blood, we identified that drug pressure was higher in districts 
of high transmission and in most accessible locations. Such places should thus be targeted 
first.  
 Target children at high endemicity and adults at low endemicity 
In high transmission areas, children represent the major infectious reservoir [289]. Improved 
case management should especially be targeted towards children, not only for a positive 
clinical outcome, but also to control the spread of resistance. In lower transmission settings, 
since adults are the major drivers of transmission [289], the use of recommended first-line 
efficacious drugs in adults should be promoted in the perspective of pre-elimination [3]. 
 Prioritize health workers training  
The majority of febrile individuals seek care outside HF. Proximity of good quality health care 
should be improved by training dedicated community health workers (who do not have any 
incentive of selling more drugs, unlike drug shops). In HF, health workers should be better 
trained and their ability in performing mRDTs should be assessed on a regular basis. Clinicians 
should also understand the stake of treating according to the test results.   
 Use of local capacities  
Resources should be used in developing local capacities, in terms of human resources and 
technology platforms. Laboratory technicians could then be involved in surveillance activities 
ranging from parasite surveillance, resistance surveillance and drug assessment in the 
population. This could also be applied to other infectious diseases [277].  
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 Increase consumer awareness
Behavior change from the consumer side is also paramount in order to achieve rational use of 
antimalarials and other antimicrobials. Interventions that increase awareness of multiple 
causes of fevers are needed to support the new rationalization for malaria treatment 
represented by parasitological diagnosis [290]. For example, radio, sms platforms could be 
used or messages could be given to children at school [3].  
In our study, many people tested positive did not have drugs in their blood. The importance 
of treatment adherence should be emphasized using logos on drug boxes or in drug shops 
and by asking patients to take the first dose under observation [194]. Poor adherence has an 
effect regarding clinical outcome, but also in the selection of mutant parasites as it leads to 
sub-therapeutical drug concentrations.    
9.1.2. Recommendations for future research 
 Choose the appropriate study design
In order to assess the impact of an intervention in a comprehensive manner, its effect should 
be evaluated both at HF level and in the community to see whether results obtained from HF 
surveys correlate with measures obtained in the population. Moreover, surveys should be 
conducted at repeated points in time to assess the sustainability of the effect, and in 
heterogeneous malaria transmission settings and heterogeneous proximity or easiness of 
transports to the HF and drug stores.  
 Use of more advanced mathematical and statistical methodologies
The use of stochastic individual-based models of malaria transmission could simulate the 
prevalence of fevers that are due to malaria and thus the number of individuals that should 
have antimalarial detected in the blood. The simulation models can be parameterized using 
the survey data such as malaria endemicity, demographics, measures of access to care, use of 
 Choose the appropriate study design
 Use of more advanced mathematical and statistical methodologies
 Monitor drug pressure and resistance
 Use dried blood spot in a broader antimicrobial stewardship effort
 Improve knowledge on drug inhibitory concentration and distribution
 Search for new drug combinations

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diagnosis and treatment regimens and outputs from the simulations compared with field data. 
Furthermore, understanding the mechanism of drug resistance both at individual and 
population level is crucial in order to embrace the dynamic of resistance [69]. The population 
component needs to be tackled using more advanced statistical methodologies such as 
bayesian statistics and mapping and taking into account other important geographical or 
climate factors which could have an influence on resistance development and spread [291]. 
Knowledge of special characteristics and predictors of diseases has proven to be valuable tools 
to assist health authorities in adapting appropriate and targeted interventions [291,292]. This 
analysis has already been initiated in collaboration with Dr. Penelope Vounatsou, Head of the 
Bayesian Modeling and Analysis group at the Swiss TPH.  
 Monitor drug pressure and resistance  
Understanding, tracking and mapping resistance is essential to understand how it spreads. 
Drug pressure, because it is linked to resistance, could thus be measured alongside with 
antimalarial susceptibility testing [277].   
In our study, we did not know whether the parasites detected in our samples had been 
selected during the previous treatment or if they were new infections. Genotyping of a highly 
polymorphic gene such as pfmsp2 [96] could define the genetic diversity of the infection and 
help distinguish reinfections from primary infections and should be used to understand the 
role of residual drug levels on parasite resistance.  
 Use dried blood spot in a broader antimicrobial stewardship effort  
Decrease in antimalarial use often goes hand in hand with an increase in antibiotic prescription 
[182,293]. For this reason, DBS should be used to simultaneously measure antimalarials and 
antibiotics to better understand the dynamic of antimicrobial consumption. A LC-MS/MS 
method for the analysis of the 12 most frequently used antibiotics in Tanzania (namely 
amoxicillin, metronidazole, ceftriaxone, trimethoprim, sulfamethoxazole, cephalexin, 
ciprofloxacin, doxycycline, chloramphenicol, erythromycin, penicillin V and G) in DBS has been 
developed by a Master student in Pharmacy [294] in the frame of the present thesis. This 
method is planned to be used in a new project aiming at assessing antimicrobial drug pressure 
at the population level and evaluating the impact of antibiotic stewardship intervention on 
antimicrobial drug pressure [295]. The spatial distribution of antimalarial and antibiotic use in 
the population will then be mapped and used to re-inforce and better target antimicrobial 
stewardship interventions.     
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 Improve knowledge on drug inhibitory concentration and distribution  
Few reliable and reproducible information on the minimum inhibitory concentrations (MIC) of 
the studied drugs are available in the literature. Furthermore, after correlating LF 
concentrations in DBS and plasma, we realized that LF distribution inside the red blood cells 
is minimal. More extensive research on the MIC and the distribution of the drugs inside the 
erythrocytes (where drugs inhibit the intra-erythrocyte development [87,88]) should be 
conducted to better assess parasites susceptibility to drugs.   
 Search for new drug combinations  
We confirmed the limitation of combining short half-life and long half-life compounds. Studies 
should examine possibilities of combining drugs with shorter and similar half-life as well as 
using triple combinations therapies to prevent resistance.  
9.2. Conclusion  
We developed a sensitive LC-MS/MS method for the simultaneous analysis in DBS of the major 
partner drugs used in ACT combinations. This methodology was suitable for field studies and 
enabled us to collect objective and reliable data to illustrate the complex interplay between 
parasite prevalence and resistance, individual factors such as age and health seeking behavior 
as well as diagnosis and treatment practices. We were able to identify the principal 
determinants of drug use, which could be used in the future in malaria control (to assess access 
to care as well as diagnostic and treatment policies implementation) and surveillance (along 
with parasite resistance surveillance for example). We also demonstrated that the presence of 
low LF concentrations in the blood of individuals surveyed in the community was associated 
with the presence of parasites harboring markers of drug resistance. Despite efforts made to 
improve access to diagnostic tools, there is still a high drug pressure in the population. A 
better targeted use of antimalarials in favor of parasitologically confirmed malaria cases only 
should be urged in order to stop the spread of resistance. To that aim, the WHO guidelines of 
systematic diagnosis and treating upon results is an essential guideline to be followed and 
there is a need to support the use of mRDTs use with proper training in the public and in the 
private sector.  
This observational work was a first step in the evaluation of drug pressure in the community, 
using reliable tools to have a deeper understanding of the relationship between drug pressure 
and parasite resistance at population level. It is now time to integrate available advanced 
technologies and statistical tools such as Bayesian statistics and mapping to create good 
quality data and predict data when they are not existing. Modeling could also be used as a 
pro-active approach to predict the effect of interventions on drug pressure.  
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The amount of drug pressure in the population should seriously be considered as Tanzania 
wants to progress towards malaria pre-elimination. High prevalence of individuals with drug 
in the blood (such as during mass drug administration) is only recommended in settings 
approaching interruption of transmission [296], where the risk of re-introduction of infection 
is minimal [297]. In other transmission settings, the temporary prophylactic effect of long half-
life compounds provides a significant selective pressure for the emergence of drug resistance, 
which threatens the sustainability of gains in malaria control and prospects for elimination 
[298]. Strategies to stop the expanding resistance to artemisinins and partner drugs are 
urgently needed [273] and this starts by avoiding parasite exposure to a single selective agent, 
which is the central principle of resistance management [298].
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11. APPENDICES 
 
APPENDIX 1: Example of flowsheet used during the inclusion visit 
 
 
 
PARTICIPANT 
Initiales (prénom, nom) :    
 
Sexe :  M    F 
Année de naissance :      
 
Code d’identification du sujet :       ̶    
 
Date de signature du consentement :   /   /      
 
 
VISITE DE SCREENING 
CRITERES D’INCLUSION :  OUI     NON 
 Sujet âgé entre 18 et 45 ans            
 Si sujet féminin : utilise une méthode de contraception 
fiable. Si une méthode de contraception hormonale est 
utilisée (orale, transdermique ou systémique), la volontaire 
a été avisée d’utiliser une méthode non-hormonale 
additionnelle jusqu’aux prochaines menstruations            
 Absence de traitement médicamenteux concomitant 
(contraception hormonale tolérée)            
 Le sujet comprend les procédures et accepter de participer 
à l’étude et souhaite donner son consentement écrit            
 Le sujet accepte de participer à minimum 5 visites après 
l’administration du médicament            
A remplir par la suite : 
 ECG 12 dérivations sans anomalie significative            
 BMI  entre 18 et 29 kg/m2            
 
 
 
 
 
 
 
 
 
 
 
  
ETUDE DBS-ALU – INVESTIGATION EN PCL 
Mesure de lumefantrine dans le plasma et dans les dried blood spots 
Date d’inclusion:   /   / 2016 
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CRITERES D’EXCLUSION : 
 OUI NON 
 Antécédents médicaux majeurs (hépatiques, 
immunologique, rénal, hématologique, gastro-intestinal, 
génital, système nerveux central, cardiovasculaire, 
pulmonaire ou rhumatismal)   
 Maladie sévère récente ou séquelles qui pourraient 
exposer le sujet à de plus gros risques ou pourrait 
confondre les résultats de l’étude   
 Prolongation congénitale de l’intervalle QT ou toute autre 
condition connue pour allonger l’intervalle QT ou causer 
une arythmie cardiaque (historique d’arythmie cardiaque 
symptomatique, bradycardie ou maladie cardiaque sévère)   
 Femme enceinte ou allaitante   
 Historique familial de prolongation congénitale de 
l’intervalle QT ou de mort subite   
 Perturbations connues de l’équilibre électrolytique   
 Troubles hépatiques connus, y compris ceux ne nécessitant 
pas de traitement (syndrome de Gilbert toléré si léger)   
 Traitement durant les 3 mois précédents avec un 
médicament connu pour avoir un potentiel de toxicité bien 
définie pour un organe majeur   
 Historique d’hypersensibilité à un des composants du 
médicament   
 Historique d’hypersensibilité à n’importe quel 
médicament, si considéré comme sérieuse     
 Historique d’abus d’alcool ou de drogues    
 Consommation d’une grande quantité d’alcool ou de vin 
(>0.5 L vin/jour)            
 Utilisation de médicaments durant la semaine précédant 
l’étude (ou basé sur la règle des 5 demi-vies plasmatiques) 
et jusqu’à 48 heures post-traitement           
 Participation à un essai clinique dans les 3 mois précédents, 
à moins qu’aucun traitement n’ait été administré et qu’un 
volume faible de sang ait été prélevé           
 Occupation qui pourrait interférer avec les visites ou les 
prises de sang durant l’étude   
 Statut psychologique qui pourrait avoir un impact sur la 
capacité du sujet à fournir un consentement éclairé   
 Toute caractéristique présente ou de l’historique du sujet 
qui, selon l’avis de l’investigateur, pourrait confondre les 
résultants de l’étude ou qui pourrait représenter un risque 
potentiel pour le sujet   
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A remplir par la suite :  
 Test de grossesse (hCG) positif 
 
 
 
 
 Hypertension (>150/90mmHG au repos) ou épisodes 
hypotensifs récurrents considérés comme cliniquement 
significatifs   
 
 
INFORMATIONS A TRANSMETTRE AU SUJET : 
OUI NON 
 Le sujet a été informé qu’il devrait s’abstenir de 
consommer du grapefruit (jus et fruit entier) ainsi que des 
boissons alcoolisées 24 heures avant et jusqu’à 48 heures 
après la prise de Riamet®   
 Le sujet a été informé qu’il devrait s’abstenir de prendre 
un médicament hors de celui administré durant l’étude 
une semaine avant et jusqu’à 48 heures après la prise de 
Riamet® (à l’exception des contraceptifs oraux). Prise de 
paracétamol acceptée après permission de l’investigateur    
 Le sujet a été informé qu’il devrait s’abstenir de participer 
à un autre essai impliquant la prise d’un traitement jusqu’à 
la fin de l’étude   
 Si sujet féminin : la volontaire a été avisée d’utiliser une 
méthode non-hormonale jusqu’aux prochaines 
menstruations      
 Le sujet a été informé des effets indésirables les plus 
fréquents survenant à la suite de la prise de Riamet® 
(céphalées, vertiges, nausées, vomissements, douleurs 
abdominales, toux, faiblesse, fatigue, arthralgies, myalgies, 
palpitations, troubles du sommeil)   
 Le sujet a été informé du fait que des vertiges et fatigues 
pouvaient survenir à la suite de la prise de Riamet® et que 
ceux-ci pouvaient limiter son habilité à conduire un 
véhicule   
 
AUTRES INFORMATIONS : 
Utilisation récente d’antimalariques :  OUI   NON  
Si OUI, nom du traitement (spécialité ou principe actif) : 
 
Quand le traitement a-t-il été pris ?    (jours/semaines/mois) 
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INFORMATIONS SUR LE PARTICIPANT : 
Taille :    cm 
 
Poids :    kg 
 
BMI :   kg/m2 
 
Température :   °C tympanique 
 
Fréquence cardiaque :     battements/min 
 
Pression artérielle:    /    mmHg 
 
Résultat du test de grossesse (hCG) :    Positif  Négatif 
 
Examen physique 
  aucune anomalie    anomalie cliniquement non significative    anomalie cliniquement significative    
Remarques concernant l’examen physique :  
 
 
 
 
VISITES FIXEES AVEC LE PARTICIPANT (5 visites minimum): 
 
Visites n° Visites choisies Date Heure 
1 H0 (±0h)     /   / 2016 
 
   :   
 
2 H3 (±0.5h)     /   / 2016 
 
   :   
 
3 H6 (±0.5h)     /   / 2016 
 
   :   
 
4 H8 (±0.5h)     /   / 2016 
 
   :   
 
5 H10 (±2h)     /   / 2016 
 
   :   
 
6 H18 (±3h)     /   / 2016 
 
   :   
 
7 H24 (±3h)     /   / 2016 
 
   :   
 
8 H48 (±6h)     /   / 2016 
 
   :   
 
9 H72 (±6h)     /   / 2016 
 
   :   
 
10 H168 (±24h)     /   / 2016 
 
   :   
 
11 H336 (±24h)     /   / 2016 
 
   :   
 
Electrocardiogramme 
Résultat : 
 Normal 
 Anormal   
(préciser) : 
 
QT :    ms 
 
QTc :    ms 
 
Fréquence cardiaque :    battements/min 
 
 
 
